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ABSTRACT 
 
 
The obligate intracellular protozoan parasite, Toxoplasma gondii, is the etiologic 
agent of an opportunistic infection affecting mainly immunocompromised patients, 
infants and neonates with immature immune system. There is a need for alternative anti-
parasitic treatment for toxoplasmosis due to the associated toxicity and teratogenicity of 
the current drug treatment regime. To investigate a potential alternative strategy, we 
have used the phage-display system and developed a novel biopanning procedure to 
isolate single-chain Fv (scFv) antibodies probed against tachyzoites – the rapidly 
replicating form of T. gondii responsible for acute disease. The resulting scFv antibody 
library (complexity of 1.62 X 104 independent transformants) was co-incubated with the 
tachyzoites in a solution phase single-round biopanning procedure that was subtracted 
against a human cell line to minimize false positives. Phage-scFv output clones from the 
biopanning showed an average of at least 5.6-fold higher binding titer to T. gondii 
relative to unpanned clones.  Here we show that despite well-acknowledged difficulties 
associated with biopanning with cells, this rapid biopanning approach was able to 
effectively generate specific scFv against T. gondii. ScFv TG130 which was isolated 
from this study demonstrated a 5-fold enrichment of binding to its’ intended target T. 
gondii tachyzoites compared to the negative control cell line WRL68. Statistical 
assessment of the titer of bound recombinant scFv TG130 phage was found to be 
significantly higher with T. gondii than with WRL68 (Mann-Whitney test, P = 0.0303, n 
= 12).  
 
In order to improve the binding properties of the anti- T. gondii scFv antibody, a 
second generation antibody library was generated based on the isolated scFv TG130 by 
using complementarity-determining region (CDR) mutagenesis for affecting an in vitro 
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antibody affinity maturation. Site-directed randomized mutations were introduced into 
specific DNA residues within the CDR known as hot spots – which are sequences that 
are prone to somatic hypermutations during the in vivo affinity maturation of antibodies. 
A screening strategy with increased stringency to select for antibodies with increased 
dissociation rate was employed to isolate improved scFv binders. Comparisons between 
the parental antibody and the affinity-matured antibody clone revealed that there was 
not a statistically significant difference in the binding titers of both antibodies to the 
target antigen T. gondii, although average titers for the affinity-matured TP60 was at 
least 1.8-fold higher than its parental counterpart. However, statistical analysis showed 
that the matured antibody fragment outperformed the parental antibody in terms of 
antibody specificity for T. gondii relative to negative control (t-test, P = 0.018, n = 3), 
indicating improved antibody selectivity for its target. These results demonstrate that 
scFv antibodies to T. gondii with improved properties can be generated through a 
combinatorial approach of phage-display and an in vitro antibody affinity maturation 
procedure. The potential implication of this study is for the enabling of the discovery 
and evolution of recombinant antibody fragments against T. gondii antigens in its native 
form and the development of bioimaging and cell-targeting ligands against this parasite.  
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ABSTRAK 
 
Toxoplasma gondii adalah parasit protozoa intersel yang mengakibatkan 
jangkitan oportunis toksoplasmosis kepada individu-individu yang mempunyai sistem 
immuniti yang lemah, termasuk bayi dan fetus dalam kandungan. Disebabkan rawatan 
anti-parasitik terkini untuk gejala toksoplasmosis adalah toksik dan teratogenik – iaitu 
boleh mengakibatkan kecacatan dan kerencatan pertumbuhan normal kepada fetus 
dalam kandungan, rawatan alternatif untuk penyakit ini adalah diperlukan. Untuk 
mengkaji strategi-strategi alternatif, antibodi rantai tunggal Fv (scFv) telah dibangunkan 
melalui teknologi ‘phage-display’ dan ‘biopanning’ terhadap parasit peringkat akut 
jangkitan, iaitu takizoit. Perpustakaan antibodi scFv yang dibangunkan melalui 
teknologi tersebut (1.62 X 104 klon) telah diprobkan dengan takizoit dalam prosedur 
‘single-round biopanning’ fasa cecair, dan penyaringan negatif terhadap titisan sel 
manusia untuk mengurangkan antibodi positif palsu. Klon-klon scFv yang terpilih 
melalui prosedur tersebut menunjukkan ‘binding titers’ 5.6-kali ganda lebih tinggi 
terhadap T. gondii berbanding output klon yang tidak disaringkan. Kajian ini 
menunjukkan bahawa walaupun terdapat kesukaran dalam keadaan mengoptimumkan 
biopanning sel, prosedur ini dapat membangunkan antibodi scFv yang spesifik terhadap 
parasit T. gondii dengan berkesan. Antibodi monoklon scFv TG130 yang terhasil 
daripada kajian ini menunjukkan ‘binding titers’ 5-kali ganda lebih tinggi terhadap T. 
gondii berbanding sel kawalan negatif WRL68. Penilaian statistik menunjukkan bahawa 
antibodi rekombinan scFv TG130 mempunyai kelebihan ketara dalam ‘binding titers’ 
terhadap T. gondii berbanding WRL68 (Mann-Whitney test, P = 0.0303, n = 12).  
 
Bagi meningkatkan keberkesanan antibodi TG130 tersebut, perpustakaan 
antibodi generasi kedua telah dibangunkan melalui prosedur ‘complementarity-
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determining region (CDR) mutagenesis’ untuk menghasilkan kematangan antibodi 
secara in vitro. Mutasi secara rawak pada lokasi spesifik di jujukan DNA antibodi 
tersebut yang dikenali sebagai ‘hot spots’ dijalankan. ‘Hot spots’ adalah jujukan DNA 
yang sering mengalami ‘somatic hypermutations’ dalam proses kematangan affiniti 
antibodi dalam sistem in vivo. Strategi penyaringan antibodi dengan kadar penceraian 
antibodi-antigen yang lebih tinggi dijalankan untuk mengasingkan antibodi generasi 
kedua dengan afiniti yang lebih baik. Walau bagaimanapun, perbandingan antara 
antibodi parental TG130 dengan antibodi generasi kedua tersebut menunjukkan bahawa 
scFv TP60 mempunyai titer yang 1.8-kali ganda lebih tinggi dalam reaksi terhadap 
antigen T. gondii. Analisis statistik menunjukkan bahawa antibodi generasi kedua 
tersebut mempunyai kelebihan ketara dalam kespesifikan terhadap antigen T. gondii 
berbanding dengan sel kawalan negatif (t-test, P = 0.018, n = 3), iaitu peningkatan 
keberkesanan antibodi tersebut untuk mendiskriminasikan di antara antigen dan sel 
kawalan negatif. Natijahnya, antibodi rekombinan dengan keberkesanan yang lebih 
tinggi boleh dikonstrukkan melalui kombinasi teknologi ‘phage-display’ dan prosedur 
kematangan afiniti antibodi in vitro. Implikasi kajian ini adalah dalam penemuan dan 
evolusi fragmen antibodi rekombinan terhadap T. gondii, serta potensi untuk 
membangunkan kaedah bioimaging, teknologi pensasaran sel serta kaedah 
‘immunotherapeutics’ terhadap jangkitan toksoplasmosis. 
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1. General Introduction 
 
1.1 – Toxoplasma gondii and the problem of the toxoplasmosis disease. 
 
T. gondii is an obligate intracellular protozoan capable of invading and 
establishing productive infection in almost any nucleated cell where it produces a life-
long chronic infection (Manger, Hehl, & Boothroyd, 1998). Consequently, up to one 
third of the world’s population is infected (Montoya & Liesenfeld, 2004). It belongs to 
the phylum Apicomplexa which includes important human pathogens such as 
Plasmodium spp., the causative agent of malaria, and Cryptosporodium spp., the 
causative agent of Cryptosporidiosis. Toxoplasmosis infections in immunocompetent 
individuals are generally asymptomatic except for the minority of cases of mild, flu-like 
illness with low-grade fever, malaise, myalgia and headache (Dubey & Jones, 2008). 
These symptoms are usually self-limiting and are quickly resolved due to the hosts’ 
immune system that puts the acute stage of infection in check. However, T. gondii can 
cause severe neurological birth defects when transmitted congenitally (Holliman, 1995) 
and is an opportunistic pathogen affecting immunocompromised individuals such as 
AIDS patients by causing the reactivation of latent infection into fulminant disease 
(Israelski, Chmiel, Poggensee, Phair, & Remington, 1993), with the most common 
clinical symptom and cause of morbidity being toxoplasmic encephalitis (B. J. Luft et 
al., 1993). Toxoplasmosis is a serious life-threatening complication in 
immunocompromised patients in the wake of emerging multi-drug resistant strains of 
the Human Immunodeficiency Virus (HIV) (Carruthers, 2002). 
 
Current drug treatment for toxoplasmosis includes the administration of 
pyrimethamine and sulfonamides – both of which can cause toxic side-effects in 
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patients most commonly resulting in rashes, vomiting, nausea and leukopenia (Porter & 
Sande, 1992) with potential injury to the urinary tract (Simon, Brosius, & Rothstein, 
1990). Toxoplasmosis treatment complications due to drug toxicity have been reported 
to range between 62 % to 71 % (Catherine et al., 1988; Porter & Sande, 1992). 
Although an effective anti-parasitic drug, pyrimethamine is known to be teratogenic and 
can cause developmental abnormalities to the developing foetus, especially during the 
first trimester of pregnancy (Sison & Sever, 1999). Therefore, an alternative treatment 
for toxoplasmosis which is safer for neonates and with lower propensity for 
inflammatory side-effects for immunocompromised individuals is needed to combat this 
opportunistic infection. 
 
To resolve this, various studies have been conducted in search for a vaccine or 
immunotherapeutics to decrease the disease burden of toxoplasmosis. The various 
efforts at the development of antibody ligands against the protozoan parasite T. gondii 
have mainly focused on the isolation of binding antibodies against the parasites’ known 
and soluble antigens which are strongly immunogenic. However, it has also been shown 
that antibody’s binding to the immunogenic antigens does not necessarily correlate with 
effective disease inhibition (J. F. Dubremetz, Rodriguez, & Ferreira, 1985). This could 
be due to the parasite’s sophisticated mechanism for immune evasion and subversion of 
infected leukocytes to cause widespread and rapid dissemination of the parasite 
throughout the host (Carruthers & Blackman, 2005; Laliberté & Carruthers, 2008).  
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1.2 – Development of recombinant antibodies by phage-display 
technology 
 
Advances in the past two decades in recombinant antibody engineering has led 
to the development of phage-displayed antibody technology that circumvents the 
bottleneck problem of antibody design and production associated with hybridoma 
technology (McCafferty, Griffiths, Winter, & Chiswell, 1990). In the phage-display 
technology, viral phagemids harbouring polyclonal antibody genes are cloned into M13 
bacteriophages, resulting in the production of phage particles expressing the antibody 
genes on the surface of filamentous bacteriophage as fusion proteins (Boel et al., 2000; 
C. Marks & Marks, 1996). Each phage particle displays one antibody, which effectively 
creates a convenient link between antibody phenotype and its’ encoded genetic 
sequences (Clackson, Hoogenboom, Griffiths, & Winter, 1991). A polyclonal pool of 
these recombinant phages is referred to as a phage-displayed antibody library. Antibody 
genes engineered into being displayed on the bacteriophages are usually smaller 
fragments derived from immunoglobulins (Ig), such as Fab and scFv. The advantages of 
smaller antibody fragments are its ability to retain its’ target specificity and affinity 
while being easier to produce in recombinant form, more amenable to mutational 
designs, higher tissue penetrability and also potentially avoids pathological immune 
effector responses. These antibodies have further potential as bioimaging and 
biotargetting tools for focused delivery of drugs to cells. 
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1.3 – Research objectives. 
 
The aims of this study were: 
 
i) To generate scFv antibodies against T. gondii tachyzoites using phage display 
technology.  
 
ii) To develop an optimized suspension cell-based subtractive biopanning method for 
the selection scFv antibodies specific to T. gondii tachyzoites native antigens.  
 
iii) To characterize the antigen-binding scFv clones by sequence, molecular structure 
and immunofluorescence analysis.  
 
iv) To perform antibody affinity maturation using site-directed mutagenesis technique 
to increase the binding capacity of scFv antibodies against T. gondii. 
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1.4 – Outline of the thesis 
 
This thesis is divided into 6 chapters: 
Chapter 1  General Introduction 
Chapter 2  Literature Review 
Chapter 3  Materials & Methods 
Chapter 4  Generation of anti-Toxoplasma gondii single chain variable 
fragment (scFv) antibodies by phage display. 
Chapter 5 Development of anti-Toxoplasma gondii scFv antibody with 
improved affinity. 
Chapter 6 Overall Conclusions. 
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2. Literature Review 
 
2.1- The structure and life cycle of Toxoplasma gondii 
 
T. gondii is an obligate intracellular apicomplexan protozoan, subclass 
coccidian; with a worldwide distribution and capable of infecting all endothermic 
vertebrates. The widespread expansion of Toxoplasma has been compounded by the 
acquisition of direct and enhanced oral transmission ability by the parasite through a 
seemingly recent evolutionary change (Su et al., 2003). T. gondii can take on several 
different forms at different life cycle stages, namely the oocyst, the tachyzoite, and the 
tissue cyst (zoitocyst) (Figure 2.1). The T. gondii genome is haploid, except during its 
sexual cycle in cats, and contains about 8 X 107 base pairs (Montoya & Liesenfeld, 
2004).  
 
The organism contains three types of specialized and morphologically distinct 
secretory organelles that are common to Apicomplexans – micronemes, rhoptries and 
dense granules (Hoppe, Ngo, Yang, & Joiner, 2000) (Figure 2.2). The molecular 
characterization and function of several proteins from these organelles have been 
reported (Brydges, Harper, Parussini, Coppens, & Carruthers, 2008; Cesbron-Delauw, 
1994; Dlugonska, 2008; M-H Huynh & Carruthers, 2006; Tomley & Soldati, 2001) and 
is generally attributed to parasite’s invasion and survival within its host. These 
organelles have a regulated function of deploying its protein content in a precisely 
orchestrated sequence throughout the invasion process and are major determinants to 
the parasitic pathogenesis, survival within its host and host interaction (Carruthers, 
1999). The initiation of the invasion process begins with micronemal secretion of 
parasite adhesins responsible for the initial attachment and penetration into host cell 
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(Carruthers, 2002). The parasite promptly re-orientates itself so that the apical surface is 
closely positioned to the host cell membrane before the micronemes fuse to the 
tachyzoite cell membrane and deploys its’ protein adhesins.  
 
 
 
FIGURE 2.1 Diagram depicting the life stages and modes of transmission of 
Toxoplasma gondii. Members of the cat family serve as definitive hosts, where the 
sexual development of the parasite takes place within the small intestines. Haploid 
micro- and macrogametes forms within the enterocytes following a round of mitotic 
replication (A-E stages). Gametes fusion results in a diploid zygote that is shed as 
resistant oocysts (spore) in the feces. Transmission occurs when oocysts (a) contaminate 
food or water. Ingestion by a wide variety of warm-blooded hosts leads to an acute 
infection, characterized by fast-multiplying tachyzoites (b). Long-lasting chronic 
infection is typified by development of tissue cysts (c), which can also be transmitted by 
carnivourous feeding or scavenging. (Adapted from Sibley & Ajioka, 2008) 
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FIGURE 2.2 The ultrastructure of a Toxoplasma gondii tachyzoite. (Adapted from 
Coppens & Joiner, 2001) 
 
 
Microneme secretion from T. gondii for initial attachment to host cell is 
followed by rhoptry secretion. Toxoplasma discharges its’ rhoptry protein complexes in 
a timely manner to facilitate the establishment of infection and facilitating host 
organellar associations (Carruthers, 1999; Hoppe et al., 2000).   Rhoptry secretions have 
been implicated to have a crucial function in the establishment of the parasitophorous 
vacuole membrane (PVM) that eventually encloses the intracellular parasite and 
delimits it from the host cell cytoplasm (Hoppe et al., 2000). As the tachyzoites invade, 
the host cell membrane invaginates and a tight junction is formed which is translocated 
backwards along the length of the parasite while host cell membrane proteins are shed 
off as the PVM envelopes the parasite (J. F. Dubremetz et al., 1985; Mordue, Desai, 
Dustin, & Sibley, 1999) and the rhoptries secrete its’ protein content into the vacuolar 
space. The interesting feature of the PVM is the ability to resist acidification and fusion 
with host cells endocytic and lysosomal compartments which prevents the parasites 
destruction by the host lysosomes (Joiner, Fuhrman, Miettinen, Kasper, & Mellman, 
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1990; Mordue, Håkansson, Niesman, & David Sibley, 1999). This enables the parasite 
to multiply rapidly in this protected environment until the host cell ruptures and further 
dissemination can occur (Mordue, Desai et al., 1999).  
 
It appears that the parasite’s dense granules secretion is the final organellar 
discharge in T. gondii’s arsenal of secretory proteins. Soon after invasion, evidence 
indicates that the dense granule proteins function in structural modifications of the PV, 
immune protection and promoting intracellular replication through the transport and 
processing of nutrients from its host cells (Carruthers, 1999; Cesbron-Delauw, 1994; 
Zhou et al., 2005). Two of the most studied dense granule secretory proteins are GRA1 
and GRA2 (Cesbron-Delauw et al., 1989; Sibley, Niesman, Parmley, & Cesbron-
Delauw, 1995), which also happens to be among the most abundant Toxoplasma 
proteins at 2.0 % and 1.3 % of the total RH strain derived cDNA library ESTs (Ajioka 
et al., 1998b). Although the definite roles of these proteins are unknown and efforts to 
determine their respective functions are significantly hindered by the lack of homology 
with characterized proteins; GRA1 is potentially involved in the Ca2+ homeostasis 
within the PV (Cesbron-Delauw et al., 1989) while GRA2 may be responsible for acute 
virulence (Mercier, Howe, Mordue, Lingnau, & Sibley, 1998). Another well-defined 
dense granule protein is the nucleotide triphosphatase (NTPase) which is responsible for 
the supply of purines in this purine-auxotrophic parasite (Asai, Miura, Sibley, 
Okabayashi, & Takeuchi, 1995; Sibley, Niesman, Asai, & Takeuchi, 1994). In addition, 
T. gondii NTPase may function cooperatively with GRA1 in promoting parasite egress 
out of its host cell through the signals of elevated intracellular Ca2+ levels and depleted 
ATP (Silverman et al., 1998; Stommel, Ely, Schwartzman, & Kasper, 1997). 
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A critical parameter in the survival and persistence of parasitic infections is its 
different life cycle that allows the parasite to escape hosts’ immune surveillance. The 
life cycle of T. gondii consists of two phases called the intestinal (or enteroepithelial) 
stage and extraintestinal stage. The intestinal phase occurs exclusively in members of 
the cat family (Felidae), which is the definitive host, and produces oocysts (Dubey, 
Miller, & Frenkel, 1970), while many mammals and birds serve as intermediate hosts 
harboring this parasite in the extraintestinal phase, including humans (Carruthers, 1999). 
The definitive hosts are not only restricted to domestic cats, but also other felids such as 
ocelots, margays, jaguarundi, Pallas cats, bobcats and Bengal tigers; although oocysts 
formation is greatest in domestic cats (Dubey, 1996). Throughout its life cycle, T. 
gondii has three morphological forms: the rapidly reproducing tachyzoites that causes 
parasite-directed host cell lytic destruction, the dormant bradyzoites that occupy tissue 
cysts and sporozoites that are contained within oocysts which are excreted in cats’ feces 
(J. Jones, Lopez, & Wilson, 2003).  
 
Cats become infected with toxoplasmosis by ingesting any of the three 
infectious stages of the organism; namely the actively multiplying tachyzoites, the 
quiescent bradyzoites that occupy cysts in infected tissues, and the oocysts shed in feces 
(Dubey et al., 1970). In the intestinal stage, when a cat ingests meat containing tissue 
cysts, the cyst wall is dissolved by the proteolytic enzymes in the stomach and small 
intestine, releasing bradyzoites enclosed within the cysts. The slowly-multiplying 
bradyzoites penetrates the epithelial cells of the small intestine and initiates the T. 
gondii asexual cycle which results in the rapidly proliferating tachyzoite form. 
Meanwhile, some of the parasites undergo the sexual cycle in which male and female 
gametes are formed and subsequently fuses to become a zygote. Oocysts (10 x 12 µm) 
are subsequently formed through the fertilization of the male and female gametes and 
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the development of two cell walls encircling the fertilized zygote (Dubey, Lindsay, & 
Speer, 1998). About 10 million uninfectious oocysts are excreted in the faeces daily for 
7-21 days in an unsporulated stage and contaminate the surrounding environment. 
Sporulation occurs outside the body, and the oocysts become infectious 1 to 5 days after 
excretion depending on environmental conditions (Dubey et al., 1998). During acute 
infection, a 20 g cat stool can contain between 2 – 20 million oocysts, and when the 
fecal matter has decomposed, the local soil contamination can be as high as 100,000 
oocysts/g (Webster, 2001).  
 
 During its maturation, the zygote undergoes differentiation to form sporozoites 
which is encased within mature oocysts – now known as sporulated oocysts and is the 
infective form (J. Jones et al., 2003). Sporulated oocysts are remarkably resistant in 
adverse environmental conditions and remain infectious for more than 1 year in a 
suitable environment (warm, moist soil). However, the infectious oocyst cannot survive 
well in arid, cool climates and can be destroyed by heating (Gagne, 2001).  Due to this 
hardiness, T. gondii is a global zoonoses and is not restricted to any known geographical 
boundaries (Carruthers, 2002). This is a unique feature considering many other parasites 
that are mostly confined to tropical or subtropical regions.   
 
The extraintestinal stage occurs in all infected animals, in both the definitive and 
intermediate hosts; and produces the rapidly multiplying form of the parasite- 
tachyzoites, and under immune pressure, eventually changes into the chronic infection 
form - bradyzoites. The causative agents for the extraintestinal stage infection are 
mostly the consumption of oocysts or bradyzoites-contaminated food and water. Other 
modes of transmission include congenital infection through transplacental transmission 
12 
 
in infected pregnant females, blood transfusion and organ transplant from infected 
donors (Hill & Dubey, 2002). 
 
In humans, ingestion of tissue cysts in uncooked, infected meat or contaminated 
water results in the rupture of the cysts, releasing bradyzoites that are either 
phagocytosed or infects epithelial cells, differentiates into tachyzoites and disseminates 
throughout the host via the blood and lymph. Tachyzoites measure approximately 6 X 2 
µm and are generally crescentic (Dubey et al., 1998). It is the acute stage form of the 
disease and is the actively replicating form that invades all organs, rapidly proliferating 
until a threshold limit where the parasite egresses and ruptures the host cell. In immune 
dysfunction, the tachyzoites’ repeated replication and host cell lytic destruction causes 
widespread necrotic lesions that are the hallmark tissue pathology of a toxoplasmosis 
infection. The tachyzoites also invades immune-privileged sites such as the central 
nervous system (CNS), the brain, eye and muscles (including the heart) (Elsheikha & 
Khan, 2010). The widespread dissemination and persistence in its host can be attributed 
to one of the parasite’s striking ability to subvert infected host cells and to breach the 
blood-brain barrier. T. gondii is known to employ the ‘Trojan horse’ mechanism in 
hijacking migratory leukocytes to transport the tachyzoites to distant tissues (Tardieux 
& Ménard, 2008); as well as to disseminate by paracellular transmigration across 
biological barriers (Barragan & Sibley, 2002). Contrary to oocyst, tachyzoites are very 
sensitive to extreme temperatures and can penetrate the buccal mucosa. Tachyzoite is 
the virulent form of T. gondii and causes a strong inflammatory response and tissue 
destruction, and therefore is responsible for the clinical manifestations of this disease 
(Montoya & Liesenfeld, 2004).  
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The host usually can arrest this phase of infection by mounting an immune 
response, and the parasite is then pressured into differentiating into the quiescent 
bradyzoite form which is eventually isolated in tissue cysts enclosed in a thin 
membrane. Studies have well established that a reduction in growth rate of the parasite 
results in a switch from tachyzoite to bradyzoite, and hence the promotion of 
cytogenesis (Ellis, Sinclair, & Morrison, 2004).  The infected individual then acquires a 
lifelong immunity against toxoplasmosis provided the host remains immunocompetent. 
Bradyzoites are morphologically identical to tachyzoites but multiply slowly, express 
stage-specific molecules, and are functionally different. Bradyzoites are also more 
resistant to proteolytic degradation than tachyzoites (Jacobs, Remington, & Melton, 
1960). Tissue cysts (about 60 µm in diameter) can contain hundreds of bradyzoites and 
are typically sequestered in the brain, liver, and muscles (Dubey et al., 1998). One of the 
most distinguishing features of its life cycle is that Toxoplasma tissue cysts  are 
generally undetected and inaccessible by the immune system, and because of this the 
parasite remains dormant for the lifetime of the host as long as the person remains 
immunocompetent (He, Grigg, Boothroyd, & Garcia, 2002; Zhang, Halonen, Ma, 
Wittner, & Weiss, 2001). However, once the immune system is impaired, reactivation 
of latent infection can cause widespread tissue damage and severe pathology such as 
cerebral encephalitis due to the rupture of the tissue cysts releasing active infection. 
 
 
2.2- Epidemiology  
 
T. gondii is a major cause for food- and water-borne protozoal infection (Tenter, 
Heckeroth, & Weiss, 2000) with the status of being the third highest cause of food-
borne mortality in the United States (Mead et al., 1999). Due to the remarkably broad 
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tissue-range and host-range of T. gondii, toxoplasmosis infection is widespread globally 
with an estimated 500 million humans being seropositive for the parasite (Dubey, 
1996). However, the prevalence of infection in both humans and animals may differ in 
different parts of the world due to varying environmental conditions, culture and 
healthcare awareness (Dubey, 1996).  
 
In the United States, approximately 20-25% of adolescents and adults have 
laboratory evidence of infection. That means at least 1 out of every 4 individuals in the 
American population is infected. Toxoplasmosis is one of the diseases comprising the 
‘TORCH’ infections (T. gondii, Others [if done, e.g. syphilis, varicella zoster virus, 
human immunodeficiency virus, parvovirus, herpes virus 6 and 8, enterovirus and 
Epstein-Barr virus], rubella, cytomegalovirus [CMV] and herpes simplex viruses 
[HSVs]). TORCH refers to a group of infections that can pose a serious threat to the 
developing foetus or neonate by causing congenital illness or death (Abu-Madi, Behnke, 
& Dabritz, 2010). T. gondii infection has been known to cause perinatal death if the 
organism is acquired during pregnancy (Nissapatorn & Abdullah, 2004), or blindness 
(retinochoroiditis), fetal mental and psychomotor retardation, encephalitis, hepatitis, 
intracranial calcifications, and hydrocephaly (Abu-Madi et al., 2010).  
 
The current prevalence of chronic toxoplasmosis among the Malaysian 
population is estimated to vary between 10-50% (Nissapatorn, Lee, & Cho, 2003). 
There is an upward trend of an increase in toxoplasmosis seroprevalence in the general 
healthy Malaysian population from 20% to 30% from 1985 to 2004 (Nissapatorn & 
Abdullah, 2004). There is also a significant percentage of latent toxoplasmosis 
seroprevalence in Malaysian pregnant women of 49% (Azmi et al., 2003), a surprisingly 
high rate compared to previous studies conducted. This implies that the rate of disease 
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transmission may be on the increase with a particular risk for mothers who are infected 
for the first time during pregnancy (J. Jones et al., 2003). In a study conducted in the 
U.S. the rate of congenital transmission of toxoplasmosis is approximately 1 in every 
1000 live births (Roberts, Murrell, & Marks, 1994), while the rate of congenital 
transmission in Malaysia is currently unknown. However, the increasing trend of 
seroprevalence in the general Malaysian population should warrant intensified research 
efforts and diagnostic vigilance for pregnant women. Mothers infected for the first time 
during pregnancy lack the secondary immune response necessary to prevent disease 
transmission to their unborn foetus during gestation and this may result in severe 
congenital disease or spontaneous abortions.  In Europe, toxoplasmosis has been 
identified as a serious disease and compulsory screening for pregnant women is being 
practiced in many countries (Fishback; & Frenkel, 1991). However, in Malaysia, the 
‘TORCH’ infections testing protocol is not yet a rule of practice. Studies done in 
different parts of the world showed a wide range of varying seroprevalence for 
toxoplasmosis, from 17.2% in Singapore (Wong, Tan, Tee, & Yeo, 2000) to 67% in 
Brazil (Reiche et al., 2000).  
 
Specific treatment for immunocompetent non-pregnant adults and adolescents is 
usually not necessary because infection of definitive and intermediate 
immunocompetent hosts is generally asymptomatic  (Newton, 1999; Piper & Wen, 
1999). In rare instances symptoms in otherwise healthy humans may include mild 
malaise, lethargy, and lymphadenopathy (Gagne, 2001). These symptoms are self-
limited, and would normally spontaneously resolve in weeks to months. Seroconversion 
occurs primarily between the ages of 15 and 35 (Gagne, 2001). Most cases of 
toxoplasmosis in humans are acquired by the inadvertent ingestion of either tissue cysts 
in infected inadequately cooked meat, or oocysts in food or water contaminated with the 
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definitive host’s (Felids) feces, through handling of litter boxes or outdoors in the soil 
through gardening and through handling of unwashed fruits and vegetables. T. gondii 
can also be transmitted through organ transplantation from an infected donor causing 
recrudescence of infection due to the immunosuppressed state of the organ recipients on 
corticosteroids (Brooks & Remington, 1986). In rare instances, infection can also occur 
through blood or leukocytes transfusions (S. E. Siegel et al., 1971) and also laboratory 
mishaps by contact with contaminated needles, glassware and animals (Jack S. 
Remington & Gentry, 1970).  
 
Following oral ingestion, the cysts releases sporozoites from oocysts or 
bradyzoites from tissue cysts which rapidly penetrates the intestinal epithelium and 
differentiates into tachyzoites (Sumyuen, Garin, & Derouin, 1995). Tachyzoites have 
the proficient ability to disseminate throughout the host through the hijacking of 
migratory leukocytes, particularly dendritic cells (DC) and macrophages (Lambert & 
Barragan, 2010) to transmit to the developing fetus through the placenta and to gain 
access to immunologically pristine sites such as the central nervous system (CNS). The 
parasite’s invasion across the blood-brain barrier results in severe neurodegeneration 
and toxoplasmic encephalitis.   
 
The most significant morbidity and mortality associated with reactivated T. 
gondii infection in AIDS patients is caused by toxoplasmic encephalitis (Elsheikha & 
Khan, 2010). Congenital infections are largely subclinical, but infants that do develop 
disease may be aborted or may suffer severe and irreversible cognitive impairments and 
retinochorditis blindness. Toxoplasmosis is touted as a significant health care burden 
due to the parasite’s ability to survive and persist within its host. Congenital disease 
manifestations often require life-long healthcare and institutionalization for children 
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suffering from the irreversible cognitive dysfunctions arising from the disease. 
Although 50% of cases of toxoplasmosis are caused by contaminated food and water, 
the economic burden is primarily related to congenital toxoplasmosis, at a cost of 
approximately USD 5.2 billion per year in 1994 (Roberts et al., 1994), and an escalating 
cost of USD 7.7 billion per year in 1996 in the United States alone (Buzby & Roberts, 
1996). Findings by the New England Screening Program in year 2000 indicates that 
screening for IgM positive neonates in the American population costs USD 220,000 to 
screen 100,000 infants per year and is translated to USD 30,000 per infant identified 
(Lopez, Dietz, Wilson, Navin, & Jones, 2000). In view of the potential lifelong 
monetary and social costs for raising a visually impaired or intellectually compromised 
child, this is quite a reasonable cost-to-benefit ratio (Roberts & Frenkel, 1990). These 
findings provide a strong basis for intensified research to be done on therapeutic 
intervention and vaccines against toxoplasmosis. Therefore, a recombinant scFv against 
toxoplasmosis would be beneficial as an alternative non-teratogenic management of this 
silent disease, which is a safer option for pregnant mothers. 
 
 
2.3- Toxoplasmic Pathogenesis  
 
Unlike many pathogenic bacteria, T. gondii does not produce any cytolytic 
toxins; tissue necrosis is caused by intracellular multiplication of tachyzoites, followed 
by localized inflammation. In adults, the incubation period for toxoplasmosis infection 
ranges from 10 to 23 days if contaminated, undercooked meat is ingested; and from 5 to 
20 days after ingestion of oocysts from cat’s feces (J. Jones et al., 2003). The acute 
infection phase generally occurs in the initial 8-12 days where tachyzoites actively 
replicate and disseminate in host tissues (Carruthers, 2002). After the parasite’s invasion 
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into enterocytes, T. gondii infects antigen-presenting cells (APCs) in the intestinal 
lamina propria, and stimulates a strong and persistent T-helper-1 (Th1) response 
characterized by production of proinflammatory cytokines including interleukin 12, 
interferon-γ (IFN-γ), and tumour necrosis factor α (TNFα) (Gigley, Fox, & Bzik, 2009). 
The synergistic action of these cytokines and other immunological mechanisms protects 
the host against rapid multiplication of tachyzoites and the resulting pathological 
implications, therefore striking a delicate balance in ensuring the survival of the host 
and the parasites’ persistence (Yap & Sher, 1999). Within 2-weeks after infection, IgG, 
IgM, IgA, and IgE antibodies against many T. gondii proteins can be detected (Montoya 
& Liesenfeld, 2004). Production of IgA antibodies on mucosal surfaces can protect the 
host against the sequelae of reinfection. In this case, reinfection can occur, but the host 
seems to be free from the clinical pathology of the disease and congenital transmission 
of the parasite (Montoya & Liesenfeld, 2004). 
 
The cytokine IFN-γ secreted from antigen-specific T-cells is the major mediator 
of resistance in acute toxoplasmosis. As the host’s proinflammatory responses gains 
momentum over several weeks, IFN-γ progressively inhibits tachyzoite replication, 
leading to differentiation to bradyzoites and encystation (Bohne, Heesemann, & Gross, 
1994; Suzuki, Conley, & Remington, 1989). The formation of the slower-replicating 
bradyzoites marks the beginning of the chronic infection phase. As a parasite adaptation 
strategy, the chronic infection phase effectively promotes the parasite’s survival by 
changing its morphological form and encapsulating itself within tissue cysts which are 
immunologically inert (Ferguson & Hutchison, 1987). The parasite persists within the 
host as a life-long chronic infection in this semi-dormant bradyzoite-containing tissue 
cysts stage. These tissue cysts are mostly sequestered within the brain, and to a lesser 
extent, in muscle tissues and other organs (Bohne et al., 1994). Within the brain, 
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bradyzoites were detected in astrocytyes, neurons and microglial cells (Fischer, Nitzgen, 
Reichmann, Groß, & Hadding, 1997). This latent form of infection remains silent 
throughout the lifetime of the host as long as the immune system is fully functional. 
However, in the wake of an impaired immune system, excystation takes place releasing 
bradyzoites from the ruptured tissue cysts which differentiates back into tachyzoites and 
rapidly begins its lytic cycle. This toxoplasmic disease reactivation causes widespread 
tissue destruction and severe pathology. 
  
 The severity of disease closely correlates with the immune status of the infected 
person. Severe disease is typically observed in congenitally infected children by 
transplacental transmission and also in immunocompromised individuals. This 
opportunistic infection is among the most major cause of mortality in AIDS patients, 
which is a situation that is exacerbated in underdeveloped countries with limited 
financial resources and infrastructure to acquire and distribute the anti-retroviral drugs 
(Brindle, Holliman, Gilks, & Waiyaki, 1991). Thirty percent to 50% of HIV-positive 
patients with latent T. gondii infection will develop toxoplasmic encephalitis (TE) when 
afflicted with severe immune dysfunction (Benjamin J. Luft & Remington, 1992).   
 
Patients with moderate to severe immune impairment are significantly more 
prone to reactivation of latent infection. Reactivated infection causes the most severe 
clinical manifestation to the CNS, which is toxoplasmic encephalitis (TE) - an important 
and severe pathology of opportunistic toxoplasmosis in immunocompromised patients. 
TE results in multiple large necrotic abscesses in the brain, some as large as over 4.0 cm 
in diameter (Figure 2.3) (Carruthers, 2002). Initiation of TE occurs through localized 
parasite growth from the initial site of tissue cysts, which rapidly expands into spherical 
plaques of tissue necrotic lesions. These multiple lesions are most often observed in the 
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cerebral hemisphere and basal ganglia through magnetic resonance imaging (MRI) and 
computed tomography (CT) scans (Carruthers, 2002). Due to the tachyzoites’ 
aggressive lytic cycle, the necrotic lesions in TE shows complete obliteration of host 
cells in the center of the plaques, with infected cells only being seen at the periphery of 
the expanding necrotic plaques (Strittmatter, Lang, Wiestler, & Kleihues, 1992). 
 
 
 
 
 
 
 
 
 
Clinical presentation of TE consists of either focal or non-focal neurological 
dysfunction. Focal neurological deficits arising from TE includes hemiplegia, 
hemisensory loss, cerebellar tremor, hemiparesis, visual field defects, cranial nerve 
FIGURE 2.3 Disease 
pathogenesis of toxoplasmosis. 
Several symptoms of Toxoplasma 
gondii infections are Toxoplasmic 
Encephalitis (TE) which can be seen in this cerebral MRI scan of an AIDS 
patient showing two ring-enhancing lesions (A); retinochoroiditis which can 
be seen as retina scarring (B); and hydrocephalus in a congenitally-infected 
infant (C). (Adapted from Dubey & Beattie, 1988 for (C); and Miro & 
Alvarez-Martinez, 2011 for (A); Stanford, Tomlin, Comyn, Holland, & 
Pavesio, 2005 for (B)) 
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palsies, aphasia, severe localized headache, and convulsions (Benjamin J. Luft & 
Remington, 1992). On the other hand, non-focal TE manifestations include weakness, 
disorientation, frank psychosis, lethargy and confusion (Benjamin J. Luft & Remington, 
1992). Progression of the infection can also lead to coma and death. Reactivation of 
latent infection leading to TE is significantly correlated to CD4 levels that drop below 
100 cells per cubic millimeter in patients with simultaneously existing human 
immunodeficiency virus (HIV) and T. gondii infection (Nissapatorn et al., 2004). In the 
weakened immune state, the bradyzoites differentiates back into tachyzoites and rapidly 
proliferates in microglia and astrocytes (Lüder, Giraldo-Velásquez, Sendtner, & Gross, 
1999). Other accompanying severe manifestations of the disease may include 
splenomegaly, polymyositis, dermatomyositis, myocarditis, hepatitis, chorioretinitis, 
pneumonitis, and multisystem organ failure (Gagne, 2001). Experimental reactivation of 
chronic latent T. gondii infection in laboratory animals can be initiated by 
administration of corticosteroids, anti-lymphocyte serum and other immunosuppressants 
(Dubey, 1996). Disease reactivation can also occur in other immunosuppressed states, 
such as systemic lupus and transplant recipients. 
 
T. gondii disease transmission can also occur from pregnant women to their 
unborn fetus via the placenta. The disease transmission rarely occurs to women who 
were infected at least 4 to 6 months or earlier prior to conception as the protective 
immunity gained from the previous infection protects the developing fetus from vertical 
transmission upon subsequent exposures (Tenter et al., 2000). However, acute infection 
and reactivation of latent infection due to immunosuppression can transmit the parasite 
transplacentally and cause severe sequelae to the fetus. The propensity for congenital 
disease is lowest in the first trimester of maternal infection (10 to 25 percent) and 
highest in the third trimester of maternal infection (60 to 90 percent) (J. S. Remington, 
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McLeod, Thulliez, & Desmonts, 2001). Clinical disease is often more severe in 
congenital infections acquired during the first two trimester of pregnancy (Dunn et al., 
1999).   Congenital T. gondii infection often involves the brain and retina and may 
result in a wide spectrum of clinical disease. Mild infection may lead to slightly 
impaired vision, whereas severely diseased infants may exhibit a classic tetrad of signs: 
retinochoroiditis, hydrocephalus, convulsions, and intracerebral calcifications. 
Hydrocephalus is the rarest but most dramatic lesion of congenital toxoplasmosis 
whereas visual impairment is the most common sequelae (Figure 2.3). Congenitally-
infected premature infants may develop CNS and ocular disease in the first 3 months of 
life, while full-term infants usually present milder symptoms such as lymphadenopathy 
and splenomegaly in the first 2 months of life (J. Jones et al., 2003; Montoya & 
Remington, 2000). Most congenitally-infected infants are born without any obvious 
clinical presentation of toxoplasmosis upon routine newborn examination. But up to 80 
percent of infants infected in utero will develop learning or visual impairments later in 
life (C. B. Wilson, Remington, Stagno, & Reynolds, 1980), with ocular disease (focal 
chorioretinitis) potentially occurring even at the third decade of life or later. Long-term 
sequelae resulting from congenital toxoplasmosis include seizures, spasticity, visual 
impairment, deafness and mental retardation (J. Jones et al., 2003).  
 
Due to its highly promiscuous ability to infect virtually all warm-blooded 
organism, T. gondii is capable of causing severe pathology in animals other than 
humans. Cats, dogs, and many other warm-blooded pets can die of pneumonia, 
hepatitis, and encephalitis due to toxoplasmosis. It is one of the leading causes of 
abortion in pigs, sheep and goats in many countries, including Australia and the United 
States (Dubey, Miller, Desmonts, Thulliez, & Anderson, 1986; J.-H. Kim et al., 2009; 
Pereira-Bueno et al., 2004). Among meat-producing animals, tissue cysts are frequently 
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found in infected pigs, sheep and goats; and less frequently found in infected poultry, 
rabbits, dogs and horses (Tenter et al., 2000). Sheep and goats show the highest titer of 
seroprevalence in many areas of the world, at 92 and 75 percent respectively. Pork is 
generally considered a major source of T. gondii infection in Europe and the U.S. with 
tissue cysts being found in most commercial cuts of pork (Dubey, Murrell, Fayer, & 
Schad, 1986). However, in 1992, a current management practice of raising pigs for 
unprocessed pork consumption in well-managed indoor facilities has led to a dramatic 
decline of T. gondii infection prevalence from 14.0 % to 0.9 % in Austria (Edelhofer, 
1994). The difference in seroprevalence in different animals may be affected by several 
factors such as animal containment, hygiene of stables, type of feed and regulatory 
enforcement of farm management (Tenter et al., 2000). 
  
 
2.4- Diagnosis of toxoplasmosis 
 
 Diagnosis of toxoplasmosis is largely dependent on serological tests. Parasites 
are normally scarce in body fluids and tissues and thus difficult to isolate for histologic 
examination, except for cases of extremely high parasite tissue burden. Clinical signs 
alone are too ambiguous for the definite diagnosis of this parasite infection as symptoms 
of toxoplasmosis appears similar to several other infectious diseases. Definitive 
diagnosis is especially vital in pregnant patients because administration of early 
treatment can protect the fetus against the sequelae of acute toxoplasmosis.  
 
In initial diagnosis screenings, the IgG and IgM antibody levels against T. gondii 
is tested in pregnant women. IgM antibody level is used to aid in determining the 
approximate time of infection and to rule out acute infection. Normally, a positive IgG 
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result and a negative IgM result is interpreted as an infection that was acquired at least 6 
months prior to testing. Recommendation for best practice is to collect a second blood 
serum sample from IgM-positive subjects at 2-4 weeks after the first sample. A 4 to 16-
fold rise in antibody titer in the second sample is indicative of an acute infection (Hill & 
Dubey, 2002). However, the persistently elevated levels of IgM antibodies even after 18 
months of T. gondii infection has made this routine diagnosis complicated (M. Wilson 
& McAuley, 1999). This diagnostic complication is further compounded by occurrences 
of false-positives in commercial tests (M. Wilson et al., 1997).   Determining the 
recency of infection is especially crucial in pregnant women due to the risk of 
transplacental disease transmission and the need for medical intervention to minimize 
damage to the developing fetus (Hill & Dubey, 2002). Therefore, a positive IgM test 
result should be followed up by a referral to a Toxoplasma Reference Laboratory where 
the possibility of acute infection is confirmed and the time-frame of infection is 
narrowed through the use of specific tests or serological profiles such as the IgG avidity 
test, IgM immunofluorescent (IFA) test, IgM enzyme-linked immunosorbent assay 
(ELISA), IgA ELISA, IgE ELISA and differential agglutination (Jenum, Stray-
Pedersen, & Gundersen, 1997; Liesenfeld et al., 2001; M. Wilson et al., 1997). 
However, at the present time, Malaysia does not have an official Toxoplasma Reference 
Laboratory to date, although the Institute of Medical Research and a few private 
pathology centers can provide serological testing for T. gondii infection. 
 
The most reliable, sensitive and specific serologic tests for toxoplasmosis 
available presently are the Sabin-Feldman or Methylene Blue dye (MBD) test (Sabin & 
H.A., 1948) and the IgM Indirect Fluorescent Antibody (IFA) tests (J. S. Remington & 
Miller, 1966). The MBD test is useful in the diagnosis of toxoplasmosis in patients with 
ocular disease as these patients normally have low titers of T. gondii antibodies. Despite 
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the advantages of specificity and sensitivity conferred by the MBD test, it has some 
significant drawbacks that render the test less suited to large volumes of infection 
analysis. The MBD test is expensive and requires the use of viable, virulent tachyzoites 
as antigen to be screened against the test serum, and thus poses a potential health hazard 
to pathology lab personnel  (Dubey & Beattie, 1988).  
 
 The IgM indirect fluorescent antibody (IFA) test overcomes some of the 
drawbacks of the MBD test. The IFA test does away with the health hazard associated 
with the use of live, virulent T. gondii and instead uses commercial preparations of 
killed tachyzoites as antigen with a test sensitivity comparable to the MBD method 
(Dubey & Beattie, 1988). However, the IFA test also has its disadvantages as it requires 
the use of microscopes with UV light, and specific fluorescent anti-species globulin for 
each species to be tested – making this an expensive assay. In addition, false positives 
may also occur in the IFA test for hosts with anti-nuclear antibodies (Dubey, 1996). 
Although the IFA test is not perfect, it is useful for diagnosis of acquired acute 
toxoplasmosis in humans (Dubey, 1996), but is not an economically-viable option for 
animal diagnostics. Other serologic tests that offer several different advantages are the 
indirect hemagglutination test, the latex agglutination test (LAT), modified 
agglutination test (MAT), and the enzyme-linked immunoabsorbent assay (ELISA). The 
agglutination tests presents low health hazard risks as soluble T. gondii antigen 
commercial preparations are used, requires no special equipments or conjugates and are 
easy to carry out. The MAT is widely used in animal diagnosis of toxoplasmosis 
(Dubey, 2007). The shortcoming of the agglutination tests is its’ low sensitivity as it 
lacks the ability to detect acute infection (Dubey, 1996). ELISA tests perform better in 
terms of sensitivity compared to the agglutination tests.  
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 Once it has been confirmed that a pregnant mother is infected with 
toxoplasmosis, the next step is to determine whether her fetus in utero is also infected. 
Monoplex and multiplex Polymerase Chain Reaction testing of amniotic fluid (PCR-
AF) is useful for the identification or exclusion of fetal T. gondii infection using the B1 
gene as a target sequence (Burg, Grover, Pouletty, & Boothroyd, 1989) . The PCR-AF 
method is also a safer and more sensitive test option compared to fetal blood sampling 
while allowing earlier detection of fetal infection (Foulon et al., 1999; Hohlfeld et al., 
1994).  
 
In clinical cases of HIV-positive or immunocompromised patients with impaired 
immune function, histologic examination or PCR screening can be used to diagnose T. 
gondii infection using cerebrospinal fluid, tissue biopsies, and vitreous body from 
patients with suspected ocular toxoplasmosis (uveitis) (Costa et al., 2001; Dabil, Boley, 
Schmitz, & Van Gelder, 2001; Vidal, Colombo, Penalva de Oliveira, Focaccia, & 
Pereira-Chioccola, 2004). Rapid diagnosis can be made by making simple impression 
smears of lesions on glass slides, fixation with methanol and staining with one of the 
Romanowsky stains such as the Giemsa stain. Other methods in aiding diagnosis 
includes the identification of T. gondii bradyzoites using periodic acid Schiff (PAS) 
staining, immunohistochemical staining of the parasite with fluorescent or other forms 
of anti-T. gondii antisera conjugates and electron microscopy (Hill & Dubey, 2002). 
When staining fails to result in definite diagnosis, for example in tissue samples with 
degenerating parasites common in lesions; inoculation of biopsy materials into 
laboratory mice or cell cultures can aid diagnosis (Hill & Dubey, 2002).  
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2.5- Treatment and management of Toxoplasmosis 
 
Toxoplasmosis in humans is widely treated with a combination of sulphadiazine 
and pyrimethamine (Daraprim) (Guerina et al., 1994). The commonly used 
sulfonamides: sulfadiazine, sulfamethazine and sulfamerazine, are all effective against 
toxoplasmosis. The pyrimethamine and sulfonamide treatment need to be administered 
in combination with folinic acid (Leucovorin) to alleviate the suppressive side effects 
on the bone marrow caused by the folic acid inhibitory reaction of the drugs. 
Pyrimethamine and sulfonamide works synergistically in interfering with folic acid 
synthesis by inhibiting the enzymes dihydrofolate reductase from the folic-folinic acid 
cycle; and dihydropteroate synthetase from the p-aminobenzoic acid (PABA) pathway 
respectively. These drugs are effective against tachyzoites, but not against bradyzoite or 
the encysted form of the parasite, and thus cannot fully eradicate the infection (Hill & 
Dubey, 2002; Hokelek, 2009). Sulfa drugs must be administered in daily divided doses 
because sulfa compounds are excreted within a few hours of administration.  
 
Pregnant women with a positive serologic profile for acute toxoplasmosis is 
treated with Spiramycin (Rovamycin) to prevent vertical transmission of the parasite to 
the fetus (J. Jones et al., 2003). Spiramycin achieves high tissue concentration in the 
placenta and inhibits parasite transmission across the placenta (Gagne, 2001). 
Generally, pyrimethamine (pregnancy category C drug) is not prescribed to pregnant 
women before confirmation of fetal infection due to the bone marrow suppressive and 
teratogenic effect of the drug. However, once amniocentesis diagnosis by PCR-AF 
confirms that the developing fetus is already infected in utero, pyrimethamine 
(Daraprim), sulphadiazine and Leucovorin (folinic acid) treatment regime is prescribed 
for the affected mother. However, it is a general rule of practice that pyrimethamine is 
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never administered before the 12th week gestation period (Pastorek, 1994). Evidence 
shows that the pyrimethamine-sulphadiazine treatment regime reduces the risk of 
congenital toxoplasmosis by 70% and effectively crosses the placental barrier (Gagne, 
2001). Postnatally, congenitally-infected infants are continued on the standard treatment 
regime of sulphadiazine and pyrimethamine in conjunction with antibiotics and 
leucovorin (folinic acid) for 1-2 years (J. Jones et al., 2003) to prevent late sequelae and 
relapse of toxoplasmosis, especially the occurrence of chorioretinitis.  
 
In HIV-positive patients with clinical presentation of TE, the standard treatment 
regime consists of pyrimethamine with sulphadiazine or clindamycin (Dannemann et 
al., 1992; Benjamin J. Luft & Remington, 1992). However, this treatment frequently 
causes severe allergic and hematotoxicity side effects that forces the discontinuation of 
therapy (Dannemann et al., 1992). An alternative treatment with less toxic side effects is 
the drug Atovaquone which blocks the parasite’s respiratory chain, and is effective 
against both the tachyzoite and cystic form of T. gondii (Baggish & Hill, 2002; 
Chirgwin et al., 2002; Shubar et al., 2009). Other drugs that have been used to treat 
more difficult cases of toxoplasmosis in sulfa-drugs hypersensitive adult patients 
includes rifabutin, doxycyclin, the macrolide antibiotic azithromycin, and 
clarithromycin (Araujo, Suzuki, & Remington, 1996; Rothova, Bosch-Driessen, van 
Loon, & Treffers, 1998). However, alternative treatments with these macrolides have 
proven to be less efficacious (Fernandez-Martin et al., 1991; Hagberg, Palmertz, & 
Lindberg, 1993; Saba et al., 1993). 
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2.6- Invasion of host cells 
 
 T. gondii invasion is by parasite-directed active penetration into host cells. This 
process is dependent on parasite motility powered by the parasite’s actin-myosin motor 
(Dobrowolski, Carruthers, & Sibley, 1997; Dobrowolski & Sibley, 1996). Initiation of 
Toxoplasma invasion begins by the orientation of the parasite’s apical end towards the 
host cell surface (Chiappino, Nichols, & O'Connor, 1984; T. C. Jones, Yeh, & Hirsch, 
1972). Invasion is an active process that not only depends on the apical-polarized 
attachment of the parasite onto host cell surface, but also the gliding motility 
locomotion of T. gondii whereby the parasite adhesin - host receptor complex linkage is 
translocated towards the posterior end of the parasite along a tight apposition structure 
known as the moving junction (MJ) during parasite penetration. As the parasite enters, it 
progressively slides into a parasitophorous vacuole (PV) which resists acidification and 
fusion with lysosomes (Joiner et al., 1990; Mordue, Håkansson et al., 1999), forming a 
safe haven for Toxoplasma to replicate within the confines of the PV (Figure 2.4). The 
invasion event is rapid with complete penetration of the parasite into the host cell by 15 
to 30 s. During invasion, there is a peculiar constriction of the parasite as it squeezes 
through the MJ into the host cell (reviewed in Black & Boothroyd, 2000) (Figure 2.5). 
This active parasite-directed invasion process is distinct from Toxoplasma phagocytosis 
observed with professional phagocytes such as macrophages. Phagocytosis is a 
comparatively slow process (2 to 4 min), with no apical orientation of the parasite, no 
obvious MJ constriction deformity, and also a more spacious endocytic vacuole 
compared to the tight confines of a PV in active invasion. 
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FIGURE 2.4 Schematic model of Toxoplasma gondii invasion. The rhoptry bulbs 
(grey), rhoptry necks (red) and microneme simultaneously release their contents during 
the invasion process and collaborate to form the moving junction (MJ). The MJ 
migrates down the length of the parasite forming a ring of contact with the host plasma 
membrane which effectively excludes host integral membrane proteins to form the 
parasitophorous vacuole membrane (PVM). (Adapted from Alexander, Mital, Ward, 
Bradley, & Boothroyd, 2005; and John C. Boothroyd & Dubremetz, 2008) 
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FIGURE 2.5 Toxoplasma gondii 
tachyzoite constriction at the moving 
junction during invasion. A TEM image 
of a T. gondii tachyzoite invading a HeLa 
cell (HC). Rhoptry exocytosis yields an 
irregularly shaped organelle (asterisk) near 
the apical cytoskeleton (AC). The host cell 
membrane-derived parasitophorous 
vacuole membrane (PVM) is seen closely 
enveloping the parasite portion that has 
invaded the host cell. Invasion is thought 
to be driven by parasite actin-myosin 
motors acting at the moving junction 
(MJ). Scale bar represents 0.5 µm. 
(Adapted from John C. Boothroyd & 
Dubremetz, 2008; and Jean Francois 
Dubremetz, 1998) 
 
 
 
 
 
 
There are 3 distinct secretory organelles in T. gondii that plays crucial roles in 
the invasion and establishment of infection within its host and whose function critically 
depends on the precisely orchestrated sequence of secretory discharge in the invasion 
process. The first two organelles – the micronemes and rhoptries, are located at the 
apical end of the parasite, whereas the third organelle – the dense granules (DG) are 
dispersed in the parasite’s cytoplasm. It is speculated that T. gondii compartmentalizes 
its secretory proteins in separate organelles according to common function, thereby 
promoting its regulated order of secretion during invasion (Carruthers, 2002).  
 
Upon initial contact of the apical pole of Toxoplasma on a host cell surface, 
micronemes would be the first to discharge its secretory contents that functions in 
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parasite attachment and penetration into host cells.  There are approximately 100 
micronemes that are localized to the apical end of T. gondii, which can dynamically 
shuttle along the parasite’s microtubules or microfilaments to the extreme apical tip 
where it fuses with the plasma membrane and deploys its protein content at the 
initiation of invasion (Carruthers, Giddings, & Sibley, 1999). Following microneme 
secretion, the rhoptries immediately begin to inject its protein contents into the host cell 
cytoplasm at the invasion loci (Barbara A. Nichols, Mary Louise Chiappino, & G. 
Richard O'Connor, 1983). Usually, there are 8-16 rhoptries per parasite. During 
invasion, the club-shaped rhoptries fuse with the parasite’s cell membrane at the apical 
tip and discharge their protein content into the nascent PV via the fused channel formed 
at the conoid (B.A. Nichols, M. L. Chiappino, & G. R. O'Connor, 1983). Besides this, 
ROP proteins from the rhoptry bulb are also deployed into the host cell via small 
vesicles known as evacuoles. Subsequently, the ROP-containing-evacuoles fuse with 
the developing PV and disperses the ROPs onto the cytosolic face of the PVM 
(Hakansson, Charron, & Sibley, 2001).  The rhoptry proteins functions in PV biogenesis 
and host organellar (mitochondria and ER) attachment to the PV as well as parasite 
virulence (Beckers, Dubremetz, Mercereau-Puijalon, & Joiner, 1994; Nakaar et al., 
2003; Qiu et al., 2009). A study to discover the composition of the PV showed that 
approximately 20% of the PV membrane is generated by the parasite rhoptries during 
penetration, while the majority of the membrane is derived from the host cell (Suss-
Toby, Zimmerberg, & Ward, 1996). Early invasion events captured on electron 
micrographs shows membranous whirls being secreted from rhoptries lumen and which 
is possibly responsible for the extension of the PV encapsulating T. gondii (Barbara A. 
Nichols et al., 1983). 
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Finally, the parasite’s DG secretes its protein into the PV lumen once invasion is 
complete with the PV budding off from the host cell membrane and T. gondii is fully 
enveloped within the PVM. The DG proteins play crucial roles in the structural 
modification of the PV, nutrient acquisition from its host cell and also promoting the 
parasites’ replication by endodyogeny within the PV confines (Cesbron-Delauw, 1994). 
  
 Among the three organelles, the micronemes have the most significant 
conservation among all apicomplexan parasites (Carruthers, 2002). Therefore, it is 
speculated that micronemes may be essential in apicomplexan parasite invasion and has 
generated a growing interest and intensified research efforts at discovering and 
characterizing its’ proteins. There are several characteristics of microneme proteins 
(MICs) that have been elucidated through several studies. The first is that nearly half of 
it is predicted to be Type 1 membrane proteins with a single membrane-spanning 
domain located near the C-terminus. This is a divergence from other previously 
characterized Toxoplasma surface proteins (SAGs) that are tethered on the cell 
membrane surface by linkage to glycosylphosphatidylinositol (GPI) anchors (J. C. 
Boothroyd, Hehl, Knoll, & Manger, 1998). This is an important distinction from the 
SAG family surface proteins because the membrane-tethered MICs allows it to be the 
bridge proteins between host cell receptors and the parasite’s internal actin-myosin (or 
actomyosin) motor that powers the gliding translocation essential for parasite invasion. 
This is because GPI-bound proteins are only linked to the cell membranes’ lipid moiety 
and do not interact with the underlying parasite actomyosin. In particular, the TgMIC2-
TgM2AP microneme-secreted protein complex is found to be co-localized to the MJ 
during Toxoplasma invasion, implicating these proteins to be directly involved in the 
motility-dependent host cell invasion (Rabenau et al., 2001). However, the MIC2 
protein is only transiently detectable on the parasite surface when there is contact with 
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the host cell and is proteolytically released from the cell surface once invasion is 
complete (Vern B. Carruthers et al., 1999). 
 
The membrane-spanning domain of several MICs characterized thus far contains 
recognition sequences for rhomboid proteases, which is essential for intramembrane 
proteolytic cleavage of the MIC adhesins in order to disengage receptors for the 
completion of its’ invasion (Brossier, Jewett, Sibley, & Urban, 2005; reviewed in 
Dowse & Soldati, 2004; Reiss et al., 2001). Interestingly, this membrane-spanning 
domain of surface MICs is a site that is conserved for all Apicomplexan microneme 
proteins (Opitz et al., 2002), implying the essential nature of the intramembrane 
proteolysis event for effective release of the PV from host cell membrane. Another 
adaptation of the MIC proteins is that it consists of domain structures homologous to 
vertebrate adhesive proteins such as integrins, thrombospondin and epidermal growth 
factor (EGF) (reviewed in Tomley & Soldati, 2001), which is a feature that potentially 
resolves the reason for the parasite’s remarkable ability at establishing infection in a 
wide range of host and nucleated cells. The MICs also appear to require being in the 
form of adhesive complexes in order for it to be functional (Carruthers, 2002). To date, 
there are three MIC complexes discovered – they are the TgMIC1-TgMIC4-TgMIC6 
(Reiss et al., 2001), TgMIC3-TgMIC8 (Meissner et al., 2002), and TgMIC2-TgMIC2-
associated-protein (or TgMIC2-TgM2AP) (Rabenau et al., 2001).  
 
There are several postulates as to the reason why it is the general rule that MICs 
function in complexes, the first is that some heterologous members of the protein 
complex function as ‘quality control’ chaperons that is needed to allow the complex to 
exit the Golgi apparatus on its way to the micronemes (reviewed in Carruthers, 2002; 
Reiss et al., 2001). Targeted genetic disruptions of TgMIC1 and knockout mutation of 
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TgM2AP caused its respective complex partner MIC proteins to be retained in the Golgi 
and endoplasmic reticulum (ER) instead of reaching its intended destination in the 
microneme (My-Hang Huynh et al., 2003; Reiss et al., 2001). The second postulate is 
that MIC proteins function in the form of complexes because each complex consists of 
one membrane-spanning protein required for correct microneme targeting, membrane 
anchoring, and intramembrane proteolytic cleavage to disengage host receptor 
attachments upon successful completion of invasion; while at least another one of the 
MIC proteins would be responsible for binding to host cell receptors. The Toxoplasma 
parasite’s broad host and target cell range may be attributed to the MIC proteins’ 
homologous vertebrate adhesive protein domains which confers the ability of pervasive 
lectin-like binding to extracellular matrix proteins commonly expressed among 
vertebrate cells such as laminin and heparan sulfate proteoglycans (HSPG) (Carruthers, 
Hakansson, Giddings, & Sibley, 2000; Furtado, Slowik, Kleinman, & Joiner, 1992). 
Therefore, the MIC proteins achieve its’ multifaceted role in the invasion of target cells 
by forming multimeric complexes of MICs with distinct functions – some for 
membrane anchoring, some for receptor binding and some as ‘quality control’ 
chaperons. 
 
Ca2+ signalling seems to play a crucial role in T. gondii invasion processes. 
Microneme discharge is triggered by a Ca2+-dependent signaling pathway. This 
condition can be simulated by the addition of calcium ionophores or short chain 
alcohols to elevate Ca2+ levels and specifically trigger microneme release (Carruthers, 
Moreno, & Sibley, 1999; Carruthers & Sibley, 1999). On the other hand, addition of a 
Ca2+ chelator, such as BAPTA-AM, not only blocked microneme secretion, but also 
abrogated parasite’s attachment to host cells (V. B. Carruthers et al., 1999), inhibited 
gliding motility and invasion into host cells by > 90% compared to controls 
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(Mondragon & Frixione, 1996; Mondragon, Meza, & Frixione, 1994). Although the T. 
gondii Ca2+-dependent signaling pathway has not been fully elucidated, there are 
evidence of two calcium-dependent protein kinases – which is TgCDPK1 and 
TgCDPK2, that  have been shown to function in the regulation of motility and host cell 
attachment (Billker, Lourido, & Sibley, 2009; Kieschnick, Wakefield, Narducci, & 
Beckers, 2001). These kinases may directly or indirectly influence micronemal 
discharge. Another invasion protein which may be dependent on Ca2+ signaling is the 
secretion of a phospholipase from rhoptries that was formerly termed as a penetration 
enhancement factor (PEF) (Lycke & Norrby, 1966; Saffer & Schwartzman, 1991) for its 
role in causing morphological degeneration of host cell membranes and thus facilitating 
host cell entry. These discoveries imply that Ca2+ signaling may be an important 
pathway to target for therapeutic inhibition of T. gondii invasion into host cells. 
 
     
2.7- Toxoplasma Replication and Egress 
 
The lytic cycle of T. gondii consists of parasite invasion, replication and egress. 
Following invasion, the parasite commences replication within the confines of the PV in 
a process known as endodyogeny (Zypen & Piekarski, 1967). However, for replication 
to effectively take place, T. gondii seems to modify its PVM to allow for nutrient 
acquisition in order to support parasitic growth. Toxoplasma is auxotrophic for purine 
biosynthesis and therefore needs purine salvage in order to persist and proliferate within 
its host (Schwartzman & Pfefferkorn, 1982). There are two features of T. gondii to 
facilitate this; firstly, the porous structure of the PVM (size exclusion limit ~ 1.3 kDa) 
which is presumably formed by DG protein secretions, allows the acquisition of purines 
in the form of ATP from the host cytosol. Secondly, the parasitic enzyme NTP 
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hydrolase (NTPase) that was discovered in the PV lumen (Asai et al., 1995; Asai, 
O'Sullivan, & Tatibana, 1983) may be responsible in the purine salvage process by 
hydrolyzing host ATP into adenosine for T. gondii utilization in nucleic acid synthesis 
(Schwartzman & Pfefferkorn, 1982). The NTPase may possibly not be the only enzyme 
involved in the purine salvage process and like many other parasitic invasion and 
metabolic processes - it may be a redundant pathway. However, this remains to be 
elucidated in greater details. Other than purines, the parasite is also auxotrophic for 
tryptophan, arginine, polyamines, cholesterol, iron and other essential nutrients 
(reviewed in Laliberté & Carruthers, 2008). To circumvent this, T. gondii acquires its 
nutrients from host cells via both passive and active transport at the PVM which 
consists of elaborate pores that allows the passage of small, soluble metabolites within 
the range of 1.3 – 1.9 kDa, such as glucose, amino acids, nucleotides and ions (Schwab, 
Beckers, & Joiner, 1994). 
 
Immediately following invasion, T. gondii also modifies the PVM to support its 
rapid growth and replication. Within 4 hours post-infection, the PVM recruits host 
mitochondria and ER to be intimately joined to its surface (Sinai, Webster, & Joiner, 
1997), presumably for lipid trafficking into the parasite; and also recruits host endo-
lysosomal vesicles selectively for scavenging host cholesterol (Coppens et al., 2006). 
The remodeling of the PVM during Toxoplasma parasitism is caused by the 
sequestration of DG proteins. In particular, GRA3 was found to be involved in ER 
attachment to the PVM (J. Y. Kim, Ahn, Ryu, & Nam, 2008), and GRA7 was found to 
be intimately associated with host endolysosomes for cholesterol salvage (Coppens et 
al., 2006). The association between the PVM and the host mitochondria and ER remains 
stable throughout the evolution of the PV. 
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T. gondii endodyogeny replication begins with the formation of a pair of nascent 
pellicular membranes from the middle of the cell. This membranous structure extends 
itself from its tip that resembles a rudimentary conoid and microtubule-organizing 
center to delineate each daughter cells. This is followed by the formation of nascent 
micronemes and rhoptries at the apical tip of each daughter cell while the mother cell 
grows more spherical to accommodate the growing daughter cells. The mitochondria, 
apicoplast and nucleus would then begin to divide between the daughters. As the 
progenies continue to grow, the cytoplasm and all of its other contents would divide 
between the 2 daughters until eventually the mother’s inner membrane complex (IMC) 
disintegrates and the original plasmalemma envelopes the two daughter cells. Finally, 
the two new cells begin to separate extending from the anterior pole throughout most of 
the cell but maintains a residual linkage at the posterior end. This posterior pole 
attachment results in the ‘rosette’ formation as the parasite continues to replicate within 
the PV (Figure 2.6) (reviewed in Carruthers, 2002; Zypen & Piekarski, 1967). 
 
 
FIGURE 2.6 Intracellular 
Toxoplasma gondii rosette 
formation. A confocal 
fluorescent microscopy 
image of a T. gondii rosette 
(green). (Image courtesy of 
Kamal, from the Albert 
Einstein College of 
Medicine, New York)   
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When T. gondii replication reaches a critical threshold within host cells, the 
parasites will rupture the PV and release highly motile tachyzoites out of the host to 
rapidly invade neighbouring cells in a process known as egress. Parasite egress causes 
cell lysis and necrotic foci that is responsible for the pathogenesis of the disease. The 
egress of even a single Toxoplasma parasite out of the host cell is enough to cause the 
lytic destruction of the cell. 
 
Parasitic egress is triggered by Ca2+ signaling, and can be induced by addition of 
calcium ionophores such as the A23187 drug to cell cultures infected with T. gondii 
(Endo, Sethi, & Piekarski, 1982; Pressman, 1976). This drug increases the permeability 
of cell membranes for the passive diffusion of Ca2+ and results in an increase of Ca2+ 
levels within the PV. This is followed by parasite movement within the PV, the rupture 
of the PV, rapid migration of the parasites through the host cytosol and puncturing out 
from the host plasmalemma and cell membrane (Endo et al., 1982). The reducing agent 
dithiothreitol (DTT) is also capable of inducing parasite egress (Stommel et al., 1997). 
DTT stimulates parasite egress by activating the parasite’s vacuolar NTPase, which 
degrades the host ATP and ADP for purine salvage, followed by elevated levels of 
cytoplasmic Ca2+ and parasite egress (Silverman et al., 1998). Activation of NTPase 
from just a single parasite is sufficient to exhaust the entire pool of host ATP within 
minutes, triggering egress (Silverman et al., 1998); which explains why cell destruction 
can occur even in infections with just a single tachyzoite. Although the link between 
NTPase activation and the parasite’s elevated vacuolar Ca2+ level is uncertain, these 
observations implies that NTPase influences the intracellular Ca2+ flux and parasite 
egress (Stommel et al., 1997).  
 
 
40 
 
2.8- Immune Evasion and Host Cell Subversion 
 
T. gondii has the remarkable ability to invade and establish infection in nearly 
all nucleated cells. This ability has led to many fascinating discoveries on the strategies 
utilized by the parasite to manipulate host cellular responses in order to establish 
infection and to cause widespread dissemination. T. gondii has an obligate intracellular 
existence, and is adapted to rapidly invade host cells to avoid the host’s cellular and 
humoral immunity capable of killing extracellular pathogens. Therefore, an 
immunotherapy strategy to circumvent the infection is to inhibit the parasite’s cellular 
invasion. 
 
Parasite dissemination occurs through several routes – the paracellular pathway, 
the transcellular traversal, and the leukocyte-assisted transfer which is also known as the 
Trojan Horse mechanism (Figure 2.7) (reviewed in Lambert & Barragan, 2010; 
reviewed in Tardieux & Ménard, 2008). Both the paracellular and transcellular systemic 
dissemination involves extracellular T. gondii, whereas the Trojan Horse mechanism 
involves intracellular T. gondii. The parasites’ competent ability at systemic 
dissemination results in unhampered Toxoplasma invasion into immunologically-
privileged sites such as the blood-brain barrier, the blood-retina barrier, the blood-testis 
barrier and the placenta where it causes the most severe pathology (reviewed in Lambert 
& Barragan, 2010).  
 
In the paracellular route, T. gondii tachyzoites uses its gliding motility 
locomotion to breach intercellular junctions and traverse between the host cell linings 
without disrupting the integrity of the epithelial layer. In a study conducted by Barragan 
and co-workers, it was shown that the parasite’s micronemal adhesin MIC2 interacts 
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with host cell ICAM-1 in the paracellular transmigration of T. gondii across cellular 
barriers (Barragan, Brossier, & Sibley, 2005). As for the transcellular pathway, active 
invasion by the parasite may result in the breaching of the apical surface of an 
endothelial cell and exit through the basolateral side. It is still a theoretical pathway as 
there has been no documented evidence to prove (or disprove) it. However, it is a 
characteristic translocation observed in the dissemination of highly motile Plasmodium 
sporozoites (Mota et al., 2001) and may possibly be a yet unobserved pathway utilized 
by T. gondii.  
 
 
 
FIGURE 2.7 Strategies for Toxoplasma gondii dissemination across cellular 
barriers. (I) Parasites may transmigrate via its gliding motility through the intercellular 
junctions without disruption of the integrity of the cellular barrier (paracellular 
traversal); or may actively invade the apical part of the cell and exit through the 
basolateral side (transcellular traversal). (II) The parasites can also disseminate through 
infected leukocytes (WBC) by the Trojan Horse mechanism, or (III) binding to 
apoptosis-inducing   ligands on the endothelial barrier which may induce parasite egress 
from the infected WBC, with subsequent parasite traversal. (Adapted from Lambert & 
Barragan, 2010) 
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In the Trojan Horse mechanism, T. gondii is known to hijack migratory 
leukocytes (WBC) to breach cellular barriers. When a host ingest oocysts or tissue cysts 
through contaminated food or water, the zoites infects enterocytes within the gut lumen 
to initiate its’ parasitic lytic cycle. Infected enterocytes secrete chemokines such as 
monocyte chemotactic protein 1 (MCP-1 / CCL-2), macrophage inflammatory proteins 
1α and β (MIP-1α and β / CCL-3 and CCL-4), and MIP-2 / CXCL2, which is 
responsible for the recruitment of leukocytes to the inflammatory site of the lamina 
propria, followed by the hijacking of the migratory leukocytes by the zoites (Buzoni-
Gatel et al., 2001; Luangsay et al., 2003).  Within 3 hours post-invasion, infected human 
and murine dendritic cells (DCs) and macrophages adopts a hypermotility phenotype 
and disseminates the parasite to distant organs and immunoprivileged sites such as the 
brain (Courret et al., 2006; Lambert, Hitziger, Dellacasa, Svensson, & Barragan, 2006). 
In an alternative mechanism, leukocytes infected with tachyzoites may cross the 
placenta to cause congenital infection through the paracellular route. The maternal-fetal 
interface consists of layers of protective fetal trophoblast cells to prevent maternal 
transmission of cytotoxic adaptive immune response, as well as cytolytic mediators 
such as perforin and Fas/Fas ligand (FasL) which normally restricts leukocytes passage 
and provide host defense against infection (Crncic et al., 2005). However, T. gondii-
infected leukocytes may still circumvent this epithelial barrier by active egress out of 
infected leukocytes upon binding of the apoptosis-inducing Fas ligand or perforin-
mediated cytotoxicity, followed by paracellular traversal into neighboring cells, 
including the specific targeting immune cells itself which triggered the parasite egress 
(E. K. Persson et al., 2007), thereby promoting its dissemination. 
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Extracellular tachyzoites are resistant to non-immune human serum but sensitive 
to antibody-mediated lysis (Couper, Roberts, Brombacher, Alexander, & Johnson, 
2005). Therefore, its dissemination strategy is to allow parasite translocation away from 
the inflammatory site and into the circulation where it can be sequestered into 
immunologically-restricted tissues for protection. Toxoplasma translocation occurs 
either through the extracellular route which involves direct tissue penetration by motile 
parasites via the paracellular pathway or through leukocyte-mediated transfer (Trojan 
Horse mechanism). The preference and kinetics of the pathways utilized by the parasite 
to assure its propagation is strain-specific and differs between each genotype. T. gondii 
is mainly divided into three distinct genotypes which differ genetically by not more than 
1 % (Sibley & Boothroyd, 1992; Su et al., 2003). The murine-virulent Type 1 parasite 
exhibits superior transmigratory capacity via the extracellular route and higher growth 
rates resulting in rapid dissemination and higher parasite tissue burden (Barragan & 
Sibley, 2002). In contrast, Type II and Type III parasites have a significantly less potent 
transmigratory capacity and demonstrates lower virulence in mice (Jeroen P. J. Saeij, 
Boyle, Grigg, Arrizabalaga, & Boothroyd, 2005). Despite this reduced virulence, it is 
the Type II genotype that is most prevalent in human infections globally (Darde, 2004). 
The Type II and Type III genotype preferentially disseminates through the leukocyte-
mediated transfer route and achieves significantly higher parasite loads in the 
circulation, while Type I tachyzoites are substantially less efficient in exploiting host 
leukocytes for dissemination (Lambert, Vutova, Adams, Lore, & Barragan, 2009). In 
acute infection, Type II and Type III parasites are found intracellularly in the circulation 
soon after infection whereas the Type I parasite preferentially invades the mesenteric 
circulation as extracellular parasites (Courret et al., 2006). In terms of disease 
pathogenesis, severe human toxoplasmosis is usually associated with Type I and rare, 
atypical strains; while the more prevalent Type II strain causes varied disease severity 
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(Darde, 2004). Mice are hypersensitive to Type I infection, and the lethal dose is a 
single viable parasite; whatever the genetic background of the mice may be. Type II and 
Type III strains cause less aggressive infections with a 50% Lethal Dose (LD50s) in 
mice of > 103 , with variations between different host genotype backgrounds (Jeroen P. 
J. Saeij et al., 2005). Taken together, this indicates that the efficiency of the tachyzoites’ 
exploitation of the host leukocytes-mediated transfer pathway or the direct tissue 
penetration pathway is strain-specific; with Type I strain being most proficient at direct 
tissue penetration via extracellular parasites, while Type II strain is superior at 
leukocyte-mediated transfer for its tachyzoite-shuttling function and dissemination. 
 
Following active invasion, T. gondii induces a hypermotility phenotype in 
human and murine macrophages and DCs. This phenotype is characterized by random 
directional amoeboid-like motion, increase in speed, distance and transmigratory 
capacity across epithelial cells (Lambert et al., 2006) which may be a post-
transcriptionally regulated event (reviewed in Lambert & Barragan, 2010). To gauge the 
impact of infected DCs on murine host parasitic burden and pathogenesis, a study was 
conducted by adoptive-transfer of T. gondii-infected DCs into immunologically-
compatible mice. The findings showed that infected DCs caused a substantially more 
rapid dissemination of T. gondii to distant organs and a more severe pathogenesis 
compared to intraperitoneal inoculation with extracellular parasites (Lambert et al., 
2006). Interestingly, this hypermotility phenotype exhibited by infected DCs can be 
abrogated by inhibiting leukocyte motility (Lambert et al., 2006).  Presumably, the 
hypermotility phenotype of infected DCs is controlled by Gi-protein coupled receptors 
(Gi-PCR) signaling which mediates leukocyte chemotaxis through binding of 
chemokines to the G protein receptors (reviewed in Lambert & Barragan, 2010; Rot & 
von Andrian, 2004). 
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The T. gondii parasite is not only capable of hijacking immune cells as a conduit 
for its dissemination, but the parasite is also capable of evading the host immune 
defenses to ensure its propagation. Cell-mediated cytotoxicity is an important immune 
defense mechanism of the host to protect against pathogen infections. Cytotoxicity can 
be induced by two mechanisms: the first is via the induction of apoptosis upon death 
receptor ligation by effector T cells (both CD4+ and CD8+) and NK cells, and the 
second is via the secretion of perforin and granzymes by cytotoxic lymphocytes. 
However, Toxoplasma infection not only renders both of these cytotoxic mechanisms 
ineffective in eradicating the parasite but is instead redirected for its disseminative 
advantage. When effector T cells engages the death receptors on infected target cells, it 
does not show characteristic signs of apoptotic degradation, but instead triggers rapid 
parasite egress which releases highly infectious parasites that infects other surrounding 
cells, including the specific effector T cell themselves (Figure 2.7) (E. K. Persson et al., 
2007). This death receptor-induced egress pathway is stimulated by caspase activation 
and a concomitant release of intracellular calcium (E. K. Persson et al., 2007). The 
perforin or granzyme-cytotoxicity pathway also triggers the same signature rapid 
parasite egress that leaves necrotic cell and tissue abscesses in its wake with 
transmission of infectious tachyzoites to its surrounding cells, although this process 
does not depend on the caspase activation of the apoptotic mechanism. T. gondii has 
also been shown to be able to infect cells of the innate immune system. In particular, 
perforin-dependent NK cells targeting infected DC for cytotoxic destruction has been 
shown to trigger parasite egress and became infected themselves along with other 
surrounding cells (C. M. Persson et al., 2009). In addition, these infected NK cells are 
themselves not efficiently targeted by non-infected NK cells for perforin-dependent 
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killing (C. M. Persson et al., 2009), which may be another novel mechanism for parasite 
sequestration and immune evasion. 
 
Toxoplasma infection of the Type I strain induces a vigorous Th1 immune 
response and extremely elevated levels of pro-inflammatory cytokines such as 
interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-12 (IL-12), and IL-
18, whereas infection with Type II and Type III strains produce a more modest Th1 
response (Gavrilescu & Denkers, 2001; Mordue, Monroy, La Regina, Dinarello, & 
Sibley, 2001). The moderated Th1 immune response seen in the less virulent Type II 
infections leads to controlled infection and minimal tissue damage with latent infection 
of bradyzoites sequestered within immune-privileged tissues (Lang, Groß, & Lüder, 
2007). It has been proposed that the inflammatory Th1 immune response to T. gondii 
infection may be necessary to prevent intermediate host mortality and thereby promote 
the parasite’s life-long quiescent persistence within its host (Lambert & Barragan, 
2010). Despite elevated levels of the principal Th1 cytokine IFN-γ in T. gondii infected 
cells, the increased cytokine level seems ineffective in the stimulation of inducible nitric 
oxide synthase (iNOS) and MHC class II within macrophages (Lüder, Algner, Lang, 
Bleicher, & Gro, 2003). Zhao and co-workers have also shown that IFN-γ-primed 
macrophages infected with T. gondii are also capable of resisting the microbicidal 
effects of the immunity-related GTPase (IRG) protein family (Y. Zhao et al., 2009). 
However, this immune-evasion mechanism is only observed within the virulent Type I 
Toxoplasma infection in which fully armed macrophages resist IRG-mediated 
disruption of its PVM and escape autophagic destruction (Y. Zhao et al., 2009). This 
IRG-mediated resistant phenotype was also observed in infected murine fibroblasts 
(reviewed in Y. O. Zhao et al., 2009). Genome-wide transcriptional profiling lends 
support to these observations as it was elucidated that there is a globally repressive 
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effect of T. gondii infection on IFN-γ activated cells that causes silencing of the 
cytokines’ default modulation of host immune response to eliminate infection (S.-K. 
Kim, Fouts, & Boothroyd, 2007). Toxoplasma infection inhibits STAT1 function in the 
nucleus and subsequently blocks the STAT1-induced expression of IFN regulatory 
factor 1 (IRF1), which is a transcription factor for many of the IFN-γ responsive genes 
(S.-K. Kim et al., 2007). This immune-silencing effect in the midst of strong IFN-γ 
activity is possibly a contributing factor to the parasite’s persistence within the host.   
 
Toxoplasma infection also induces the production of immune-regulatory and 
anti-inflammatory cytokines such as IL-10, transforming growth factor-β (TGF-β) and 
lipoxin which dampens the Th1 immune response, deactivates macrophages and lessens 
immune-associated pathology (reviewed in Lang et al., 2007; Machado & Aliberti, 
2006). Collectively, this indicates that T. gondii maintains a delicate balance between 
stimulation and suppression of host immune responses in order to persist and survive 
within its host and to allow propagation to subsequent intermediate hosts. 
 
Another host immune response to limit infections caused by viruses, bacteria, 
and eukaryotic pathogens is by the induction of apoptosis or programmed cell death. 
Apoptotic cells emit signals for macrophages activation and phagocytic engulfment of 
the infected cells. In addition to the ability of the parasite to subvert host cells to its 
advantage for dissemination across cellular barriers and nutrient acquisition, T. gondii 
has also evolved mechanisms to impede the apoptotic immune response and avoid rapid 
clearance by macrophages. The apoptosis pathways involve the activation cascade of a 
class of cysteine proteases known as caspases. It has been observed that Toxoplasma 
normally manages to silence the apoptotic immune response by impairing the host’ 
caspase activation at multiple points in the pathway. The apoptotic process for the 
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elimination of pathogen-infected cells can be induced via several pathways: the 
mitochondrial apoptotic pathway (Williams, 1994), the death receptors (Fas/CD95 or 
TNF-R) ligation pathway (Dockrell, 2003; Krammer, 2000), and the perforin and 
granzymes-mediated killings by NK cells or T cells (reviewed in Lieberman, 2003). T. 
gondii has been shown to inhibit apoptosis in the first two pathways, and to redirect 
perforin and granzymes-mediated cytotoxicity to cause rapid parasite egress for its 
dissemination to adjacent cells, including the immune cells that triggered the egress 
itself (Denkers et al., 1997; C. M. Persson et al., 2009; E. K. Persson et al., 2007). 
 
In the death receptor pathway, ligation of the TNF-R or Fas death receptors on 
the target cell plasma membrane will trigger the assembly of a complex known as the 
death-inducing signaling complex (DISC). The DISC complex then activates caspase 8, 
which in turn induces the suicide spiral of the caspase cascade of apoptosis. In T. gondii 
infection, activation of caspase 8 is antagonized by aberrant proteolytic cleavage and 
degradation, leading to inhibition of apoptosis in infected cells (Vutova et al., 2007). In 
the mitochondrial apoptotic pathway, the suicide spiral is normally induced by stress or 
DNA damage to the cell, and is initiated by the mitochondrial release of cytochrome c 
into the cytosol. Cytochrome c then induces the caspase cascade beginning with the 
activation of caspase 9 and followed by the proteolytic cleavage of caspase 3, which 
leads to the cell undergoing self-catabolism (Lemasters et al., 1999). However, this 
apoptotic process is also inhibited in T. gondii-infected cells by the substantially 
lowered cytochrome c release and consequently the muted activation of caspase 9 and 
caspase 3 activity (Carmen, Hardi, & Sinai, 2006; Keller et al., 2006). 
 
In addition to the ability of T. gondii infection to impair or evade elimination by 
the three apoptotic pathways, the parasite also modulates the host cell signaling factors 
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to enhance anti-apoptotic mechanisms. Toxoplasma infection has been shown to be able 
to restrain apoptosis via interference of the NF-κB pathway. The NF-κB proteins are 
transcription factors that promotes the transcription of anti-apoptotic factors such as the 
cellular inhibitors of apoptosis proteins (c-IAPs) and Bcl2-family proteins (Stehlik et 
al., 1998). It is maintained in an unactivated state by the inhibitor κBα (IκBα) protein 
within the cytosol. When the IκBα protein is phosphorylated by the IκB kinase (IKK) 
complex, this leads to the degradation of IκBα and the subsequent activation of NF-κB 
which is translocated to the nucleus. At the nucleus, the NF-κB proteins upregulates the 
transcription of anti-apoptotic genes (reviewed in Ghosh & Karin, 2002). In T. gondii-
infected cells, phosphorylated IκBα (p-IκBα) protein is found not only in elevated levels 
(Molestina, Payne, Coppens, & Sinai, 2003), but in sustained increase and concentrated 
on the T. gondii PVM (Molestina et al., 2003), implying a parasite-directed event and 
resulting in the upregulation of the NF-κB target genes (Molestina & Sinai, 2005). A 
study conducted by Molestina and co-workers showed that this sustained NF-κB target 
genes upregulation is a result of a two-step process in which the host’s IKK is 
responsible for the initial NF-κB activation, and the parasite’s IKK (TgIKK) sustains 
the activation when the host IKK activity wanes; resulting in effective maintenance of 
the host cell in an anti-apoptotic state (Molestina & Sinai, 2005). However, this pattern 
of  NF-κB activation does not happen for all cell types infected with T. gondii, 
particularly in macrophages whereby the translocation of NF-κB to the nucleus is 
blocked (Butcher, Kim, Johnson, & Denkers, 2001). Another factor that complicates the 
disease intervention endeavours of this highly complex parasite is that there are also 
some differences in the modulation of host immune responses between immune cells of 
monocytic origins (such as macrophages and dendritic cells) and other non-immune 
cells in a T. gondii infection.  
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Other than the inhibition of NF-κB to the nucleus, Toxoplasma infection in 
macrophages induces the phosphorylation of the transcription factors STAT3 and 
STAT6 from the Janus kinase (JAK)/STAT pathway. The parasitic protein responsible 
for this is the rhoptry protein ROP16, which is implicated to be involved in parasite 
replication and virulence (J. P. J. Saeij et al., 2007). However, the ROP16-induced 
phosphorylation of STAT3/6 differs between different parasite strains. Infection with 
Type II parasites results in a transient increase in phosphorylated STAT3/6, but it is not 
sustained; unlike infection with Type I and Type III parasites with sustained 
phosphorylation of STAT3/6 even after 18 hours post infection (J. P. J. Saeij et al., 
2007). The lack of STAT3/6 suppression in Type II parasites may explain the reason 
why it is a less virulent infection. The inability to sustain STAT3/6 phosphorylation in 
Type II infection leads to overproduction of proinflammatory cytokine IL-12 (Robben 
et al., 2004; J. P. J. Saeij et al., 2006), which stimulates specific T-cells to produce IFN-
γ, resulting in the activation of NK cells to limit the infection and suppress parasite 
replication (reviewed in Laliberté & Carruthers, 2008). By contrast, the dampening of 
the production of IL-12 in Type I-infected macrophages leads to unhampered parasite 
replication and febrile disease. Although there is effective sustenance of STAT3/6 
phosphorylation in Type III strain infection, it still lacks the aggressive virulence 
observed in Type I infection, suggesting that there are more virulence factors at play 
other than ROP16. It has been speculated that the absence of ROP18 expression within 
Type III T. gondii may be the explanation for its suppressed virulence (reviewed in 
Laliberté & Carruthers, 2008).   
 
Another anti-apoptotic mechanism within mammalian host cells is the 
phosphoinositol 3 kinase (PI3K) pathway, which stimulates a phosphorylation cascade 
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that ultimately activates a key kinase known as Akt/PKB. T. gondii-infected cells shows 
elevated levels of phosphorylated Akt/PKB (L. Kim & Denkers, 2006).  The activated 
Akt/PKB kinase seems to be like a pivotal point where it influences several pro- and 
anti-apoptotic factors, such as causing the inactivation of pro-apoptotic proteins caspase 
9 and Bad, suppressing several pro-apoptotic factors like Bim and FasL, and also 
inducing the NF-κB pathway to trigger the transcription of anti-apoptotic genes 
(reviewed in Laliberté & Carruthers, 2008). Although the molecular mechanism of the 
parasite’s interaction with the NFκB and PI3K signaling pathways are not fully 
elucidated, what is clear is that T. gondii possesses the ability to manipulate these 
pathways for the maintenance of infected cells in an antiapoptotic state, and thereby 
promoting its survival and propagation within the host. 
 
 
2.9- Antibody-mediated resistance to Toxoplasmosis 
 
While T cells and IFN-γ are important mediators of the host immune responses 
to resist T. gondii infection, B cells are essential for long-term resistance to the disease 
by the production of specific antibodies (Kang, Remington, & Suzuki, 2000). Kang and 
co-workers demonstrated that although mice deficient in B cells production are capable 
of surviving the acute stage of T. gondii infection, they were susceptible to mortality in 
the chronic stage of infection – mainly due to unrestricted parasite proliferation in the 
brain and lungs causing widespread tissue necrosis (Kang et al., 2000). It was also 
discovered that the absence of specific antibodies is correlated with an increased 
prevalence of tachyzoites and parasitic tissue cysts in the brain and lungs of B-cell 
deficient mice (Kang et al., 2000).  This implies that even with unimpaired T 
lymphocytes response and undisrupted expression of IFN-γ, TNF-α, and iNOS, the 
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absence of antibody production in the host results in reduced resistance to T. gondii and 
chronic stage mortality.  
 
In an experiment where unimmunized mice were repeatedly administered with 
T. gondii-immune serum, the mice still seemed to lack effective disease resistance; 
suggesting that both humoral and cellular immunity of the host needs to act in synergy 
for effective resistance to toxoplasmosis (unpublished observation in Sayles, Gibson, & 
Johnson, 2000). In addition, B cells-deficient mice immunized against T. gondii also 
showed substantially prolonged survival to challenge infection with the virulent RH 
strain compared to unimmunized B cell sufficient mice (Sayles et al., 2000). This again 
lends support to the point that even when humoral immunity is impaired, some host 
resistance from cellular immunity is still developed but is unable to completely stave off 
infection, especially in the chronic stage. However, it is also worth noting that at present 
time, there is no effective and safe human vaccine against the disease of toxoplasmosis. 
 
Although CD8+ T cells and IFN-γ has been established to be critical in host 
resistance to T. gondii, the knockdown of CD4+ helper T cells and the resulting deficient 
antibody responses has been shown to significantly reduce host resistance and impairs 
the host’s successful response to T. gondii vaccination (Johnson & Sayles, 2002; Sayles 
et al., 2000). It was also shown that adoptive transfer of immune serum to syngeneic 
mice with deficient antibody response substantially improved resistance and prolonged 
survival to infection (Johnson & Sayles, 2002), lending further support to the notion that 
antibodies play critical roles in limiting toxoplasmosis pathogenesis. Antibody-mediated 
resistance to T. gondii was previously believed to limit infection in two ways: antibody-
dependent activation of the host’s complement system to rapidly lyse tachyzoites 
(Fuhrman & Joiner, 1989; Schreiber & Feldman, 1980), and phagocytic killing of 
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antibody-coated tachyzoites by activated macrophages (Anderson, Bautista, & 
Remington, 1976). However, a relatively more recent study showed that direct antibody 
inhibition of tachyzoites’ host cell invasion may be the critical factor for resistance 
rather than macrophage and complement-mediated effector mechanisms (Sayles et al., 
2000). Therefore, the protective role of B cells in toxoplasmosis is via the production of 
specific anti-T. gondii antibodies. For complete disease resistance, specific and 
neutralizing antibodies targeted to the parasite are needed. 
 
 
2.10- Engineered antibody fragments 
 
Engineered antibodies have emerged as a strong frontrunner in the arsenal of 
biopharmaceuticals. The global market for monoclonal antibodies (mAb) has been 
increasing since 2009 and achieved the highest combined sales in 2011 worth USD 65 
billion, which included sales of therapeutic, diagnostic and research reagent mAbs 
(Maggon, 2012). Table 2.1 shows this increasing market for mAbs by listing the 
revenues generated by the top ten therapeutic mAbs for the past 3 years. As of year 
2010, there are 30 IgGs and their mAb derivatives on the market (17 mAbs marketed, 
and 1 withdrawn) and at least 130 more in clinical trials (Beck, Wurch, Bailly, & 
Corvaia, 2012). Using recombinant DNA technologies, humanized murine mAbs have 
been developed with enhanced clinical efficiency and have led to regulatory approvals 
for immunoglobulins (Ig) and Fab molecules as immunotherapeutic agents for cancer, 
infectious and inflammatory diseases. Since the advent of mouse, chimeric and 
humanized IgG1 antibodies in the market during the late 1990s, the diversity of 
engineered antibody structures have greatly expanded (Table 2.2). Currently, the 
majority of recombinant protein pharmaceuticals in use in the clinic comprise of mAbs, 
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with a significantly higher success rate (29% for chimeric antibodies, 25% for 
humanized antibodies) (Reichert, Rosensweig, Faden, & Dewitz, 2005) compared to 
small-molecule drugs (11%) (Kola & Landis, 2004).  
 
Recombinant antibodies come in various forms, either as smaller fragments such 
as Fab and single-chain variable fragment (scFv), which are the classic monovalent 
forms; or as engineered variants such as diabodies, triabodies, minibodies and single-
domain antibodies (reviewed in Holliger & Hudson, 2005). Much interest has been 
generated in the area of antibody engineering because of the potential to form potent 
therapeutic and diagnostic agents, particularly for targeting inflammatory, cancer, 
autoimmune and viral diseases (Holliger & Hudson, 2005). This is accompanied by 
many advances in scaffold design, repertoire construction and selection methodologies. 
 
Engineered antibody fragments have the added advantage of being less 
immunogenic with receptors mediating unwanted, inflammatory effector functions 
omitted. The bivalent, Y-shaped IgG is the main serum antibody that is most frequently 
used in nearly all approved antibody drugs (Reichert et al., 2005). In its intact form, IgG 
is a multidomain protein and carries its antigen-binding sites on its two Fab tips while 
the recruitment of effector functions is mediated by the stem Fc domain. There are 
many immunotherapeutic applications however, whereby the Fc-mediated effects are 
undesirable because of the immunogenic response it illicits as well as its cytotoxic 
effects resulting from massive cytokine release. To circumvent this, the Fc domains of 
the IgGs are removed, and genetically engineered into monovalent (Fab, scFv, single 
variable VH and VL domains) or bivalent fragments (Fab’2, scFv2 diabodies, minibodies) 
(Figure 2.8). As only the conserved Fc domains are removed from the final antibody 
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fragment, this exercise does not compromise on the antibody’s specificity or affinity on 
its targets (Holliger & Hudson, 2005). 
 
 
TABLE 2.1 Top ten monoclonal antibodies in 2011 and revenue generated.  
 
Generic Name Brands ®  Companies Indications* Sales $ Billion (USD) 
2009 2010 2011 
     
Infliximab Remicade J&J, Merck, 
Mitsubishi 
Tanabe 
RA, UC, CD, 
Ps, PsA, AS 
6.91 8.0 9.0 
Adalimumab Humira Abbott RA, Ps, JIA, 
PsA, AS, CD 
5.49 6.5 7.9 
Rituximab  Rituxan Roche NHL, RA 5.8 6.7 6.6 
Bevacizumab Avastin Roche Colon Cancer 5.92 6.8 5.8 
Trastuzumab Herceptin Roche Breast Cancer 5.02 5.5 5.7 
Rarubizumab Lucentis Roche, Novartis Wet Macular 
Degeneration 
2.43 3.1 3.6 
Cetuximab Erbitux BMS, Merck 
Serono 
Colon, Head 
and Neck 
Cancer 
2.57 3.2 3.4 
Natalizumab  Tysabri Biogen Idec, 
Elan 
Multiple 
sclerosis 
1.06 1.75 2.6 
Omalizumab Zolair Roche, Novartis Allergic 
Asthma 
0.91 1.1 1.3 
Palivizumab Synagis Astra Zeneca RSV 1.1 1.0 0.975 
Source: Maggon K., Monoclonal Antibodies Market 2008 – 2011, Top Ten Monoclonal Antibodies 2011. 
URL: http://monoclonalantibodies.wordpress.com/2012/03/18/top-ten-mabs-2011/ 
*NHL Non Hodgkin’s Lymphoma, RA Rheumatoid Arthritis, JRA Juvenile Rheumatoid Arthritis,  
JIA Juvenile Idiopathic Arthritis, Ps Psoriasis, PsA Psoriatic arthritis, CD Crohn’s Disease;  
UC Ulcerative Colitis, AS Ankylosing Spondylitis, RSV Respiratory syncitial virus 
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 Engineered antibody fragments are also more economical to produce (compared 
to intact IgG molecules) and more tractable to mutational designs for improvements in 
in vivo pharmacokinetics, stability, affinity, and specificity (Holliger & Hudson, 2005). 
Engineered antibodies have been constructed into multivalent and multispecific 
reagents, conjugated to therapeutic payloads (such as toxins, liposomes, enzymes, 
radionuclides and viruses), mutated for enhanced therapeutic effects on immunosilent or 
refractory targets in enzymes, cell receptors, haptens and other infectious agents. It has 
also been shown that antibody fragments can be designed as robust diagnostic reagents, 
or as non-immunogenic in vivo biopharmaceuticals with better biodistribution and blood 
clearance properties (reviewed in Holliger & Hudson, 2005). Additional benefits 
include amenability to mutational designs which increase the potency of antibody 
fragments and increasing its plasma half-life, therefore allowing for its reduced dosage 
and frequency of administration. This leads to cost reduction for the immunotherapeutic 
drugs, better convenience and improved quality of life for patients (Carter, 2006). 
 
 
 
FIGURE 2.8 Diagram of different antibody formats. An intact classic IgG molecule 
is shown alongside the unusual immunoglobulin-like structures of camelid VhH-Ig and 
shark Ig-NAR. The different formats of antibody fragments shown here include the Fab, 
scFv, single-domain VH, VhH and V-NAR. A variety of multimeric formats depicted 
here are the minibodies, bis-scFv, diabodies, triabodies, tetrabodies and chemically 
conjugated Fab multimers. Approximate size of each antibody format is given in 
kilodaltons. (Adapted from Holliger & Hudson, 2005) 
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TABLE 2.2 Therapeutic antibodies with alternative protein and antibody 
scaffolds.  
 
 Source: (Beck et al., 2012. Strategies and challenges for the next generation of therapeutic antibodies. 
Nat Rev Immunol 10(5), 345-352) 
 
 
 
2.11- Phage-displayed scFv antibody libraries 
 
Library phage display has overtaken hybridoma technology through the creation 
of large natural and synthetic in vitro repertoires of antibody fragments with affinities 
comparable to those generated from hybridoma technology, and the ability to design 
greater antibody affinity to levels that were previously out of reach of the natural 
immune system (Bradbury & Marks, 2004). Phage display enables the presentation of 
large protein or antibody libraries on the surface of filamentous phage, which leads to 
the selection of binding ligands with high affinity and specificity to almost any target. 
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ScFv antibody libaries displayed on phage was first described in 1990, and 
demonstrated how antigen-binding phages can be recovered from selective screening, 
with the added advantage of having the displayed antibody phenotype being encoded 
within the phagemid sequence (McCafferty et al., 1990). Figure 2.9 shows the basic 
overview of a phage-display technology workflow. Additional key strengths of phage-
displayed antibody libraries are that it is a platform that enables direct selection of rare 
binding properties, such as specific species or strain crossreactivity (Popkov et al., 
2004); and also enables the generation of very large panels of polyclonal antibodies 
against a particular antigen (Edwards et al., 2003). At this time of writing, one human 
antibody derived from phage-display technology has been approved and is widely used 
for the treatment of rheumatoid and psoriatic arthritis (Humira, adalimumab; Abbott 
Laboratories) (Carter, 2006), and at least 8 more are in clinical development phase 
(Lowe & Jermutus, 2004).  
 
The intense interest in engineered antibodies development has much to do with 
designing new binding specificities, especially to refractory and immune-evasive targets 
that are inaccessible to the natural immune response (Holliger & Hudson, 2005). Single-
chain variable fragment (scFv) antibodies consist of the antigen-binding domains of Ig 
heavy (VH) and light (VL) chain regions connected by a flexible peptide linker, all 
encoded by a single gene cassette. This popular engineered antibody format retains the 
specificity and antigen-binding affinity of its parent IgG while providing improved 
pharmacokinetics of tissue penetration. ScFv antibodies are preferred over Fab antibody 
formats due to their superior expression levels in bacteria – which leads to cost-
effectiveness, although its yield varies according to the monoclonals to be expressed 
(reviewed in Holliger & Hudson, 2005). In a relatively recent development, the smallest 
known engineered antibody fragment known as domain antibodies (dAbs) (11-15 kDa),  
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whereby the antigen-binding site is concentrated over a smaller area, was developed 
against HIV-1 envelope glycoprotein gp120. This dAb antibody format was derived 
from an initial scFv antibody format and has proved to be potently neutralizing against 
HIV-1 (W. Chen & Dimitrov, 2009). Together with the slew of anti-cancer and anti-
inflammatory scFv-based immunotherapeutics currently developed, this suggests that 
scFv antibodies are being widely established as stable recombinant protein 
biopharmaceuticals. 
 
 
 
 
FIGURE 2.9 Schematic representation of the phage display technology. A phage-
displayed antibody library has its genotype (phagemid) linked to its phenotype. The 
phage-displayed antibody library is used to infect E. coli and subsequently rescued by 
helper phage to produce functional recombinant phage particles. The phage display 
library is then processed through affinity selection (biopanning), and selected phages are 
amplified, characterized and expressed. (Adapted from Galanis, Irving, & Hudson, 
2001) 
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A scFv antibody library is constructed with VH and VL gene pool derived from 
source B-cells (from diverse lymphoid sources such as spleen, bone marrow, peripheral 
blood or tonsils) by PCR-based or similar cloning techniques and subsequently cloned 
into a suitable vector for expression as a combinatorial antibody library. The single gene 
design of scFv simplifies the construction of fusion proteins such as cancer 
immunotoxins and facilitates intracellular expression in eukaryotic cells to suppress or 
neutralize antigen functions. Besides improved tissue penetration, the smaller size of the 
scFv antibodies also means that it is potentially useful for targeting cryptic epitopes that 
reside within immunosilent crevices in many pathogenic agents (especially viruses) 
(Holliger & Hudson, 2005). These cryptic epitopes may be part of the pathogens 
adaptation to allow binding to target receptor but evade host immunosurveillance. Due 
to the limited complementarity-determining region (CDR) diversity in the natural 
immune system, antigen-binding sites of antibodies produced are mainly constrained to 
flat or concave topologies, and rarely penetrate into the cavities of cryptic epitopes 
(Cardoso et al., 2005; Hudson & Souriau, 2003).  
 
An alternative antibody development to target immune-evasive cryptic epitopes 
is the discovery of single V-like domains in camelids (camels and llamas) and 
cartilaginous fish (wobbegong and nurse sharks) (De Genst et al., 2004; Dooley & 
Flajnik, 2005). The distinct characteristic of these high affinity V-like domains from 
these two organisms is that they express long cavity-penetrating loops that are often 
longer than conventional murine and human antibodies which are effective at accessing 
deep cavities and canyons in enzyme active sites and disease biomarkers (De Genst et 
al., 2005; Streltsov & Nuttall, 2005). However, these V-like domains are unsuitable for 
in vivo applications due to its high immunogenicity (reviewed in Holliger & Hudson, 
2005). 
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Generation of scFv using antibody phage display library is now an established 
procedure for the rapid production of panels of high-affinity monoclonal antibodies 
(mAbs) to a wide variety of protein antigens. The advent of the antibody phage display 
system also overcame the limitations associated with the slow and laborious processes 
involved in hybridoma technology. Basically, the scFv gene repertoires are constructed 
by cloning the antigen-binding VH and VL fragments fused to a minor coat protein of 
bacteriophage (PIII). The resulting phage has a functional antibody protein on its 
surface and contains the gene encoding the antibody incorporated into the phage 
genome. The number and affinity of the antibodies generated against a particular 
antigen is a function of library size and diversity, with larger libraries yielding a greater 
number of high-affinity antibodies.  
 
However, it should be noted that most scFvs are a mixture of monomer and 
homodimer (Viti, Tarli, Giovannoni, Zardi, & Neri, 1999). It is essential that when the 
role of binding affinity in targeting antigens is being studied that purified antibodies of 
defined oligomeric state be used for the research. This is because that although the 
affinity of these molecular species towards a monomeric antigen is identical when 
measured in solution, the avidity (or functional affinity) may be higher for a dimerized 
scFv binding to an immobilized antigen due to rebinding effects and by the 
simultaneous binding of two antigens (Crothers & Metzger, 1972; Neri, Montigiani, & 
Kirkham, 1996). Monomeric and dimeric scFvs also have different sizes and 
pharmacokinetics (Adams et al., 1993). It is worth noting that in a study done by Viti 
and co-workers, it was demonstrated that the bivalence and slower clearance of 
antibodies seem to drive the antigen targeting process, despite the increased antibody 
size (Viti et al., 1999). Bivalent antibodies may also present some therapeutic 
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advantages as was demonstrated in a work by Adams and his co-workers, whereby 
divalent antibody-binding has improved tumor retention compared to its monovalent 
counterpart (Adams et al., 1993). 
 
A previous study elucidated that synthetic VH diversity alone may be sufficient 
for the generation of high-affinity antibodies from phage-display; thus, it may be 
possible to do without the VL light chain altogether, significantly simplifying the design 
of scFv libraries (Sidhu et al., 2004). However, although VH domain does play a 
dominant role in antigen binding, several other studies indicate that the VL and non-
hypervariable domains of engineered antibodies do play a significant role in increasing 
antigen binding affinity and overall stability; and thus cannot be ignored in affinity 
maturation refinement endeavours (Boder, Midelfort, & Wittrup, 2000; Lu et al., 2003). 
In general, there are two kinds of library which can be generated: naïve or immune 
antibody libraries. Generally, antibodies isolated from immunized libraries tend to have 
much higher affinities for the immunizing antigen used compared to a naïve library of 
an equivalent size (Bradbury & Marks, 2004; Schoenberger & Crotty, 2008). 
 
Construction of a recombinant scFv targeted against T. gondii could be an 
alternative source of antibodies for diagnostics and perhaps treatment of opportunistic 
and congenital toxoplasmosis. The production of recombinant scFv antibody library 
could potentially be a more cost-effective and easier approach in the development of 
diagnostic reagents for T. gondii and as an alternative anti-toxoplasmosis 
immunotherapy without the risk of teratogenicity associated with some present 
treatment regimen. 
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2.12- The design of phage-displayed antibody libraries 
 
Antibody’s V-regions differ in various pharmacokinetics properties which affect 
the expression of the antibody fragments - such as stability, solubility and folding 
kinetics (Carter, 2006). A key strength of using the phage-display platform to express 
antibody libraries is that it directly selects for favorable antibody properties such as 
optimized binding affinity, robust expression, high stability and solubility during the 
selective screening stage; while disadvantaging weaker and less favorable clones from 
selection (Holliger & Hudson, 2005). Incorporation of rational antibody design into the 
phage-displayed library could also enhance the selection of improved biophysical 
properties, for example, a high-affinity specific antibody could have its’ CDR grafted 
into a more stable antibody framework and subsequently include point mutagenesis at 
framework region residues for increased thermodynamic stability (Ewert, Honegger, & 
Plückthun, 2004; Ewert, Huber, Honegger, & Plückthun, 2003). There are numerous 
qualities that define a prime candidate engineered antibody fragment for clinical 
evaluation as an immunotherapeutic agent. The desirable properties of an antibody 
molecule are subnanomolar affinities, low dissociation constant, potent receptor-
mediated killing of target cells, absence of extracellular toxicity, low immunogenic 
potential and ease of production. As for a high-quality phage-display library, it is one 
that provides high diversity, good expression, stability and solubility; which are 
properties often observed to be co-selected with binding activity (Holliger & Hudson, 
2005).  
 
Generally, the affinity of the antibodies isolated is proportional to the initial size 
of the library used for selection (Vaughan et al., 1996). Therefore, the creation of large 
antibody libraries has become an important goal for the selection of antibodies against 
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any antigen and giving rise to new specificities. Commonly, such libraries are made by 
performing a large number of ligations and transfections. To generate a large repertoire 
of antibody fragments it is certainly necessary to have a large amount of good quality 
DNA and to have good transformation efficiency of competent cells (at least 109 CFU 
transformation efficiency). It is possible to construct libraries of a great size by 
increasing the number of electroporations, from which relatively high affinity antibodies 
can be directly rescued without any further modifications. The number of 
electroporations depends on the amount of DNA- as a general guideline: 500 ng of 
DNA in 4-5 µL of ligation mix with 50 µL of E.coli cells should be used per 
electroporation (Pini, Giuliani, Ricci, Runci, & Bracci, 2004).   
 
However, these libraries are limited resources as reamplification cannot be 
carried out without potential loss of diversity (Rader, Steinberger, & Barbas, 2001). An 
elegant strategy to circumvent this and to create large antibody libraries has taken 
advantage of the Cre recombinase bacteria expression system to drive recombination of 
a primary phage scFv library in a phagemid vector containing two nonhomologous lox 
sites, and infecting the bacteria at a high multiplicity of infection (MOI- 200:1) to cause 
many different phagemids to enter a single bacterium (Sblattero & Bradbury, 2000). 
The primary library can be amplified without a reduction in diversity because diversity 
is regenerated each time recombination comes into play to create each new secondary 
library. Using this approach, a high library diversity of 3 x 1011 has been reported 
although a relatively small primary library was used as starting material (7 X 107 was 
used) (Sblattero & Bradbury, 2000). The in vivo shuffling of the VH and VL genes 
between the lox sites of the polyclonal phagemid vectors creates many new VH/VL 
combinations, all of which are functional (Sblattero & Bradbury, 2000). Recombination 
to create a large library can only be effective when there are many phagemids interred 
65 
 
within each single cell for gene shuffling to take place. But p3 expression from the 
phagemids inhibits this multiple infection from occurring by retarding pilus synthesis. 
However, this inhibition can be lifted by inhibiting p3 synthesis with glucose. 
 
Another effective method of boosting antibody library size involves the use of a 
new generation helper phage, known as hyperphage; integrated into any compatible 
phage display system used. The use of hyperphage may increase the number of scFvs 
presented on filamentous phage particles generated with antibody display phagemids by 
more than two orders of magnitude and significantly blocks the generation of ‘blank’ 
phages (Rondot, Koch, Breitling, & Dubel, 2001). As a result of this considerable 
increase in the fraction of phage particles carrying an antibody fragment on their 
surface, there is a concurrent increase of antigen-binding activity of up to 400-fold, and 
about 17-fold increase in the percentage of positive scFv-phage particles in a selective 
screening using an initial naïve human scFv antibody repertoire (Rondot et al., 2001). 
 
Natural human and mammalian antibody response is restricted by the limited 
diversity of complementarity-determining region (CDR) loop lengths, which constrains 
the displayed antigen-binding surface to mostly flat or concave topologies (Hudson & 
Souriau, 2003). This phenomenon bars the immune system from recognizing and 
accessing cryptic epitopes in the form of narrow cavities (canyons) on antigenic 
surfaces that have evolved within many pathogenic microorganisms to escape 
immunosurveillance. 
 
Further refinements to generate better performing antibodies can include point 
mutations (either random or justified) or combinatorial mutagenesis to improve affinity, 
antigen localization, yield and stability, resistance to aggregation and protease resistance 
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of phage-displayed proteins. The process of creating targeted mutations in the 
antibodies is known as affinity maturation (which will be dealt with in a following 
section). For example, it has been shown in recent structural studies that specific 
targeted mutations in the VH region (such as Gly35) brings dramatic effect to the 
stability of antibody scaffolds and may therefore be the preferred choice in engineering 
more stable antibody variants (Jespers, Schon, James, Veprintsev, & Winter, 2004). 
However, it is worth noting that these mutations to improve stability may only apply to 
some, and not all VH-like domains; and the significant contribution of VL domain to 
stability and overall binding affinity cannot be disregarded as documented in a study 
done by Boder E.T. and coworkers (Boder et al., 2000). The development of 
recombinant antibodies for diagnostic and therapeutic applications demands that the 
designed antibody provides efficient targeting while retaining its’ high-affinity and 
high-specificity. In lieu of this, studies have shown encouraging results that increased 
binding affinity and valence of recombinant antibody fragment could potentially lead to 
improved targeting of antigenic epitopes of up to 760-fold (Viti et al., 1999), and even 
up to the femtomolar range by increased affinity of 1800-fold (Midelfort et al., 2004). 
 
Another aspect in antibody engineering that needs to be considered is the 
expression system used to drive the production of stable, high-affinity mAb in high 
yield. Among the diverse range of expression systems available today (bacteria, yeasts, 
plants, insects, mammalian cell lines and transgenic animals), bacteria expression 
systems are favored for their high expression levels of small, nonglycosylated Fab and 
scFv fragments, diabodies and V domains, with low-cost associated with it (Carter, 
2006); whereas mammalian or plant cells are preferred hosts for high-yield expression 
of larger intact antibodies and minibodies.  
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Efforts to improve recombinant antibody expression have led to the 
development of several strategies. Quite frequently, recombinant antibodies are 
engineered to carry terminal polypeptides such as c-Myc, histidine, GST and the ‘Flag’ 
epitope for the purpose of affinity purification after expression into the periplasm of E. 
coli. Simple and inexpensive large scale recombinant expression is also made possible 
by using a heat-inducible system that minimizes the risk of immunogenicity related to 
using terminal polypeptides (Power et al., 2001). 
 
 
2.12.1 - Antibody multivalent designs 
 
For the purpose of immunotherapeutic applications, the nonequilibrium 
environment of the vasculature and tissues demands that engineered antibodies provide 
slower dissociation rates and higher retention times while maintaining high affinity; 
basically properties that are lacking with even high-affinity monovalent interactions 
(Holliger P. et al, 2005). Therefore, for therapeutic applications it may be favourable to 
fuse monovalent Fab, scFv or V-domain molecules into multivalent formats which are 
capable of engaging two homologous or heterologous targets simultaneously, thereby 
increasing avidity and lowering dissociation rates for cell surface or multimeric 
antigens. The antibody multimers remain smaller than intact immunoglobulin molecules 
(55-110 kDa) and still provide improved antigenic site penetration and faster blood 
clearance (Holliger P. et al., 2005). 
 
In addition, a multivalent antibody fragment can be designed to bind to cell 
surface receptors or effector molecules leading to a desired macrophage activation 
and/or apoptosis through transmembrane signaling pathways, which may result in the 
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neutralization of the target antigen (Linsley, 2005; Teeling et al., 2004). The multivalent 
antibody format is also pliable to conversion to multispecific molecules which allow the 
direct association of 2 differing targets for the engagement of cytotoxic cells or gene 
delivery capsules and immunodiagnostics. It is also now possible to target intracellular 
antigens either through intracellular monoclonal antibody (mAb) fragments 
(intrabodies) by joining the intrabody to a membrane translocator sequence, or through 
a naturally internalizing mAb or direct selection for internalization properties (Milroy, 
2006). 
 
Engineered dimeric, trimeric or tetrameric conjugates of scFv and Fab fragments 
using chemical or genetic cross-links have shown improved avidity, retention and 
internalization properties as compared with the parent IgG (Adams et al., 1993; Holliger 
& Hudson, 2005). It is also interesting to note that the avidity of an antibody seems to 
be more important than affinity, with diabodies formed from lower-affinity scFv 
antibodies consistently achieving increased tumor uptake and retention despite innate 
difficulties for antibodies penetration to the tumor mass due to its surrounding 
vasculature network (Nielsen, Adams, Weiner, & Marks, 2000). Thus, it is now possible 
that antibody fragments with relatively enhanced potency can be engineered by forging 
into multivalent formats to target hitherto immunoevasive epitopes such as those present 
on T. gondii invasion proteins. 
 
The pharmacokinetic properties of engineered mAb fragments can also be 
biochemically altered by several strategies. For instance, polyethylene glycol (PEG) 
linkage (PEGylation) has been very efficient for increasing half-life and scFv stability, 
as well as reducing immunogenicity (Knight et al., 2004). Antibody fragments have 
significantly shorter half-lives (few hours) than its intact antibody counterparts (few 
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weeks) (Carter, 2006). Fusion or noncovalent interaction with long-lived serum proteins 
such as albumin (Huhalov & K.A., 2004) or serum immunoglobulin (Holliger, Wing, 
Pound, Bohlen, & Winter, 1997) is also another effective strategy to extend the serum 
half-life of mAb fragments. Increasing the terminal half-life of antibodies may be 
desirable for improved efficacy, target localization, and reduced dosage and 
administration frequency. However, it may not always be such a good option to extend 
the antibody terminal half-life in applications where it would be more advantageous to 
decrease whole-body exposure or to increase the ratio of target to non-target binding – 
especially in immunodiagnostics imaging settings (Carter, 2006). Therefore, in antibody 
fragment design, the final application in clinical settings needs to be carefully kept in 
mind before embarking on antibody enhancements and modifications. 
 
 Antibody fragments have been conjugated or genetically fused to a wide range 
of molecules that confer auxiliary function following target binding for enhanced 
immunotherapeutics applications; such as cytotoxic drugs, toxins (Bang, Nagata, Onda, 
Kreitman, & Pastan, 2005; Vallera et al., 2005), peptides, proteins (Halin et al., 2002), 
enzymes (Krauss, Arndt, Vu, Newton, & Rybak, 2005; Sharma et al., 2005), liposomes 
for improved drug delivery (Schnyder & Huwyler, 2005) and even viruses for targeted 
gene therapy (Nakamura et al., 2004). However, the problem of immunogenicity 
associated with these bifunctional antibodies will still need to be resolved in order to 
pass clinical testings. A highly promising concept that is of relevant interest to this 
project of generating recombinant antibodies targeted to T. gondii, is the advent of 
immunoliposomes; which are mAb fragments that can potentially deliver drugs to the 
brain as they are able to cross the blood-brain barrier.  
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Although the use of engineered antibody fragments gives the advantage of 
reduced immunogenicity in target recipients, in some applications the mediation of 
immune effector functions such as  antibody-dependent cell-mediated cytotoxicity 
(ADCC) and complement-dependent cytotoxicity (CDC) are desirable in contributing to 
the immunotherapeutic efficacy of target cell destruction (Carter, 2006). Therefore, 
there are antibody fragments that are grafted with engineered Fc regions to stimulate 
effector functions while ameliorating disease pathogenesis. The most convincing 
example of the designed synergy of engineered antibody fragments and the immune 
effectors it stimulates is the drug rituximab (Genentech Inc., and Biogen Idec Inc.) 
which contains a Fc region that interacts with the recipients’ FcγRn and may trigger 
ADCC for antitumor activities in non-Hodgkin’s lymphoma (Weng & Levy, 2003). 
Other examples of engineered antibody fragments with designed mutations for 
enhanced Fc-mediated effector responses include the drugs alemtuzumab (Genzyme 
Corporation and Schering AG; for treatment of B-cell chronic lymphocytic leukaemia), 
trastuzumab (Genentech Inc. and F.Hoffman-LaRoche Ltd., for treatment of metastatic 
breast cancer) (Lazar et al., 2006) and ocrelizumab (Genentech Inc., F.Hoffman-
LaRoche Ltd., and Biogen Idec Inc., for treatment of rheumatoid athritis) (Vugmeyster 
et al., 2005). Due to the immune-evasive nature of T. gondii bradyzoites-filled tissue 
cysts and to a lesser degree – the rapidly proliferating tachyzoites, an Fc-mediated, 
precisely-targeted effector function coupled to scFv antibodies targeted to T. gondii may 
prove to be therapeutically beneficial in future developments.  
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2.12.2-     Selection and Screening Strategies 
 
 The creation of the antibody phage display library provides a rapid selection 
platform for isolating antibodies based on its antigen-binding behaviour from a 
combinatorial pool of millions of clones; thereby bypassing hybridoma technology, 
which was the traditional means of manufacturing mAbs. The connection between 
phenotype and genotype in phage libraries allows for the selection of clones binding to 
desirable antigens and many different selection methods have been developed that 
separate clones that bind from clones that do not (Figure 2.10). 
 
For phage display libraries, selection involves the exposure of the antibody 
library to the antigen of interest to allow for antigen-specific phage antibodies to bind to 
their targets during biopanning. This is followed by recovery of antigen-bound phage 
and reinfection in bacteria. Iterative rounds of biopanning are carried out to enrich for 
the best binders from the library (Figure 2.9). Tailoring the selection procedure of an 
antibody library can lead to the selection of antibody fragments with improved binding 
affinity and kinetics. For instance, by using limited and decreasing amounts of antigen, 
the selection favors clones with lower Kd; by increasing and lengthening the washing 
steps after the incubation of target antigen, clones with improved off-rate are selected; 
and by using very short incubation times, the selective pressure favors clones with 
improved on-rates. Generally, low density target coating and extensive washing of the 
tube enrich high-affinity binders. When selecting from a secondary phage antibody 
library to improve affinities, the antigen concentration is typically decreased below the 
Kd of the parent clone to allow preferential selection of higher affinity mutants. 
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The antibody phage display platform also allows another effective system of 
selection, which is selection by competition. Briefly, in this system specific phage 
binders can be detached from the target antigen by exposure to a competitor molecule, 
which binds the antigen naturally and causes the elution of the reactive phages (Mourez 
et al., 2001). 
 
In the future, protein microarrays may also become important for high-
throughput analysis of antibody specificity and affinity. Apart from enabling the 
discovery of mAb with high-affinity bindings to specific targets, selection strategies can 
also be applied to improve other properties, such as enhanced stability, resistance to 
proteases, aggregation behaviour, expression level in heterologous systems, 
intracellularly-expressed antibodies (or intrabodies) and even antibody-mediated 
catalysis (reviewed in Hoogenboom, 2005). Rising to the attractive prospects of creating 
intrabodies, Desiderio, A. and co-workers described a library which enables the 
isolation of intracellularly stable new binding specificities to be exploited as 
immunochemical reagents (Desiderio et al., 2001). Basically, synthetic phage antibody 
libraries can be constructed on the scaffold of a scFv previously proven to be endowed 
with high intrinsic thermodynamic stability and functionally expressed in the reducing 
environment of bacterial and plant cytoplasm. 
 
 Current antibody libraries commonly display synthetic or natural diversity in 
multiple CDRs and routinely produce single-digit nanomolar or subnanomolar affinity 
antibodies, which are affinities equal to the affinities of antibodies regularly isolated 
from immunized mice or recombinant immune libraries. In general antibody affinities 
from libraries are proportional to the size of the library- a library of 107 to 108 clones 
can yield up to 10 nM affinity, and the best libraries of over 1010 members can yield up 
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to 0.1 nM in antibody affinity (Hoogenboom, 2005). These libraries used in conjunction 
with high-throughput screening can facilitating the identification of antibody leads with 
the highest potencies (Edwards et al., 2003). Table 2.2 shows examples of antibodies 
that have been obtained by in vitro selection and / or optimization. 
 
 
 
FIGURE 2.10 Methods for in vitro selection screening of antibody library displays. 
(a) Antigen (Ag) immobilization on solid supports or BIAcore sensorchips; (b) 
Biotinylated Ag (red) captured by streptavidin-coated beads (gray); (c) diverse 
recombinant antigens such as incorporation into paramagnetic liposomes (left) and 
immunoadhesins (right); (d) fixed prokaryotic cells-Ag display; (e) enriched subcellular 
or membrane fracions; (f) binding selection on transfected or tumor cells; (g) alternating 
selection on Ag+ cells and quenching on Ag- cells; (h) subtractive selection using flow 
cytometry; (i) selective enrichment on tissues; (j) proximity to another bound ligand; (k) 
injection into living animals; Selection via modulation of elution conditions, such as via 
(l) trypsin digestion; (m) and (n) mild disulfide-bridge reduction; and (o) competitive 
elution to displace the relevant binding phage antibody. (Adapted from Hoogenboom, 
2005) 
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TABLE 2.3 Examples of engineered antibodies generated by in vitro selection 
and / or optimization. (Adapted from Hoogenboom, 2005) 
 
MHC, major histocompatibility complex; VEGF, vascular endothelial growth factor; 
GCN4, general control protein 4; FITC, fluoroisothiocyanate; CEA, carcinoembryonic 
antigen.  
 
 
 
2.13- Antibody affinity maturation 
 
An antibody’s potency is frequently associated with its affinity for its target 
antigen (Carter, 2006), with higher affinities leading to increased pharmacokinetics and 
safety profiles while reducing dosing, toxicity and cost of therapy. Although initial 
antibody leads from display libraries shows many promising characteristics, their 
potency is sometimes insufficient for therapeutic or sensitive diagnoses applications. 
Therefore, a popular strategy for successful increm
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affinity maturation of existing antibodies with subsequent functional screenings (Carter, 
2006). 
 
 Antibodies are affinity matured in the natural immune system in a stepwise 
fashion by incorporating mutations and selecting variants under increasing selective 
pressures. However, there are inherent limitations to this in vivo somatic hypermutation 
mechanism. An in vitro antibody directed evolution approach developed by Boder, E.T. 
and co-workers demonstrated that in vitro affinity maturations are generally able to 
sample areas of antibody sequence space infrequently accessed by the in vivo process 
(Boder et al., 2000). It was shown in this study that 9 out of 10 consensus mutant 
substitutions introduced by in vitro evolution into murine scFvs occurred in fewer than 
10% of known mouse antibody sequences (Boder et al., 2000).  
 
Diversity in the antibody genes may be introduced ex vivo via a variety of 
methods, which are either random or localized; as reviewed by Bradbury, A.R.M. and 
Marks, J.D. (Bradbury & Marks, 2004). The first and simplest form of ex vivo library 
affinity maturation basically focuses diversity at a small number of residues that are 
most likely to interact with the antigen, namely the CDRs, using oligonucleotides and 
PCR. For example, residues that modulate affinity may be randomized, ideally four to 
six residues at a time to allow efficient sampling of the sequence space (Bradbury & 
Marks, 2004). Screening is then carried out to isolate variants with improved affinity, 
and mutations conferring the highest affinities are combined in a single clone. 
Randomization may also be focused at various positions identified with sequence motifs 
frequently targeted for somatic hypermutation in vivo, known as ‘Hot spots’, which are 
most likely to result in improved affinity or influence affinity based on structural 
analysis. It was demonstrated that affinity maturation focused on germline hot spots 
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mutagenesis results in substantially improved antibody binding affinity as compared to 
non-germline hot spots mutagenesis (Ho, Kreitman, Onda, & Pastan, 2005).  
 
 In general, mutations introduced into the CDR loops leads to affinity gain as a 
result of providing new contacts with the antigen, influence of positioning the side 
chains contacting the antigen or the replacement of low-affinity contact residues with 
those of more favorable binding kinetics (Hoogenboom, 2005). Examples of successful 
affinity maturations of phage-displayed mAb fragments by point mutagenesis are the 
improved mAb affinity for HIV-1 envelope glycoprotein gp120 (W.-P. Yang et al., 
1995); and HER-2 (or ERBB2) antigen associated with metastatic breast cancer (Schier 
et al., 1996).  
 
 There is also substantive evidence that the fine-tuning of antibody interactions 
from nanomolar to femtomolar affinity levels involves affinity maturation mutations at 
the residues outside of the antigen contact cavities or CDR loops. Observations indicate 
that ultra high affinity antibodies in the femtomolar range may be also effectively 
developed via changes in ‘vernier’ or second sphere residues (residues with one or more 
atoms directly contacting any residues in the first sphere of antigen contact) rather than 
contact residues, such as mutations in the VH-VL interfacial sites which improves 
stability and / or orientation of the V domains pairing (Boder et al., 2000; Midelfort et 
al., 2004). Interestingly, while it is a normal assumption that large binding 
improvements should be attributed to dramatic changes in either structure, hydrogen 
bonds or salt bridges; a previous study showed that improved engineered antibody 
binding affinity to the femtomolar range is formed through the interaction of a variety 
of interactions and the sum of many small changes, with a lack of visible structural 
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changes – whereby the structural comparisons of both the parent scFv and affinity-
matured variant showed very small rmsd deviations (Midelfort et al., 2004).  
 
While the many contributing factors to the affinity gains of antibodies subjected 
to affinity maturation is complex and not fully understood at present time, it remains 
that any recombinant antibody should be empirically tested to determine the extent of 
enhancement of a produced antibody’s efficacy, if any. 
 
 
2.14- Phage display applications 
 
 The advantage of the phage display technology is its ability to isolate bio-
interactive proteins and other molecules without pre-existing knowledge about the 
interactions (M. A. Arap, 2005). This versatile technology has benefited studies and 
discoveries done in the fields of cell biology, immunology, and pharmacology. 
Applications of phage display can be grouped into three main categories, they are: in 
vitro identification of receptor-ligands, selection of receptor-ligands in complex 
biological systems, and in vivo selection of receptor-ligands.  
 
 For the in vitro identification of receptor-ligands, phage display peptide libraries 
have been used for the isolation of antigenic mimotopes of the human hepatitis B viral 
envelope (HBsAg), with potential diagnostics application (Folgori et al., 1994). The 
phage display platform had also enabled the determination of peptide structures 
recognized by major histocompatibility (MHC) molecules, which has important 
implications for the development of MHC-specific antagonists in the control and 
treatment of MHC-associated autoimmune conditions in humans (Hammer, Takacs, & 
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Sinigaglia, 1992). Besides selection for interacting proteins, the phage display 
technology also proved to be a useful tool in the identification of peptides affecting 
protein-DNA interactions, peptides binding to carbohydrates, and even peptides binding 
to small chemical compounds such as taxol (reviewed in M. A. Arap, 2005). One of the 
unique applications of this phage display technique is for the isolation of allergens by 
expression of a cDNA library on phage particles (Rhyner et al., 2004). Another 
powerful approach in utilizing the phage display technology is for the in vitro directed 
evolution of enzymes and antibodies For instance, a mechanistic-based study described 
by Pedersen and co-workers enables the in vitro isolation of enzymes based on its 
ability for reaction catalysis, rather than merely its structure or substrate binding 
(Pedersen et al., 1998). The rapid and high-throughput directed evolution of antibodies 
with improved stability and antigen-binding properties have also been made possible by 
using phage display libraries (O'Neil & Hoess, 1995).  
 
Conventional methods of biopanning entail antigen purification and 
immobilization on an inert substrate, followed by probing with binding ligands, such as 
an antibody library. This is a relatively straightforward and reliable protocol for certain 
specific, soluble protein antigens. However, the conventional biopanning method has its 
limitations and is not amenable for screening of binding ligands for native 
conformational states of cell surface receptors or functional cell membrane epitopes 
(Eisenhardt, Schwarz, Bassler, & Peter, 2007) or in instances where the antigen is yet 
unknown or has not been fully characterized. Common methods of antigen 
immobilization normally involves either extended time incubations or desiccation 
(Sorokulova et al., 2005) or even the use of poly-L-lysine coated surfaces (Yavin & 
Yavin, 1974), each of which can cause the loss of native protein structure, conformation 
and functionality. 
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 In the second category of phage display applications, which is the selction of 
receptor-ligands in complex biological systems, a phage display library can be directly 
screened against molecules expressed on living cells and tissues. This allows for the 
binding receptors on viable cells to be selected in its native conformation and doesn’t 
require production of purified epitopes. However, optimization for specific phage 
binders is usually necessary for such complex targets as unspecific background phage 
adherence is a common problem with this method (M. A. Arap, 2005). This method is 
most frequently applied for studies related to cancer cells; such as the discovery of 
antibodies against melanoma cells (Kupsch et al., 1999) and a tumor target known as 
the Glucose-regulated protein-78 (GRP78) (Mintz et al., 2003), and also the isolation of 
binding peptides to urothelial carcinoma cells (Ardelt et al., 2003). In fact, the vast 
number of applications of phage display for the isolation of tumor-targetting peptides 
includes the development of targeted cytotoxic chemotherapy, pro-apoptotic peptides, 
cytokines-targeting to angiogenic vasculatures and tumor-imaging ligands (reviewed in 
M. A. Arap, 2005). Besides cancer cells, the application of phage display has also been 
extended for use in the discovery of binding ligands as antagonist to thrombin receptor 
(Doorbar & Winter, 1994) and antibody clones against parasitic diseases (Hoe, Wan, & 
Nathan, 2005; Wajanarogana, Prasomrothanakul, Udomsangpetch, & Tungpradabkul, 
2006).   
 
A common difficulty in all types of biopanning is the tendency of non-specific 
phage binding to its target of interest. This effect is more pronounced in cell-based 
biopanning because cell surfaces are complex and contains many non-specific 
carbohydrate, lipids and protein-conjugated antigens (D. L. Siegel, 2001). Therefore, 
although the cell-based biopanning approach offers several important advantages such 
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as facilitating the screening of antibodies on target antigens in its’ native environment, 
the challenge of minimizing the false positives must be addressed. Several strategies of 
optimizing cell-based biopannings have been documented, including tweaking the input 
phage titers, incubation duration and temperature, and number of washing steps 
(Watters, Telleman, & Junghans, 1997); doing a negative and positive cell selection 
rounds to quench non-specific phages (Cai & Garen, 1995; Eisenhardt et al., 2007; J. D. 
Marks et al., 1993); differential centrifugation of phage-probed cells through a non-
miscible organic phase (Giordano, Cardo-Vila, Lahdenranta, Pasqualini, & Arap, 2001); 
using fluorescent activated cell sorting system (de Kruif, Terstappen, Boel, & 
Logtenberg, 1995); and using magnetically-activated cell sorting (MACS) system 
(Chang & Siegel, 2001). This is not an exhaustive list of the strategies that has been 
employed in optimizing cell-based biopanning approaches; but what is clear from each 
is that there are advantages and disadvantages associated with each strategy, and this 
caveat needs to be noted in its application of cell-based biopannings in other 
experimental conditions with its own unique settings. For instance, application of the 
(Giordano et al., 2001) strategy of biopanning with differential centrifugation through a 
non-miscible organic phase was found to be not ideal for biopanning against T. gondii 
as the high shear force and the toxic organic phase employed in this method results in 
tachyzoite cell disruption (unpublished observations).  
 
 In the application of phage display for the in vivo selection of receptor-ligands, 
phage libraries are injected into animals and organs or tissues are subsequently 
harvested for the recovery of binding phages. The advantages of this method is the 
ability of selection based on ligand functionality, stability in in vivo systems, and the 
depletion of low-affinity unspecific binders from the circulation (M. A. Arap, 2005). 
The in vivo phage display system has been successfully applied in studies to reduce 
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prostate cancer risks (W. Arap et al., 2002), targeting of adipose tissues to reduce high-
calorie related obesity in live animals (Kolonin, Saha, Chan, Pasqualini, & Arap, 2004), 
and also to elucidate the molecular heterogeneity of organ-specific vasculature – with 
potential implications for the development of these molecular targets for diagnostics or 
targeted therapeutics (Rajotte et al., 1998). The vast number of applications of phage 
display for both basic and clinical research highlights the versatility of this technology 
in facilitating the diagnosis and treatment of human diseases. 
 
 
2.15- Phage display strategies for enhanced specificity 
 
 While phage display is a powerful tool for discovering ligands to various protein 
and even non-protein targets, false positives in the form of binding phages with no 
actual affinity to the intended target may be recovered. As reviewed by Vodnik and co-
workers recently, there are several consensus peptides recovered from different 
laboratories targeting commercial phage display libraries to different targets, causing 
these binding peptides to be highly suspect as target-unrelated peptides (Vodnik, Zager, 
Strukelj, & Lunder, 2011). Thus, strategies to avoid their isolation need to be studied 
and implemented as an important step towards phage display selections of greater 
integrity. A successful biopanning experiment of a phage display library entails the 
screening of the peptide or antibody library against a target, followed by the removal of 
a vast majority of non-binders during washing steps and the final elution of only a few 
clones capable of high-affinity binding to the target. False positive phages with no 
actual affinity to their target can be recovered due to binding to other components of the 
screening system, such as contaminants in the target sample, solid phase (immobilizing 
plastic plates, beads), capturing reagents (streptavidin, protein A/G, biotin, secondary 
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antibodies), blocking reagents (BSA, milk) (Vodnik et al., 2011). Another contributing 
factor to the occurrence of false positive phages is due to propagation advantages. In 
this case, selection is driven by faster propagation of some phage clones. Therefore, 
these phages are recovered not because of their target affinity, but because their intrinsic 
replication advantage enables them to predominate in the phage pool (Brammer et al., 
2008; Thomas, Golomb, & Smith, 2010). 
 
 In order for a phage display selection system to distinguish between true binders 
and false positives, careful design of experimental conditions can reduce the possibility 
of recovering target-unrelated peptides or antibodies. Binding to immobilizing solid 
phase, such as plastics, can be circumvented by blocking the surface or using higher 
density of target immobilization on the surface (Adey, Mataragnon, Rider, Carter, & 
Kay, 1995). However, a higher target density will inadvertently reduce the stringency of 
selection and may cause the isolation of more abundant low affinity binders (Vodnik et 
al., 2011). Another strategy to reduce background phage binding is through subtractive 
biopanning. In this strategy, the input phage pool is incubated with a negative capturing 
agent or blocking reagent in the subtractive biopanning round to adsorb non-specific 
binders, prior to selection against target (de Kruif et al., 1995). For instance, in the 
application of a phage display antibody library to select for tumor targeting antibodies, 
the phage display library can be subtracted against a normal human cell line prior to 
screening on the intended cancer cell line (Kupsch et al., 1999). 
 
 A recurrent problem in phage display systems is the propagation advantage of 
some phage clones. Phage clones with normal propagation rates may be outnumbered in 
the library by clones with propagation advantage, and are therefore likely to be 
eliminated in affinity-driven selections by abundant clones that are target-unrelated 
83 
 
binders (Thomas et al., 2010). In this situation, a clone population bottleneck can cause 
even rare target-unrelated clones with propagation advantage to have an opportunity to 
predominate, especially if many amplification steps are performed. Therefore, in 
general, serial amplifications of a phage display library is to be avoided. In addition, 
reamplification of the input phage after the subtractive biopanning round is also not 
recommended (Vodnik et al., 2011). Another option to overcome propagation-related 
false positive clones is to use the T7 lytic phage-displayed peptide libraries. The T7 
phage display library system is less prone to sequence bias in comparison to M13 phage 
display libraries, and is less likely to carry radically faster propagating phage clones due 
to its lytic nature – as host cell membrane transport cannot affect phage particles 
assembly (Krumpe et al., 2006). 
 
 While many precautions can be taken to minimize false positives, it is 
impossible to completely avoid recovery of background phage binders. Traditional 
approaches in identifying phage clones with true binding affinity to its target often 
involved ELISA assays and surface plasmon resonance (SPR) experiments. Testing 
selected clones to each component of the selection system separately is also 
recommended to discriminate target-unrelated peptides from specific binders (Vodnik et 
al., 2011). Recent advances now allows the bioinformatics analysis of phage display 
selection outputs through a web server known as SAROTUP, an acronym for ‘Scanner 
And Reporter Of Target Unrelated Peptides’ (Huang, Ru, Li, Lin, & Guo, 2010). 
SAROTUP (http://immunet.cn/sarotup/) is a freely accessible web tool for scanning, 
reporting and excluding possible target-unrelated peptides from phage-displayed 
antibody libraries. Phage display investigators need to only input the peptide sequences 
of their clones in FASTA format, and the server compares each sequence with its 
database and potential false positives are reported in a table. Although a highly useful 
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tool, this approach has its limitations as the SAROTUP database is rather limited with 
only 23 target-unrelated motifs recognized. Complementary analysis of the phage 
display library output can also be done by performing a search on the MimoDB (Ru et 
al., 2010) and PepBank (Shtatland, Guettler, Kossodo, Pivovarov, & Weissleder, 2007) 
databases. Both are free web-accessed databases with a large depository of peptides 
obtained by phage display on different targets. Comparing phage clones from an 
experimental output to other phage clones selected to various targets within these 
databases can provide some clues to distinguish true binders from target-unrelated 
peptides.      
 
 Despite the many advantages of the phage display technology in the high-
throughout selection for antibodies or peptides against any target, the integrity of the 
phage output clones can be further strengthened by careful examination for non-specific 
binding, comparisons to known target-unrelated peptide motifs and bioinformatics 
analysis via web tools. Thus, it is important incorporate these strategies to facilitate the 
discovery of binding ligands with true affinity to its target. 
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CHAPTER 3.  METHODOLOGY 
 
3.1.  Key Research Questions 
 
There are three primary aims of this study: The first is to develop an optimized 
procedure for T. gondii cell-based biopanning to screen for scFv antibody binders 
against tachyzoite cells. The second is to isolate and characterize the anti-T. gondii scFv 
antibodies obtained through the optimized biopanning, and the third is to improve the 
binding affinity of the isolated antibodies through a combinatorial molecular biology 
and computational design approach. This study is focused on addressing the main 
research questions of whether or not a recombinant scFv antibody with rationally-
designed mutations could lead to enhanced binding affinity or selectivity to its antigenic 
target parasite.  
 
 
3.2. Research design 
 
This study was exploratory and interpretative in nature as it did not begin with a 
screening of the scFv antibodies against defined antigens, but rather the immunized-
scFv antibody polyclonal repertoire was subjected to solution-phase binding with the 
native antigenic landscape of viable T. gondii tachyzoites to mimic in vivo conditions. 
To date, various methods have been employed for cell-based biopannings, each with its 
own advantages and drawbacks. The most persistent and common problem in cell-based 
biopannings is the issue of false positives or also known as the problem of ‘noise’. The 
key in optimizing for the best method is to strike a balance between significantly 
lowering false positives or ‘noise’, while preventing the loss of specific binders by 
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stringent conditions. This study’s approach in optimizing the cell-based biopanning of 
the scFv library against T. gondii is by incorporating a multiple round subtractive 
biopanning step against a normal human hepatocyte cell line WRL68, followed by a 
single-round antigen biopanning against T. gondii.  
 
To date, various methods have been developed incorporating a single subtractive 
biopanning round followed by multiple rounds of library selection against the antigen of 
interest. However, it was decided that the inverse method of selection (i.e. multiple 
rounds of negative selection followed by a single-round of positive selection) was the 
best method to adopt for this investigation due to several factors: First, recombinant 
phages displaying scFv antibodies on its g3 protein will not all be carrying full-length 
antibody fusions. In fact, it is a common problem for truncated sequences to be 
displayed along with the full-length functional scFvs due to stop codons and frame shift 
mutations (Kramer et al., 2003); second, the complex native landscape of cells means 
that smaller truncated protein fragments are easily ‘trapped’ on the cell surface even 
though there is no real specificity for the antigens of interest, leading to false positives 
(D. L. Siegel, 2001); third, there may be an aberrant enrichment of non-functional and 
non-full-length fragments above the truly functional full-length scFvs due to the innate 
enhanced growth rates of bacteria not expressing the full-length protein.   
 
Through the optimized cell-based biopanning method developed for this study, 
scFv antibodies that were isolated were verified to be full-length, functional genes 
before proceeding with antibody characterizations and homology modeling. Analysis of 
antigen-binders and in silico homology modelling of selected scFv antibody enables the 
rational design of point mutations at antibody hot spot residues, with the aim of 
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increasing antibody binding affinity or selectivity against T. gondii tachyzoites. The 
overview of the research design is illustrated in Figure 3.1. 
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FIGURE 3.1 Isolation and development of phage-displayed scFv antibodies against T. gondii. Immunized mice are euthanized to 
harvest its splenic B cells, from which the scFv library was generated. Library biopanning was done in 2 steps, with a negative selection round 
against WRL-68 cells preceding the Ag biopanning. Molecular structure of isolated scFv is modelled in silico, before antibody affinity 
maturation was performed. Finally, the recombinant scFv antibodies are tested for binding to target cells by immunofluorescence assay.   
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3.3 Research procedures 
 
3.3.a. Mouse immunization against Toxoplasma gondii 
 
3.3.a – i Parasites and in vivo passaging in mice 
 
Tachyzoites of the T. gondii RH strain (Pfefferkorn & Pfefferkorn, 1976) was 
maintained by serial passage in either 6 – 8 weeks old ICR albino or BALB/c mice. 
Mice were inoculated intraperitoneally with 104 to 105 tachyzoites each. Three to 7 days 
post-inoculation, the peritoneal exudate containing extracellular T. gondii parasites was 
aspirated from anesthetized mice, and this parasite suspension was then added with 15% 
DMSO in a 1:1 ratio, incubated at 37°C for 15 min, and followed by rapid cooling in a 
pre-chilled -80°C bath of ethanol before storage in a -80°C freezer. The frozen antigen 
was thawed and aliquot for use as and when it was needed within a time frame of 4 
months from the date of exudate collection. 
 
Parasites were purified for use as antigen in the biopanning experiments as 
previously described (Dempster, 1984) with some modifications. Thawed parasite 
suspensions were washed 3 times in PBS (0.15 M NaCl, 5 mM NaH2PO4, pH 7.2) by 
centrifuging at 1000xg for 5 min to pellet the cells in 10-ml polypropylene tubes. In the 
final centrifugation step, the tachyzoites cell pellet was resuspended in Toxoplasma 
Homogenization Buffer (THB) (20 mM HEPES/KOH pH 7.0; 50 mM potassium 
acetate; 10% (w/v) sucrose, 1 mM EDTA) (M. Yang et al., 2004) and the washed 
peritoneal exudate was then homogenized by passaging through a 27-gauge needle 3 
times. The homogenized parasite suspension was then filtered through a 3.0 µm 
Nucleopore polycarbonate filter (Whatman, 1980-002 and 110612) to remove 
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contaminating mouse leukocytes and other cell debris. The filtered parasites were then 
quantified with a haemocytometer and trypan blue cell viability staining according to 
standard procedures (Sambrook & Russell, 2001). A 0.2 ml aliquot of filtered cell 
suspensions were mixed with an equal volume of a solution of Trypan Blue (0.4% w/v). 
The cells were incubated with the dye for approximately 3 minutes before loading 9.0 µl 
of the mixture unto each chamber of a coverslipped-haemocytometer by capillary 
action. The trypan blue viability staining method works on the premise that normal, 
viable cells are able to exclude the dye, but unviable cells would have the dye diffused 
into it due to lost membrane integrity. The number of viable cells in 5 out of the 9 
squares in each chamber was scored to obtain the total number of cells in 10 squares. 
The total number of cells was then multiplied by the cell suspension’s dilution factor 
and by 1000 to result in the number of tachyzoite cells per ml in the filtered cell 
suspensions. 
 
 
3.3.a – ii  Mice immunization 
 
Immunization was carried out with BALB/c mice, 6-8 weeks old; with a 
subcutaneous injection interval of 2 weeks (Day 0 and Day 14). Each mice were given 
the first immunization with 2.02 x 106 – 4.04 x 106 T. gondii RH tachyzoites emulsified 
in Freund’s Complete Adjuvant (FCA) (Sigma, F-5881) (ratio of 1:1), followed by a 1st 
and 2nd booster injection on Day 14 and Day 21 respectively with approximately the 
same amount of tachyzoites as the prior inoculations. The booster antigen was not 
mixed with any adjuvant because the use of cells as immunogens obviates the need for 
further use of adjuvants (Andris-Widhopf, Rader, & Barbas, 2001). The immunized 
mouse was bled 4 days after the final booster and its serum was tested for the presence 
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of IgG antibodies to T. gondii by Western Blotting  according to standard procedures 
(Towbin, Staehelin, & Gordon, 1979). All procedures were performed in accordance 
with the Faculty of Medicine’s guidelines of the Animal Care and Use Ethical 
Committee (ACUC) with approved applicable number PAR/18/06/2007/FMY(R). 
Briefly, T. gondii crude tachyzoite proteins was separated on a 10% (w/v) discontinuous 
SDS-polyacrylamide gel (Laemmli, 1970) and was subsequently transferred to a 
hydrophobic PVDF membrane (Hybond-P, Amersham Biosciences, RPN303F). The 
membrane was blocked in 5% skim milk in PBS (PBS-M) for 1 hour at room 
temperature and followed by 3 cycles of 5 min washes with 0.1% (v/v) Tween-20 in 
PBS (PBS-T). In the following steps, membrane was sequentially probed with 
immunized mouse sera diluted in 2% PBS-M (1:500) for 30 min at room temperature, 
washed in alternating cycles of PBS and PBS-T (1 X 5 min with PBS, 3 X 15 min with 
PBS-T, and final rinse with PBS), and finally incubated in alkaline-phosphatase 
conjugated goat anti-mouse IgG (whole molecule) (Sigma, A-3562) (1:30 000) for 1 
hour at room temperature. After a final washing cycle similar to that described 
previously in this section to thoroughly remove any excess secondary antibody; T. 
gondii – positive IgG was detected by adding the corresponding substrate (Western 
Blue® stabilized substrate, Promega, S3841) to the membranes. An unimmunized mouse 
serum was incorporated in these steps as a negative control. Following the positive 
demonstration of IgG antibodies to T. gondii on Western Blots, the mouse spleens were 
harvested, snap-frozen in liquid N2 and stored in a -80°C freezer until needed.  
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3.3.b. Construction and biopanning screening of a phage-displayed scFv 
antibody library 
 
3.3.b – i  ScFv phage-display library construction 
 
Total RNA was prepared from homogenized mouse spleen using the RNeasy 
Mini Kit (QIAGEN GmbH, Hilden, 74104) according to the manufacturer’s 
instructions. This was followed by mRNA purification using the MicroPoly(A) Purist™ 
small scale mRNA purification kit (Ambion, 1919). Following a spectrophotometric 
check on mRNA concentration and purity, the resultant mRNA (7.8 µg) was used as 
template for cDNA synthesis using the Superscript™ III Reverse Transcriptase 
(Invitrogen, 18080-093) according to the manufacturer’s protocol. Typically, 0.2 µg of 
mRNA was utilized as template for first-strand reaction and primed by Oligo-(dT)20 
primer (Invitrogen, 18418-020). The resulting first-strand cDNA was used as a template 
for the amplification of the murine IgG variable heavy (VH) and variable light (VL) 
chain gene regions. V-region PCR amplifications were performed using a protocol 
modified from Nathan, S. et al. (Nathan, Li, Mohamed, & Embi, 2002) to incorporate 
Sfi I and Not I restriction sites flanking the assembled scFv fragments at the VL 5’ and 
VH 3’ domains respectively. All primer sequences are listed in Appendix III. These 
primers were adapted for the pCANTAB5E phagemid vector (Amersham Biosciences) 
(Appendix IV) and the primer combinations were designed to amplify most of the 
known mouse antibody sequences.  
 
A total of 23 Vκ region PCR reactions in 50 µl volumes were carried out for 
amplification of κ light chain variable region as follows: 0.4 µM of MSCVκ (Vκ 5’ 
sense / Sfi I) primer mix, 0.4 µM of MSCJκ (Vκ 3’ antisense / short linker) primer mix, 
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2 µl of the first-strand reaction, 0.3 mM dNTP mix (Promega, U1515), 1X PCR Buffer 
and 2.0 U DyNAzyme™ II DNA Polymerase (Finnzymes, F-501L). Meanwhile, Vλ 
gene region amplifications were prepared using one set of forward and reverse primers 
only. The Vλ amplifications were set up as above except that the primer mixes were 
substituted with the MSCVL-1 (Vλ 5’ sense / Sfi I) and MSCJKL-B (Vλ 3’ antisense / 
short linker) primers. A total of 4 Vλ PCR reactions were prepared. 
 
For the VH gene regions, PCR amplifications were done using a combination of 
19 forward primers and 3 reverse primers, making up a total of 30 VH region PCR 
reactions prepared as described above. The VH regions PCR reactions utilized the 
MSCVH (VH 5’ sense) and MSCG (VH 3’ antisense / Not I) primer mixes for the 
amplification of VH regions IgG1, IgG2a, IgG2b, IgG3 and IgM. All amplifications 
were performed in a thermal cycler (Mastercycler Gradient 96, Eppendorf, Germany) 
(94°C for 3 min, 30 cycles of 94°C for 30 s, 56°C for 30 s, 72°C for 90 S; 72°C for 2 
min). The PCR products were analysed on 1% (w/v) agarose gel electrophoresis and 
purified by QIAquick Gel Extraction Kit (QIAGEN GmbH, Hilden, 28704). Multiple 
PCR reactions were set up to obtain a more diverse V-gene library by avoiding possible 
bias likely to occur in a single reaction. 
 
Subsequently, the VH and VL coding sequences were fused using the flanking 
primers MSCF (5-GCGGGGCCCAGCCGGCCGAGCTCG-3) and RSCB (5-
GCCTGCGGCCGCACTAGTGACAGA-3) through splice-overlap extension PCR 
(SOE-PCR) to produce the single-chain variable fragment (ScFv) with an 8-amino acid 
flexible linker in between (Figure 3.2). The scFv assembly reaction was carried out as 
follows: 1 µM of MSCF primer, 1 µM of RSCB primer, approximately 50 ng of each of 
VH and VL coding sequences, 1 mM dNTP mix, 2X Amplification Buffer, 1 mM 
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MgSO4, 2X PCRX Enhancer solution, 1 U of Platinum Pfx DNA Polymerase 
(Invitrogen, 11708-013). The cycling conditions for the assembly reaction is: 7 cycles 
of 92°C for 1 min, 63°C for 30 s, 58°C for 50 s, and 72°C for 1 min; followed by 23 
cycles of pull-through reactions of 92°C for 1 min, 63°C for 30 s, 72°C for 1 min; with 
final extension at 72°C for 10 min. 
 
The resulting polyclonal pool of scFv fragments library was approximately 0.75 
kb in size and was gel purified. This was followed by a sequential restriction digestion 
of the scFv fragments with SfiI (NEB, R0123S) and NotI (NEB, R0189) according to 
manufacturer’s instructions. The restriction digested and purified scFv DNA was cloned 
into the SfiI and NotI pre-digested pCANTAB5E phagemid vector (GE Life Sciences – 
formerly Amersham Biosciences, RPAS Expression Module, 27-9401-01). Cloning of 
the generated scFv antibody fragment pool into the SfiI - NotI polyclonal cloning site 
within the pCANTAB5E phagemid vector results in a COOH-terminal E-tag and a 
UAG-amber stop codon between the E-tag and a g3p gene encoding the phage minor 
coat protein (Appendix IV). Transformation of the scFv-pCANTAB5E vector into the 
E. coli suppressor strain TG1 makes it possible to produce phage-displayed scFv when 
co-infected with M13 helper phage that provides the gene apparatus for the assembly of 
recombinant phage particles. Sub-cloning of the recombinant phagemid vector into the 
non-suppressor E.coli strain HB2151 would lift the UAG stop codon suppression 
present in TG1 and result in the expression of soluble scFv antibodies.  
 
To prepare the DNA for electroporation, the ligation reactions were cleaned up 
using the StrataClean Resin (Stratagene, 400714) according to the manufacturer’s 
protocol. The purified ligation products (10 – 20 µl) were transformed into E. coli TG1 
electroporation - competent cells (Stratagene, 200123) by electroporation (2.5 KV, 200 
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ohms, 25 µF; time constant > 3.6 msec). Five sets of library electroporation 
transformations were done resulting in a complexity of 1.62 X 104 independent 
transformants. 
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FIGURE 3.2 Strategy of scFv fragment assembly. A short peptide linker 
(SSRSSGG) was incorporated into VH and VL and fused into scFv fragments by splice 
overlap extension PCR. Restriction sites for both Sfi I and Not I are incorporated at both 
ends of the scFv for subcloning into phagemid vector pCANTAB5E. 
ScFv DNA fragment 
with restriction sites 
5’…GCˇGGCC GC…3’ 
3’…CG CCGGˆCG…5’ 
5’…GGCCN NNNˇNGGCC…3’ 
3’…CCGGNˆNNN NCCGG…5’ 
VL VH 
MSC - Forward 
RSC - Back 
Sfi I Digest 
Not I Digest 
MSCJK - Back 
MSCVK / MSCVL 
cDNA 
MSCG - Back 
MSCVH 
cDNA 
Primary PCR 
SOE – PCR (Splice Overlap Extension PCR) 
Digested scFv DNA fragment ready for ligation 
into pCANTAB5e 
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3.3.b – ii  Recombinant phage-scFv rescue 
 
All subsequent steps from the library construction which involves the 
recombinant phage-scFv antibody rescue, biopannings and phage titering procedures 
were carried out with tubes and lab consumables treated against phage contamination as 
described in Phage Display – A Laboratory Manual (Burton, 2001) and in Appendix II. 
All recycled tubes and lab consumable were autoclaved (121°C, 15 p.s.i., 15 minutes) 
followed by baking at 105°C for at least 4 hours in a dry oven. This extra dry heat-
treatment of autoclaved lab wares is necessary as phages are known to survive standard 
autoclaving conditions. The rescue of the recombinant phage-scFv antibody library 
from the electro-transformed TG1 cells was carried out according to standard 
pCANTAB5E phagemid (Amersham Biosciences, 27-9401-01) manufacturer’s protocol 
using VCSM13 interference-resistant helper phage (Stratagene, 200251). The 
recombinant phage suspension was precipitated with Polyethylene glycol 8000 (PEG) 
as previously described (Rader et al., 2001). The recombinant scFv-phage supernatant 
was precipitated by the addition of 2.0 ml PEG/NaCl (20.0 % PEG, and 14.6 % NaCl) 
to 10.0 ml of supernatant. The mixture was then allowed to stand for 1 hour on ice, 
before centrifugation at 13,000xg in a pre-chilled Beckman JA-20 rotor for 20 min at 
4°C. The supernatant was carefully decanted and all traces of buffer were drained by 
blotting on a clean paper towel. The resulting scFv-phage pellet was aseptically 
resuspended in 3.0 ml of 2x YT medium (1.7 % (w/v) Bacto-tryptone, 1.0 % (w/v) 
Bacto-yeast extract, and 0.5 % (w/v) NaCl). The PEG-precipitated phage suspension 
was subsequently blocked with BSA Blocking Buffer (1% BSA in PBS) in a 1:1 ratio in 
preparation for the biopanning procedure. Biopanning procedures are carried out 
immediately following phage rescue and PEG precipitation to avoid proteolysis of scFv 
fragments as some recombinant phage preparations may be unstable. 
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3.3.b – iii  Subtractive Biopanning 
 
Subtractive biopanning was performed on normal hepatocyte human cell line 
WRL68 to remove phages that binds non-specifically to cells. The WRL68 cell line was 
kindly provided by Wong Yau-Hsiung and Dr. Habsah A. Kadir (Department of 
Biochemistry, Institute of Biological Sciences, University of Malaya, Kuala Lumpur). 
Prior experiments were carried out to determine the amount of absorber WRL68 cells 
and panning rounds required to sufficiently reduce non-specific binding phages. Each 
successive panning rounds for this phage-quenching study was monitored for the 
average phage-binding titers to the absorber cells. A plateau in the binding titer is taken 
to indicate as a sufficient threshold for the subtractive biopanning rounds. Through this 
study, it was determined that at least 3 rounds of subtractive biopanning would be 
required (Appendix V). 
 
For phage absorption, WRL68 cells (1.27 x 104) were transferred to a pre-
blocked microcentrifuge tube. The cells were pelleted by centrifuging at 1000xg, 4°C, 
for 5 minutes, and the supernatant removed. The pre-blocked and precipitated 
recombinant phage-scFv suspension (1.10 x 1011 cfu/ml) was then added in and the cell-
phage mixture was rotated at 8°C for 30 min. The cells were then pelleted as before, and 
the supernatant with unbound phages was transferred to another aliquot of WRL68 cells 
(1.27 x 104) for another round of phage absorption. A total of 3 rounds were carried out 
before proceeding with the selective biopanning on T. gondii. 
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3.3.b – iv  Selective Biopanning on Cells 
 
The subtracted recombinant phage fraction was added to a filtered T. gondii 
tachyzoites cell suspension (2.88 x 104) in a pre-blocked microcentrifuge tube, and the 
mixture was incubated at 8°C for 2 hours on rotation. At the end of the incubation, 
tachyzoite cells were pelleted by centrifugation at 1000xg, 4°C, for 5 minutes; and the 
supernatant was discarded. The cells were then washed 5 times with THB-T (THB with 
0.05% Tween-20) with vigorous vortexing at each rounds and similar spin conditions. 
Bound phage was eluted by resuspending cells in 200 µl Glycine-HCL (pH 2.2) elution 
buffer at 4°C for 10 min and subsequently neutralized by addition of 26.7 µl Tris-Cl 
(pH 8.0). The phage eluate was then re-infected with 1.0 ml of log-phase E. coli TG1 
and plated on SOBAG media (2.0% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast 
extract, 0.05% (w/v) NaCl, 1.5% (w/v) Bacto-agar, 10 mM MgCl2, 100 mM Glucose, 
and 100 µg/ml ampicillin) overnight at 30°C, at 100x and 10x dilutions for phage output 
tittering of transformed clones with ampicillin resistance. Phage output titer was 
calculated from the mean of triplicate sets of each dilution to determine the number of 
phage captured on the cells. The remaining phage-infected E. coli TG1 suspension was 
plated on large SOBAG plates (145 x 20 mm) (Greiner Bio-One, 639102) and also 
incubated at 30°C overnight to obtain single colonies of T. gondii-binding scFv clones. 
 
 
3.3.b – v  Polyclonal phage-scFv output binding screening 
 
To verify the polyclonal phage-scFv output derived from the single-round 
selective biopanning procedure is specific for the target antigen – T. gondii tachyzoites, 
and quenched from unspecific binding to WRL68; an output binding screening was 
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performed. Because the single-round selective biopanning phage-scFv recovery tends to 
be low, it needs to be re-amplified prior to the binding screening. 
 
For phage-scFv re-amplification, 1.0 ml of the biopanned polyclonal phage 
output fraction was transferred aseptically to a 50 ml centrifuge tube and subsequently 
diluted to an O.D. at A600 of 0.3 with 2x YT medium. The diluted culture is then 
incubated at 37°C at 250 rpm for 30 min. Following this incubation, sterile ampicillin 
and glucose was aseptically added into the culture at a final concentration of 100 µg/ml 
and 2.0 % respectively; and the culture was further incubated for another 1 hour at 37°C 
and 250 rpm. At the end of this, the turbid culture was inoculated with the VCSM13 
helper phage to a multiplicity-of-infection (m.o.i) to the E. coli cells of 5:1, with the 
assumption that the O.D. at A600 by then is 0.5 and which is equivalent to an amount of 
2.5 x 108 cells in the sampled volume. The estimated amount of cells in the sampled 
volume is multiplied by the total volume of the E. coli culture to obtain the total number 
of cells in culture. The VCSM13-infected E. coli culture was incubated again at 37°C, 
first without shaking for 15 min to allow for phage infection, and next with shaking at 
250 rpm for 45 min. Next, the culture was centrifuged at 1000xg for 10 min and the 
supernatant was discarded. The pellet was gently resuspended in 10.0 ml of 2x YT-AK 
medium (2 x YT medium with 100 µg/ml ampicillin and 50 µg/ml kanamycin) and 
incubated for 16 hours or overnight at 37°C and 250 rpm. On the next day, the 
overnight culture was centrifuged at 1000xg for 20 min. The supernatant which 
contained the amplified recombinant phage-scFv was carefully transferred to a 50.0 ml 
Beckman centrifuge tube and was PEG-precipitated as described previously. After 
allowing the PEG-precipitation mixture to stand on ice for 60 min, the mixture was 
centrifuged in a Beckman Avanti™ Centrifuge J-25 I machine at 13,000xg, 4°C for 20 
min. The supernatant was discarded and the resulting phage pellet was resuspended in 
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2.0 ml of 2x YT medium and blocked for at least 15 min with 2.0 ml of BSA Blocking 
Buffer containing 0.01 % sodium azide as preservative. 
 
Four sets of experimental conditions and one negative control were designed to 
compare the binding between the biopanned-output phage repertoire and unpanned 
original phage library with the tachyzoites and the WRL68 absorber cells (Table 3.1). 
The procedure carried out was similar to the methods in subtractive biopanning (for 
WRL68 cells) and selective biopanning (for T. gondii tachyzoites) with the exception 
that only 1 round of negative selection biopanning was done for the binding study sets 
with WRL68 cells. Each experimental condition sets were performed in triplicates and 
the mean average titers from each set was calculated and normalized against the 
background phage-binding negative control reading (Set 5, Table 3.1). 
 
 
Table 3.1. Experimental condition sets for polyclonal phage-scFv output antigen 
binding screening. 
Experimental 
Sets Binding conditions 
1 Biopanned-output phage-scFv with T. gondii tachyzoites 
2 Unpanned -phage-scFv library with T. gondii tachyzoites 
3 Biopanned-output phage-scFv with WRL68 cells 
4 Unpanned -phage-scFv library with WRL68 cells 
5 Biopanned-output phage-scFv without cells (Negative control) 
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3.3.c. Analysis of putative anti-Toxoplasma gondii scFv antibodies 
 
3.3.c – i   Sequencing Analysis 
 
Each scFv clone was further screened by PCR to verify for the presence of full-
length scFv genes. The colony PCR screening was carried out with the primer pairs 
pCANTAB5 S1 (Forward) (5-CAACGTGAAAAAATTATTATTCGC-3) and 
pCANTAB5 S6 (Reverse) (5-GTAAATGAATTTTCTGTATGAGG-3) (Amersham 
Biosciences, 27-1585-01) with the following conditions: 0.2 µM of S1 primer, 0.2 µM 
of S6 primer, 0.2 mM dNTP mix, 1X Amplification Buffer, 4.0% DMSO, 1 U of 
DyNAzyme™ II DNA Polymerase (Finnzymes, F-501L). The screening PCR was 
carried out in a thermal cycler (Mastercycler Gradient 96, Eppendorf, Germany) 
programmed at 94°C for 3 min, 30 cycles of 94°C for 20 s, 56°C for 20 s, 72°C for 20 
S; 72°C for 2 min. Short-listed full-length scFv genes were then fingerprinted with the 
DNA restriction enzyme MvaI (Fermentas, FD0554) in conditions according to 
manufacturer’s instructions. Full-length scFv genes with unique fingerprint patterns was 
selected and the clones were sequenced using the dideoxy method with the pCANTAB5 
sequencing primer pairs – S1 and S6 (Amersham Biosciences, 27-1585-01). DNA 
Sequencing was performed using ABI PRISM BigDye™ or Amersham Pharmacia 
Biotech DYEnamic ET Terminator kit (AIT Biotech, Singapore). 
 
The ScFv sequences were analysed with BioEdit v 7.0.5.3 (Hall, 1999) for full-
length coding sequences without any internal stop codon and truncation mutations. Out 
of this analysis, 4 full-length scFv clones were selected. The full-length VH and VL 
chain region sequences were numbered according to the IMGT unique numbering 
scheme (Lefranc et al., 2003), and analysed using the online software V-Quest provided 
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by the International ImMunoGeneTics (IMGT) database (imgt.cines.fr/textes/vquest) 
for the determination of the CDR regions and the germline origins of V regions of the 
scFv clones. 
 
 
3.3.c – ii   Monoclonal ScFv Binding Titer Assay 
 
Phage rescue of the monoclonal full-length scFv clones was performed as 
outlined in the manufacturer’s protocol (RPAS Expression Module, Amersham 
Biosciences, 27-9401-01) using VCSM13 interference-resistant helper phage 
(Stratagene, 200251). The recombinant phage suspensions (mean titer of 2.03 x 1011 cfu 
/ ml) were each blocked with 1% BSA blocking buffer before incubation with T. gondii 
tachyzoites (1.0 x 105 cells / reaction). Each verified functional full-length scFv clone 
was also tested for binding with negative control WRL68 cells (1.0 x 105 cells /reaction) 
in parallel with the T. gondii binding study to analyse for the binding titer comparison. 
A second negative control was also incorporated into the experimental set-up, which 
was the testing of the binding titer of non-scFv fusion-VCSM13 or ‘blank’ phages with 
T. gondii.  All of these reactions were incubated at 8°C for 2 hours with rotation. The 
centrifugation, washing and phage-elution steps from the cells were carried out as 
described before; except that 4 rounds (instead of 5 rounds) of washing were conducted 
with THB-T wash buffer. The phage eluate recovered was reinfected with log-phase 
TG1 and titered to determine phage capture from the mean of replicates. Comparison of 
means between both the samples and negative controls were done by using the one-
tailed Wilcoxon-Mann-Whitney statistical test (H0 < HA, α = 0.05), on the Analyze-It 
v.2.2 platform. 
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3.3.c – iii   Structural Modelling of V Regions 
 
The structural modelling of the V-regions of the scFv clones and its’ germline 
counterparts were accomplished by using the web-based antibody modelling software – 
Rosetta Antibody: Structure Prediction Server (Sircar, Kim, & Gray, 2009) provided by 
the Department of Chemical and Biomolecular Engineering, Johns Hopkins University 
(http://antibody.graylab.jhu.edu/). The modelling protocol incorporates an ab initio loop 
modeling of CDR H3, simultaneous optimizing of the CDR backbone dihedral angles 
and the relative orientation of the light (VL) & heavy (VH) chains (Sivasubramanian, 
Sircar, Chaudhury, & Gray, 2009). Only 1st rank predictions were used for each scFv 
model. 
 
The resulting molecular models were viewed and analysed using the software VMD 
version 1.8.7 (2009) (www.ks.uiuc.edu/). The analysis and superimposition of the 
recombinant and germline scFv molecular models was generated with the SwissPdb-
Viewer (DeepView) version 4.0.1 (2008) (http://spdbv.vital-it.ch/) and also PyMOL for 
windows.  
 
 
3.3.d. Affinity maturation of anti-Toxoplasma gondii scFv antibodies and its’ 
analysis 
 
3.3.d – i  Construction of Hotspots Affinity-Matured Phage-display 
Libraries 
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Hot spots are regions within an antibody’s CDRs that are naturally prone to 
somatic hypermutations during the in vivo affinity maturation of an antibody 
(Neuberger & Milstein, 1995). Based on the identification of hot spots residues within 
the scFv antibodies’ CDR using the V-Quest software (imgt.cines.fr/textes/vquest), the 
hot spot motif RGYW (R = A or G, Y = C or T, W = T or A) was chosen as the loci for 
introducing randomized mutations to produce a 2nd generation scFv antibody library for 
the purpose of affinity maturation against T. gondii. A RGYW-hot spot region on the VL 
fragment, CDR1 of TG130 scFv was targetted for the affinity maturation procedure. 
 
Completely overlapping sense and antisense DNA oligomers were designed to 
generate a library randomizing 4 nucleotides (2 consecutive amino acids) at the targeted 
hot spot region, while preventing the introduction of stop codons through the 
randomized mutations. The following degenerate oligomers were used: pCANTAB5 E 
– RGYW Fwd (Sense), 5’- G  GCC  AGT  CAG  GAT  GTG  VNS  NCT  GCT  GTA  
GCC -3’; pCANTAB5 E – RGYW Rev (Antisense), 5’- GGC  TAC  AGC  AGN  SNB  
CAC  ATC  CTG  ACT  GGC C  3’, (V = A or C or G, S = C or G, B = C or G or T). 
The 4-nucleotide-point mutation was carried out on scFv TG130 as the parental 
template and using the QuickChange Lightning Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA, Cat. No. 210518).  
 
Usage of degenerate DNA oligomers in PCR is normally a less efficient process; 
therefore before commencing the site-directed mutagenesis PCR reaction, 
oligonucleotide adaptors were generated from the degenerate oligomers to improve the 
mutagenesis PCR run. Equimolar amounts of point mutagenesis degenerate 
oligonucleotides (pCANTAB5 E – RGYW Fwd and pCANTAB5 E – RGYW Rev) 
were resuspended in Annealing Buffer (10 mM Tris-HCl pH 7.5 / 60 mM NaCl), and  
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subsequently heated to 95°C for 10 min before allowing to cool to room temperature 
overnight to form an oligonucleotide duplex. 
 
Following the generation of the degenerate oligonucleotide adaptors, the 
mutagenesis PCR reaction was carried out using 10.6 ng of the phagemid 
pCANTAB5E-TG130 which contains the scFv TG130 as template; with 30.0 pmol of 
the degenerate DNA adaptors (15.0 pmol or 153.4 ng each of the degenerate DNA 
oligomers pCANTAB5 E – RGYW Fwd and pCANTAB5 E – RGYW Rev). The scFv 
template and DNA adaptors were mixed with the QuikChange Lightning enzyme and its 
component reagents according to manufacturer’s protocol in a total of 50.0 µl volume 
and cycled according to this condition: 1 cycle at 95°C for 2 min, followed by 18 cycles 
at 95°C for 20 s, 60°C for 10 s, and 68°C for 2.5 min, and 1 final extension cycle at 
68°C for 5 min. The mutagenesis PCR product from this described reaction was Dpn1-
digested to remove all parental phagemid dsDNA, ethanol precipitated, and 
subsequently cloned into XL-10 Gold® ultracompetent cells according to manufacturer’s 
protocol provided in the kit. Transformed clones were verified by colony PCR using the 
S1 and S6 primers (similar protocol to section 3.3.c-i) and sequenced to check for 
successful sequence diversification at the targeted mutation loci. 
 
Once sequence verification has confirmed the presence of the targeted 
mutations, the point-mutated phagemids were isolated from the XL-10 Gold cells using 
the conventional alkaline lysis minipreparation procedure (Sambrook & Russell, 2001), 
and transformed into chemically-competent E. coli TG1 using an optimized protocol 
published by Tu Zhiming and co-workers (Tu et al., 2005). The point-mutated scFv 
library was rescued from the transformed TG1 E.coli, titered and immediately used for 
the 2nd generation biopanning procedure. 
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3.3.d – ii  Biopanning screening of 2nd generation clones (RGYW-point 
mutants) 
 
The resulting recombinant phage derived from the phage rescue in section 2.3l 
was PEG-precipitated, and blocked in 2% BSA (1:1 ratio) before biopanning. The 
panning antigen, T. gondii tachyzoites was purified and prepared as previously 
described in section 3.3a. The phage mixture (~2.7 x 1012 cfu) from the RGYW-point 
mutated library was added to the purified tachyzoite cells suspension (~ 4.0 x 105 cells) 
in pre-blocked microcentrifuge tubes, and the mixture was rotated at 4 rpm at 8°C for 1 
hr. This biopanning reaction was run in triplicate sets in parallel with double negative 
controls: T. gondii tachyzoites incubated with the parental strain scFv TG130 as the first 
control; and T. gondii tachyzoites (~2.0 x 105 cells) incubated with non-recombinant 
VCSM13 helper phages as the second control. All experimental conditions for the 
controls were similar to those applied for the samples unless otherwise stated. 
 
As the purpose for this biopanning screening of the 2nd generation scFv clones is 
for the isolation of antibody fragments with improved affinity; a shorter co-incubation 
time and a longer and more stringent wash conditions was employed compared to the 
protocol described in section 3.3f. Antibody fragments with faster on-rates (kon) and 
longer off-rates (koff), would result in a lowered affinity constant (KD) and therefore an 
improved binding affinity. Following the 1h incubation, cells were pelleted by 
centrifugation at 1000xg, 4°C for 5 min and the supernatant was discarded. The cells 
were washed by resuspension in cold THB-T (0.05%), vortexed and subjected to a 
further washing incubation for 5 min at 4 rpm, 8°C. This washing step was repeated for 
10 consecutive rounds, and bound phage were eluted by resuspending the washed cells 
in 200 µl of ice-cold Glycine-HCL (pH 2.2) Elution Buffer (EB) and incubated on ice 
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for 10 min. The eluted mixture was then neutralized by addition of 26.7 µl Tris-HCL 
(pH 8.0) and reinfected with 1.5 ml of log-phase E. coli TG1 cells. The eluted phages 
from each experimental sets and controls were titered to determine the amount of 
captured phages on the antigens, and glycerol stocks of the eluate were prepared and 
stored at -80°C. 
 
 
3.3.d – iii  Immunofluorescence Assay 
 
Extracellular live tachyzoites were prepared for the surface indirect 
immunofluorescence assay according to the procedure described in section 3.3a. 
Filtered tachyzoites were blocked with 2% BSA in PBS-T (Blocking Buffer) prior to 
antibody co-incubations. Blocked tachyzoites were probed with the candidate 
recombinant phage-displayed scFv antibodies suspension in Blocking Buffer for 1 hour 
at 4°C. This was followed by a double washing round in 2 ml of Toxoplasma 
Homogenization Buffer (THB) by centrifuging the mixture at 1000xg for 4 min at 4°C.  
 
Anti-M13 g8p phage coat protein monoclonal antibody (Pierce Biotechnology, 
MA1-06603) was conjugated to Alexa Fluor® 488 chromogen using the Alexa Fluor® 
488 Monoclonal Antibody Labelling Kit (Molecular Probes, A20181); and was 
subsequently used as the secondary antibody for the detection of scFv binding to the 
target. The secondary antibody (1:50 dilution) was incubated with the washed 
tachyzoites for 30 min at 4°C in the dark, followed by a similar double washing round 
with THB as mentioned previously. Labelled parasites were subsequently fixed in 1 ml 
of cold 2.5% formaldehyde in PBS, pH 7.4, for 20 min on ice. After 20 min, the fixed 
tachyzoite cells were immediately washed in double rounds of ice-cold THB. The fixed 
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and labelled tachyzoite cells were then embedded with ProLong Gold mounting 
medium with DAPI (Molecular Probes, P36935) for microscopy. Slides were allowed to 
cure for at least 24 hours before microscopy. A magnification of × 63 was used to view 
the cells on a Leica TCS SP2 AOBS Confocal microscope. 
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CHAPTER 4.  RESULTS & DISCUSSION (PART 1): GENERATION OF 
ANTI-TOXOPLASMA GONDII ScFv ANTIBODIES BY 
PHAGE-DISPLAY. 
 
4.1 Strategy 
 
The purpose of this study was to construct a scFv phage display library targeted 
against T. gondii tachyzoites from an immunized mouse B-cell repertoire. The resulting 
antibody library was then screened against the whole tachyzoite cells to isolate and 
further characterize the binding scFv antibodies. The antibody screening procedure was 
optimized to reduce false positive binding to the target cell surface as well as to 
minimize loss of functional full-length scFvs and diversity of clones captured. The 
binding specificity of the candidate scFv antibody that was developed in this study was 
verified through determination of target binding titers and immunofluorescence 
localization. The strategy for the generation of anti-Toxoplasma gondii scFv by phage-
display is shown in Figure 4.1. 
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Mouse immunization 
 
 
mRNA isolation from immunized mouse spleen 
 
 
Construction of polyclonal scFv antibodies fragments by SOE-PCR 
 
 
 
 
 Generation of phage-displayed scFv antibody library (1.62 X 104 independent 
transformants) 
 
 
Subtractive biopanning screening of scFv antibody library to T. gondii 
 
 
Characterization of scFv antibodies recognizing T. gondii 
 
 
FIGURE 4.1 The workflow of procedures for the generation of anti-T. gondii scFv 
antibodies by phage-display is summarized in this schematic diagram. 
 
 
  
 
• Cloning into phagemid 
vector pCANTAB5E 
 
• Electroporation 
transformation of E. coli 
TG1. 
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4.2 Results 
 
4.2.1 - Mouse immunization with T. gondii 
 
BALB/c mice that were immunized with T. gondii tachyzoites according to 
standard procedures as detailed in Methodology section 3.3a were bled on the 4th day 
after the final 2nd booster. A total of 3 mice were immunized and its serum tested for the 
presence of IgG antibodies to T. gondii antigens by an immunoblot assay. Results of the 
immunoblot analysis showed seropositivity of all 3 mice to T. gondii with serum IgG 
that was reactive to a wide range of T. gondii antigens separated on the blots (Figure 
4.2). This provides the verification needed to proceed with the splenic harvest of the 
immunized mice. 
 
 
 
FIGURE 4.2 Immunoblot verification of mouse serum immunized against T. 
gondii. Western blot strips of T. gondii parasite separated on SDS-PAGE were probed 
with immunized mouse serum individually. The immune mice serum (lanes 1 – 3) 
showed IgG reactivity with the parasite antigens. Uninfected mouse serum was used as 
negative control (lane NC). The migration of size markers is indicated in kilodaltons 
(Prestained protein ladder, Fermentas, SM0671).  
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4.2.2 - Assembly of T. gondii-immunized scFv phage-displayed library 
 
Total RNA isolated from splenic cells of T. gondii immunized mice (Figure 4.3) 
was evaluated for integrity and purity. As shown in the gel electrophoresis of Figure 
4.3, total RNA isolation samples showed sharp bandings of 18S and 28S ribosomal 
RNA at approximately 1.9 kbp and 4.7 kbp respectively; indicating intact total RNA. 
There was a total of 8 batches of total RNA isolated from a single mouse spleen organ. 
Although sectioning the spleen tissues to 8 batches may slightly lower the isolated RNA 
concentration, this was necessary to avoid the clogging of the RNA spin columns due to 
the inherent viscosity of homogenized animal tissues. The purity and the concentration 
of the total RNA isolated were assessed by spectrophotometric readings (Table 4.1). 
These RNA samples were then pooled together into 3 batches and used for mRNA 
isolation by Poly(A) selection. Messenger RNA samples isolated were 
spectrophotometrically assessed for purity, and only  mRNA samples with an A260 / 
A280 absorbance value ratio of 1.45 – 1.80 were used for downstream cDNA synthesis 
and primary PCR amplification (Table 4.2). 
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FIGURE 4.3 Quality of RNA isolated from immunized mouse spleen tissues. A 
fraction of approximately 5 – 10 µg of total RNA prepared from approximately 30 mg 
tissue samples were loaded into each well (lanes 1-4). The 18S and 28S rRNA bands are 
indicated (arrowheads). The size of the RNA ladder marker (Fermentas RNA Ladder, 
High Range, SM1821) is indicated at the left in kbp. 
 
 
 
TABLE 4.1. Total RNA isolation and quantitation. 
Immunized mouse spleen was harvested and its tissue sectioned into 30 mg cubes for 
total RNA isolation and purification. Results of the 8 batches of samples showed good 
RNA recovery, but with lowered purity. However, these RNA samples were of 
satisfactory quality for mRNA isolation. 
 
 
Total RNA 
Sample 
Dilution 
Factor 
A260 Concentration 
(µg/ml) 
A260 / A280 
1 100 0.093 372.0 1.34 
2 100 0.071 284.0 1.32 
3 100 0.093 372.0 1.40 
4 100 0.138 552.0 1.32 
5 100 0.160 640.0 1.35 
6 100 0.122 488.0 1.35 
7 100 0.157 628.0 1.33 
8 100 0.073 292.0 1.30 
 
 
 
kbp 
28S 
 
18S 
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TABLE 4.2. mRNA purification and quantitation. 
Total RNA isolated from immunized mice were pooled and purified for mRNA fraction. 
mRNA samples 1 and 3 were used for further downstream work, while sample 2 was 
discarded due to poor purity. A total of approximately 240 mg of splenic tissues were 
used to derive a combined mRNA total yield of 7.8 µg.  
 
mRNA 
Sample 
Dilution 
Factor 
A260 Concentration 
(µg/µl) 
A260 / A280 
mRNA 1 50 0.020 0.04 1.62 
mRNA 2 20 0.331 0.26 1.03 
mRNA 3 50 0.019 0.04 1.51 
 
 
Primary PCR amplification of VH and VL gene fragments using primer mixes of 
MSCVκ and MSCJκ (for VL); and MSCVH and MSCG (for VH) (Appendix III) from 
the immunized mouse splenic mRNA resulted in gene fragments of approximately 340 
bp and 325 bp in size respectively. This was followed by the assembly of the scFv 
constructs by Splice-Overlap Extension (SOE) PCR of VH and VL gene repertoires with 
an intervening 8-amino acid flexible linker sequence, resulting in a 750 – 800 bp 
polyclonal gene fragment pool (Figure 4.4). At least 10 separate PCR rounds for the 
construction of the scFv fragments were carried out to increase library size and 
diversity.  The peptide linker sequence bridging the 2 gene fragments was necessary to 
provide a degree of flexibility and hydrophilicity to the recombinant antibody fragment 
in binding to its’ target parasitic antigen. 
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FIGURE 4.4 Primary PCR amplification of V-region genes and scFv assembly. 
A, Amplified VH and VL fragments. Lane 1, VL fragment; lane 2, VH fragment; lane 3, 
VH size-marker (GE Life Sciences, formerly Amersham Pharmacia). B, lane 1, SOE-
PCR-assembled scFv antibody fragment. The size of the DNA ladder marker is 
indicated on the left in kbp. 
 
 
 
4.2.3 - Rapid selective screening for scFv antibodies binding to T. gondii 
tachyzoites. 
 
The recombinant phage-display library generated through 5 rounds of 
electroporations contained at least 1.62 × 104 independent transformants of scFv 
antibodies and was used to screen for binding to T. gondii tachyzoites in a single-round 
solution-phase biopanning. Transformants that were generated through the 
electroporations were verified by colony PCR for full length scFv antibody inserts 
(Figure 4.5). After 3-rounds of subtractive biopanning followed by a single-round of 
antigen biopanning screening, 3.13 × 103 cfu/ml phages were recovered. 
 
 
kbp kbp 
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FIGURE 4.5 Colony PCR results of the scFv genes cloning into E. coli TG1 by 
electroporation. A recombinant phage display library was generated by 
electroporations of pCANTAB5e phagemid vector carrying scFv antibody fragments 
into electrocompetent E. coli, resulting in a scFv-phage display library size of 1.62 × 
104 transformants. Transformants were verified by colony PCR to check for full length 
scFv inserts (~750 – 800 bp). A total of 180 single colony clones were amplified by 
PCR. A representative of 69 clones that was amplified is shown here. M, 2-Log DNA 
ladder marker (NEB, N3200). 
 
 
 
In order to ascertain whether the phages recovered from the antigen biopanning 
output had selective binding advantage to T. gondii; we subjected the pool of recovered 
phages to another round of selective screening against the binding target in parallel to 
negative control absorber cells WRL68 and the un-panned scFv library fraction. The 
WRL68 cell line is a normal human hepatocyte cell line used as a sink to absorb 
unspecific binding phages from the scFv library. The study found that the single-round 
biopanned output phage fraction had a binding titer of at least 5.6 fold higher than the 
un-panned phage fraction from the primary library (Figure 4.6), indicating moderate 
enrichment for T. gondii-binding phage scFv.  To further investigate the antibody’s 
specificity against the tachyzoites, we compared the phage scFv binding titers between 
T. gondii and absorber cells WRL68. The results showed that the single-round 
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biopanned phage scFv had at least a 2.3 fold higher binding titer to T. gondii relative to 
WRL68 (Figure 4.6), indicating a binding advantage to the target antigen.  
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FIGURE 4.6 Pooled scFv-phage binding titers on T. gondii and the WRL68 human 
cell line. ScFv-phages were co-incubated with either T. gondii or WRL68 for 1 hour 
with conditions described under Methodology section 3.3b. The binding titers of the 
pooled scFv - phage population through a rapid single round biopanning procedure with 
preceding subtractive biopanning rounds is shown here in the bar graph, with a tabled 
description of each binding experiment set-up. ScFv-Phages incubated in BSA Blocking 
Buffer without any cells were used as background controls. Binding titers from triplicate 
experiments of these background controls was consistently non-detectable. Single-round 
biopanned phage-scFvs pool were at least least 2.3-fold higher in its binding affinity for 
T. gondii compared to binding with the normal human liver cell line – WRL68. Error 
bars, ± S.D. from the means of duplicate experiments. Asterisks (*) denotes a 
statistically significant difference between experiment set [t-test, Power of performed 
test with alpha = 0.05; 0.630 (Experiment set 1-2) and 0.666 (Experiment set 1-4)] 
 
Experiment 
Set 
Antigen-binding screening Average 
Output Titer 
(103) 
ScFv-Phage Antigen cells 
1 Single-round Output Phage T. gondii tachyzoites 12.10 
2 Unpanned Phage Library T. gondii tachyzoites 2.15 
3 Single-round Output Phage WRL68 5.25 
4 Unpanned Phage Library WRL68 1.30 
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From the single-round of selective biopanning followed by 5 rounds of stringent 
washes, up to 131 clones were selected and PCR screening was carried out for full 
length clones from the eluted phage binders (Figure 4.7). Out of these clones, 9 full 
length scFv gene sequences were selected (Figure 4.8) and fingerprinted with the 
restriction enzyme Mva1 with each showing a unique DNA fingerprinting pattern 
(Figure 4.9), indicating the recovery satisfactory diversity in the scFv gene sequences 
captured. Through analysis of the unique scFv clone sequences, the candidate scFv list 
was further shortlisted to 4 translational full-length clones that were free from any 
frameshift mutations and intervening stop codons – scFvs TG64 (GenBank accession 
no. JN104603), TG69 (GenBank accession no. JN104604), TG116 (GenBank accession 
no. JN104605) and TG130 (GenBank accession no. JN104602) (Appendix VI). 
Sequencing results and protein translation of the remaining 5 truncated scFv sequences 
with intervening stop codons are also provided in Appendix VII. 
 
 
 
FIGURE 4.7 Colony PCR screening of eluted scFv-phage displayed clones from 
antigen biopanning. ScFv antibody clones binding to T. gondii cells were recovered 
from biopanning and amplified to select for full-length antibodies (~ 900 bp). A total of 
131 clones were screened by PCR. This figure shows a representative of 24 clones from 
the PCR screening. M, GeneRuler 100 bp Plus DNA Ladder (Fermentas, SM0323). 
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FIGURE 4.8 PCR amplification of full-length scFv clones from antigen 
biopanning. Amplification of 9 full-length scFv antibodies eluted from T. gondii 
biopanning using the S1 and S6 primers show the expected DNA fragment sizes of 
approximately 900 bp. 
 
 
 
 
FIGURE 4.9 Unique fingerprint profiles of full-length scFv gene fragments. 
Monoclonal scFv antibody clones obtained after elution from the biopanning reactions 
with tachyzoites were fingerprinted, showing diversity in captured scFv clones (lane 1-
9). Fingerprint profiles were generated by digestion with the restriction enzyme – Mva I. 
 
bp 
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4.2.4 -  ScFv antibodies with specific binding advantage to T. gondii tachyzoites 
isolated through the rapid selective screening procedure. 
 
To assess whether the functional scFv antibody clones that were recovered 
through our optimized cell-based biopanning procedure possesses true binding 
advantage to the intended target – T. gondii tachyzoites, monoclonal scFvs binding titers 
were determined against both the target cell and the negative absorber cell WRL68 in 
independent experiments (Figure 4.10). As shown in figure 4.10, among the four scFv 
clones that were assessed in its binding capacity, clone TG116 showed the highest mean 
binding titer to T. gondii at 5.62 x 105 cfu/ml, while TG130 showed the lowest mean 
binding titer to T. gondii at 2.05 x 105 cfu/ml. The one-tailed Wilcoxon-Mann-Whitney 
statistical analysis test was applied to test the hypothesis that the recombinant scFv 
clones has a higher binding capacity to T. gondii tachyzoite cells compared to negative 
control WRL68 normal hepatocyte cell line for each clone, with an alpha value of 0.05 
with n = 12. As the data set did not fit a normality curve, the non-parametric Wilcoxon-
Mann-Whitney test was chosen for the statistical analysis (Wilcoxon, 1945).  This two 
group comparison was carried out to investigate the specificity of the scFv antibodies 
for T. gondii, based on whether there is a statistically significant preference for the 
parasite cells compared to normal cells. It was found that there was no statistically 
significant difference in the binding capacity of the 3 scFv antibodies isolated – scFvs 
TG64, TG69 and TG116 in its interaction between T. gondii tachyzoite cells and 
WRL68 (exact P value = 0.44; 0.11; and 0.50 respectively), despite moderately high 
binding titers of up to 5.62 x 105 cfu/ml (scFv TG116) (Figure 4.10). In other words, 
these antibodies were not significantly able to distinguish for specific binding to the 
target parasite antigen. 
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However, further analysis elucidated a statistically significant difference in the 
binding capacity of scFv TG130 to T. gondii compared to WRL68 at the p = 0.05 level 
(exact P value = 0.0303, n = 12) and a 97% exact confidence interval of 5.0 x 103 cfu/ml 
(Appendix X and XI). Despite demonstrating the lowest binding titer to T. gondii (1.74 
x 105 cfu/ml) compared to our other 3 candidate antibodies, the scFv TG130  displayed 
at least a 5-fold higher binding titer relative to absorber WRL68 (Figure 4.10). It’s also 
shown through this study in figure 4.10 that the scFv binding advantage to tachyzoites 
was not a result of phage background binding as the untransformed VCSM13 controls 
showed either negligible binding titers with T. gondii (mean = 1.0 x 103 cfu/ml), or no 
detectable binding at all  with WRL68.   Viewing these preliminary findings from the 
premise that antibody binding specificity should take precedence over mere binding titer 
values as indication of a bona fide ligand targeted against T. gondii, the TG130 clone is 
selected as superior in its selectivity in binding to T. gondii in comparison to the other 
isolated scFv clones; and thus this antibody fragment was chosen for further 
characterization. 
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FIGURE 4.10 Monoclonal functional scFv binding titers to T. gondii tachyzoites 
and WRL68 human cell line. Candidate scFv antibody clones recovered from the 
biopanning procedure were tested to compare its binding capacity between T. gondii 
and WRL68. An asterisk (*) denotes a statistically significant difference in scFv binding 
advantage to T. gondii. The titers of phage captured from co-incubation with the cells 
shown are average values of duplicate or triplicate experiments, and untransformed 
VCSM13 binding titers are shown as equivalent negative controls to rule out 
background binding. Determination of negative control VCSM13 binding titers were 
done with Kanamycin-resistance selection instead of Ampicillin as the untransformed 
phage does not contain the pCANTAB5E phagemid which carries the Amp resistance 
gene. Error bars, ± S.E.M. from the means of duplicate or triplicate experiments. 
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4.2.5 -  Sequence analysis of putative anti-T. gondii scFv antibodies 
 
The sequence assessment of the short-listed 4 translational full-length scFv 
clones – TG64, TG69, TG116 and TG130, was done through the V-Quest at IMGT 
program (imgt.cines.fr/textes/vquest) (Lefranc, 2001). The V-Quest analysis carried out 
includes the identification of IgG antibody framework and CDR regions, and a 
homology search for germline sequences of origin (Table 4.3). The closest homology 
germline gene sequences of the V and J regions for each of the scFv clones were 
manually assembled and translated into amino acid sequences for both the VH and VL 
chain fragments; which was subsequently aligned with the nucleotide and amino acids 
sequence of its respective scFv VH and VL chains. As the focus for the antibody 
characterization was on TG130 due to its binding selectivity to T. gondii, the alignment 
for scFv TG130 is shown in figure 4.11 while the alignments for scFvs TG64, TG69 
and TG116 are provided in the Appendix VIII. The aligned scFv sequences were 
compared for sequences which differs from its’ germline counterpart; and amino acid 
sequence changes within the hypervariable CDRs were identified (Figure 4.11). The 
findings of our investigation on the sequence divergences of the scFv genes from its 
germline counterparts are summarized in Table 4.4. This is pertinent to our antibody 
characterization because deviations of the scFv DNA and amino acid sequences imply 
the occurence of somatic hypermutational events of B cells through antigenic exposure 
(reviewed in Li, Woo, Iglesias-Ussel, Ronai, & Scharff, 2004; and MacLennan, 1994).  
 
The CDR regions are hypervariable sites that are juxtaposed to form the antigen-
binding site of an antibody, with the VH chain CDR3 usually presenting the greatest 
length and sequence variability, especially following an in vivo immune response 
(Burton, 2001). As can be seen in Figure 4.11, the comparison of the candidate scFv 
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sequences shows that scFv TG130 has the highest number of amino acid point 
mutations in the CDR regions accumulated, which is 6 residues within the VH and VL 
chains combined (Table 4.4). These somatic mutations are mostly localized to the 
CDR3 regions for both the VH and VL chains, which is the antibody region that is 
known to contribute the most significant contacts in antigen interactions. 
Comparatively, the non-specific scFv clones (scFvs TG64, TG69 and TG116) were 
found to have an overall lesser deviation from germline sequences and therefore exhibit 
less somatic mutations in in vivo affinity maturations resulting from an immune 
response. ScFv TG69 and TG116 had only 2 residue mutations within the VH CDR3 
and VL CDR1 regions respectively, while scFv TG64 had no mutation at all found 
within its CDR regions. It was therefore hypothesized that scFv TG130 could be the 
most affinity-matured antibody fragment for specific binding to T. gondii amongst the 
clones which merited further examination and study. 
 
Through a V-region sequence analysis using the V-Quest program (Appendix 
IX), it was found that the light chain variable region of scFv TG130 originates from the 
Vκ6 class, and has the highest sequence homology with the germline light chain gene 
IGKV6-17*01 (GenBank™ accession number Y15978) at 96% identity at the 
nucleotide level. It was also found that the VL chain region of TG130 was possibly 
formed through the recombination of the Vκ6 gene IGKV6-17*01 with the Jκ5 gene 
IGKJ5*01 (GenBank™ accession number V00777) which has the highest homology 
with TG130 sequence at a 94.6% identity at the nucleotide level. Overall, the VL region 
showed multiple somatic mutations and had a 91% amino acid identity with its’ closest 
germline sequences. 
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A similar V-Quest sequence assessment was done for the heavy chain variable 
sequence of TG130 to identify the germline origin of the fragment (Appendix IX). The 
analysis showed that the heavy chain variable sequence is of the VH germline gene 
IGHV1S29*02 (GenBank™ accession number J00488) origin which displayed the 
highest sequence homology at 97.6% identity at the nucleotide level. The C-terminal 
region of the scFv TG130 fragment possibly arose through the somatic recombination of 
the VH germline gene IGHV1S29*02 with the closest homology germline J gene 
IGHJ3*01 (GenBank™ accession number V00770) (93.8% identity at the nucleotide 
level). The overall homology of the VH region to its’ closest germline sequences stands 
at 94.8% at the amino acid level. 
 
Non-synonymous somatic mutations in the genes of the V regions as compared 
to its’ germline counterparts leads to 15 amino acid changes (Figure 4.11). In the VL 
chain: Phe  Leu-L70 (FR-L3), Ser  Asn-L74 (FR-L3), Ala  Ser-L77 (FR-L3), Val 
 Glu-L82 (FR-L3), Tyr  Phe-L84 (FR-L3), His  Tyr-L88 (CDR-L3), Tyr  Asn-
L89 (CDR-L3), Thr  Tyr-L91 (CDR-L3), and Pro  Tyr-L93 (CDR-L3). For the VH 
chain, the mutations are: Gln  His-H3 (FR-H1), Gln  Val-H5 (FR-H1), Gln  Glu-
H6 (FR-H1), Ser  Arg-H84 (FR-H3), Ala  Asp-H100 (CDR-H3), Trp  Gly-H101 
(CDR-H3). Out of these 15 amino acid changes, 6 of these mutations are found within 
the CDR and are all concentrated to the CDR-H3 and CDR-L3. 
 
The sequence analysis of scFv TG130 via V-Quest also generated an IMGT 
Colliers de Perles diagram of the antibody’s V domains (Figure 4.12). The Colliers de 
Perles diagrams (Ruiz & Lefranc, 2002) are standardized two-dimensional graphical 
representations of antibody V domains annotated according to IMGT unique numbering 
rules (Lefranc et al., 2003), which allowed for the visualization of the framework and 
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CDR residues. Due to the parity of resolved antibody three-dimensional structures 
available, Collier de Perles diagrams are particularly useful in antibody engineering 
studies to help identify the connection between linear amino acid sequences and its’ 
structural features within an antibody such as turns, loops, and strands; as well as 
positions likely to be involved in antigen contacts. 
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TABLE 4.3. Anti-Toxo ScFv IGHV and IGKV subgroup usage and H / κL-CDR3 motifs 
Candidate scFv clones binding to T. gondii were analysed to determine its CDRs and origin of murine germline V-regions using the online V-Quest 
software provided by the International ImMunoGeneTics data base (IMGT, imgt.cines.fr/textes/vquest/). 
 
 
 
 
 
 
 
 
Clone 
ID 
IGHV H chain CDR3 H 
chain 
CDR3 
length 
(bp) 
IMGT - H 
[CDR1.CDR2.CDR3] 
length 
GenBank 
accession 
no. 
IGKV L chain CDR3 L 
chain 
CDR3 
length 
(bp) 
IMGT - L 
[CDR1.CDR2.CDR3] 
length 
GenBank 
accession 
no. 
TG64 1-4*01 CAREAWFAYW 8 [8.8.8] AC073561 4-70*01 CHQRSSYPYTF 9 [5.3.9] AJ235943 
TG69 14-3*02 CARLPYW 5 [8.8.5] AJ851868 6-23*01 CQQYSSYHTF 8 [6.3.8] AJ235961 
TG116 14-3*02 CASSHGYEDYFDYW 12 [8.8.12] AJ851868 6-13*01 CQQYSSYPYTF 9 [6.3.9] J00569 
TG130 1S29*02 CARGDGFAYW 8 [8.8.8] J0048 6-17*01 CQQYNSYPYTF 9 [6.3.9] Y15978 
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VL                                              CDR1 - IMGT    
  1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44   
TG130 (aa)  M   T   Q   S   H   K   F   M   S   T   S   V   G   D   R   V   S   I   T   C   K   A   S   Q   D   V   S   T   A   V   A   W   Y   Q   Q   K   P   G   Q   S   P   K   L   L    
TG130 (nt)    atg acc cag tct cac aaa ttc atg tcc aca tca gta gga gac agg gtc agc atc acc tgc aag gcc agt cag gat gtg agt act gct gta gcc tgg tat caa cag aaa cca gga caa tct cct aaa cta ctg 
Germ (nt)      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)       -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -    
 
                              CDR2 - IMGT 
  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88                     
TG130 (aa)  I   Y   S   A   S   Y   R   Y   T   G   V   P   D   R   F   T   G   S   G   S   G   T   D   F   T   L   T   I   S   N   V   Q   S   E   D   L   A   E   Y   F   C   Q   Q   Y    
TG130 (nt)     att tac tcg gca tcc tac cgg tac act gga gtc cct gat cgc ttc act ggc agt gga tct ggg acg gat ttc act ctc acc atc agc aat gtg cag tct gaa gac ttg gca gag tat ttc tgt cag caa tat 
Germ (nt)      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- t-- --- --- --- -g- --- --- g-- --- --- c-- --- -tt --- -a- --- --- --- c-- 
Germ (aa)       -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   F   -   -   -   S   -   -   A   -   -   -   -   V   -   Y   -   -   -   H    
 
 
                            CDR3 -  IMGT 
  89  90  91  92  93  94  95  96  97  98  99  100                        
TG130 (aa)   N   S   Y   P   Y   T   F   G   A   G   T   K    
TG130 (nt)     aac agc tat ccg tac acg ttc ggt gct ggg acc aag          
Germ (nt)        t-t --t ac- --t cc- --- --- --- --- --- --- ---                               
Germ (aa)        Y   -   T   -   P   -   -   -   -   -   -   -                                
                  
                                
                                              
VH            CDR1 - IMGT    
                 1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44       
TG130 (aa) E   V   H   L   V   E   S   G   P   E   L   V   K   P   G   A   S   V   K   I   S   C   K   A   S   G   Y   T   F   T   D   Y   N   M   H   W   V   K   Q   S   H   G   K   S    
TG130 (nt)     gag gtg cat ctt gtt gag tca gga cct gag ctg gtg aaa cct ggg gcc tca gtg aag ata tcc tgc aag gct tct gga tac aca ttc act gac tac aac atg cac tgg gtg aag cag agc cat gga aag agc 
Germ (nt)     --- --c --g --- cag c-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)      -   -   Q   -   Q   Q   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -    
  
                                     CDR2 - IMGT 
               45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88   
TG130 (aa)  L   E   W   I   G   Y   I   Y   P   Y   N   G   G   T   G   Y   N   Q   K   F   K   S   K   A   T   L   T   V   D   N   S   S   S   T   A   Y   M   E   L   R   S   L   T   S    
TG130 (nt)    ctt gag tgg att gga tat att tat cct tac aat ggt ggt act ggc tac aac cag aag ttc aag agc aag gcc aca ttg act gta gac aat tcc tcc agc aca gcc tac atg gag ctc cgc agc ctg aca tct 
Germ (nt)      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- a-- --- --- --- --- 
Germ (aa)      -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   S   -   -   -   -    
 
                               CDR3 - IMGT 
              89  90  91  92  93  94  95  96  97  98  99  100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115       
TG130 (aa)    E   D   S   A   V   Y   Y   C   A   R   G   D   G   F   A   Y   W   G   Q   G   T   L   V   T   V   S   A   
TG130 (nt)    gag gac tct gca gtc tat tac tgt gca aga ggg gat ggg ttt gct tac tgg ggc caa ggg act ctg gtc act gtc tct gca                       
Germ (nt)     --- --- --- --- --- --- --- --- --- --- --- -cc t-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)     -   -   -   -   -   -   -   -   -   -   -   A   W   -   -   -   -   -   -   -   -   -   -   -   -   -   -     
  
 
                             
 
 
FIGURE 4.11 Alignment of the VH and VL regions sequences of TG130 with its germline counterparts. The CDR domains are defined according 
to the IMGT numbering scheme (Lefranc et al., 2003). For germline genes, V gene IGKV6-17*01 and J gene IGKJ5*01 fragments were manually 
assembled for VL region; while V gene IGHV1S29*02 and J gene IGHJ3*01 fragments were manually assembled for VH region. An exact residue 
match is indicated by a dash; and a sequence gap is indicated by a dot. Somatic mutational divergences from germline sequences identified in the scFv 
are shown in red-highlighted boxes. 
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TABLE 4.4.  Anti-Toxo ScFv IGHV and IGKV percentage identity and somatic mutations at the nucleotide and amino acid level 
DNA (nt) and amino acid (a.a) sequences of recombinant scFv-phages isolated after biopanning with T. gondii tachyzoites were aligned and 
comparatively analysed against its’ closest homology V-region germline counterparts. V-regions’ and J-regions’ identity levels were determined through 
the V-Quest program analysis; while CDR mutational events were manually identified and calculated. 
 
 
 
 
 
 
 
                                                           
a
 Percentage of total number of CDR1 – CDR3 a.a residues that differs from its germline a.a sequence of origin, presumably produced during the somatic hypermutation of B cells on 
exposure to antigens. 
b
 Total number of a.a residues mutated from the germline sequence of origin in CDR1 – CDR3. 
c
 Amino acid residue mutations present in CDR3. 
d
 Amino acid residue mutations present in CDR1. 
Clone 
ID 
IGHV  IGKV 
V-region 
identity 
(%) 
V-region 
identity 
(nt/nt) 
J-region 
identity 
(%) 
J-region 
identity 
(nt/nt) 
CDR a.a. 
mutationsa 
(%) 
CDR a.a. 
mutationsb 
(nt) 
V-region 
identity 
(%) 
V-region 
identity 
(nt/nt) 
J-region 
identity (%) 
J-region 
identity 
(nt/nt) 
CDR a.a. 
mutationsa 
(%) 
CDR a.a. 
mutationsb 
(nt) 
TG64 96.5 278 / 288 100.0 48 / 48 0.0 0 97.8 261 / 267 97.3 36 / 37 0.0 0 
TG69 99.0 285 / 288 90.7 39 / 43 9.5 2c 99.6 269 / 270 100.0 35 / 35 0.0 0 
TG116 100.0 288 / 288 100.0 48 / 48 0.0 0 98.2 265 / 270 97.3 36 / 37 11.1 2d 
TG130 97.6 281 / 288 93.8 45 / 48 8.3 2c 95.9 259 / 270 94.6 35 / 37 22.2 4c 
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FIGURE 4.12  IMGT Collier de Perles of scFv antibody TG130 V domains. These standardized graphical representations of the antibody V 
domains here show the 2-D structure of TG130 VL chain (A) and VH chain (B) with one-letter amino acid codes. The standardized delimitation of the 
strands of the framework regions (FR) and loops of the CDRs (CDR) are based on IMGT nomenclature. CDR loops are highlighted in colours, 
positions where hydrophobic amino acids are found at more than 50% of analyzed sequences are coloured in blue, all proline residues are in yellow 
and hatched circles represents missing positions. The antibody CDR loops are delineated by ‘squared’ sequences which are anchor residues. Arrows 
show the direction of the beta strands. The CDR-IMGT loop lengths are [6.3.9] for VL (A) and [8.8.8] for VH (B), corresponding to [CDR1. CDR2. 
CDR3]. 
A B 
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4.2.6 –  Molecular modelling of a putative anti-T. gondii scFv antibody. 
 
In this study, the Rosetta Antibody Structure Prediction Server program was 
used to generate the 3-dimensional antibody molecular model for this work. The PDB 
files of both scFv TG130 fragment and the assembled VH and VL germline counterpart 
sequences generated through this program was viewed using the SwissPdb Viewer 
(DeepView). The structural divergence of TG130 scFv from its germline counterparts 
was subsequently investigated by performing a molecular superimposition of the 2 
structures via the DeepView program. The structural alignment output of the 
superimposed ribbon diagrams of the germline and scFv TG130 V-regions is shown in 
Figure 4.13a, which displays a slight displacement at the VL chain CDR L3 region, but a 
significant displacement at the VH chain CDR H3 region from its’ germline molecular 
structure – implying of a somatic hypermutational event and that the CDR H3 loop may 
be directly involved in antigen binding interactions. The structural alignment of the 
antibody models revealed the highest displacement point for the VL chain is at the L3 
Thr94 germline residue which had been mutated to Tyr94 in scFv TG130, showing a root 
mean square deviation (rmsd) value of 2.523 Å. Whereas in the VH chain CDR H3 
region, the highest displacement point was found to be at the Ala96 germline residue 
which was mutated to Asp96 in the scFv TG130 fragment, with the average distance 
between the atoms computed to be rmsd value of 4.729 Å. 
 
A space-filled model of the antibody scFv TG130 (Figure 4.13b) was generated 
by molecular modelling using the web-based antibody modelling software WAM 
(antibody.bath.ac.uk/index.html) which uses a modified form of the algorithm used in 
the AbM antibody modelling software of Oxford Molecular (Accelrys, San Diego, CA). 
The atom coordinates was viewed and analyzed using the VMD program 
(www.ks.uiuc.edu/). The accessibility screen and the CONGEN iterative algorithm was 
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chosen (Bruccoleri & Karplus, 1987) for the antibody modelling side-chain building. 
The amino acid residues of CDR H3 and CDR L3 that are most significantly displaced 
from its germline counterparts based on its structural rmsd value are highlighted as red 
and blue molecules for VH Asp96 and VL Tyr94 respectively in this model (Figure 4.13b). 
A view of the antigen-binding surface of the TG130 antibody demonstrates that these 
residues are strategically positioned to be exposed on the surface and extends from the 
antibody’s groove pocket, suggesting that they may form the antibody-antigen interface. 
 
Taken together, the antibody’s V-region sequence and structural divergence 
from its germline counterparts is characteristic of an in vivo affinity maturation from 
antigenic exposure. This may correlate with its’ binding specificity, although not 
necessarily with its’ binding affinity to the target antigen.  
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FIGURE 4.13 Structural divergences of CDR loop regions of scFv specific for T. 
gondii. A, ribbon diagram of scFv TG130 variable regions (orange) is superimposed 
with that of its germline counterpart (cyan). H1, -2, and -3, heavy chain CDR1, -2, and -
3; L1, and -3, light chain CDR1, and -3. L2, or light chain CDR2 is located on the upper 
right loop directly above the L1 loop. Heavy chain CDR3 for TG130 shows significant 
displacement from that of its closest germline counterpart, suggesting that heavy chain 
CDR3 is directly involved in antigen binding. B, a space-filled model of scFv TG130. 
The view is looking down on the antigen-binding surface pocket groove. CDR1, -2, and 
-3 for light chain of TG130 are coloured (yellow, lime, and orange respectively). CDR1, 
-2, and -3 for the molecule’s heavy chain are coloured (purple, cyan, and pink 
respectively). The amino acid residues of CDR H3 and CDR L3 that are most 
significantly displaced from its germline counterpart (up to rms: 4.7) and most likely to 
be involved in antigen binding – VH Asp 96 (D96), and VL Tyr 94 (Y94) are labelled 
and shown as red and blue molecules respectively.   Residues are numbered according 
to the IMGT unique numbering scheme (Lefranc et al., 2003). 
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4.2.7 –  Detection of T. gondii – binding scFv antibody by 
immunoflouorescence. 
 
 To further test whether scFv antibody TG130 specifically recognized T. gondii 
tachyzoites, confocal microscopy was used to localize the antibody’s antigen 
recognition. Negative control immunofluorescence staining using untransformed 
VCSM13 filamentous phages did not show specific staining on the cells (Figure 4.14), 
while the entire surface of extracellular tachyzoite cells were stained when tested with 
scFv TG130 (Figure 4.15). From these experiments, we can conclude that the scFv 
TG130 binding antibody fluorescence was not a result of background false positives, 
but that the phage-displayed antibody is specifically reactive to T. gondii tachyzoites. 
 
 
 
FIGURE 4.14 Negative control untransformed phage immunofluorescence probing 
with T. gondii tachyzoites. Confocal laser-scanning microscopy of negative control 
VCSM13 filamentous phage reacted against tachyzoite cells showed weak background 
staining and negligible signals. Images are a representative of duplicate experiments 
with similar results. DAPI, 4’,6-diamidino-2-phenylindole; DIC, differential 
interference contrast. Scale bar represents 3 µm. 
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FIGURE 4.15  Confocal laser-scanning microscopy of extracellular T. gondii tachyzoites surface recognition by scFv antibody TG130. These 
cells were incubated with phage-displayed TG130 scFv and then with Alexa Fluor 488-labelled monoclonal antibody to bacteriophage coat protein g8p 
(green). Nuclei were counterstained with DAPI (blue). A magnified view of tachyzoites showing surface staining with the scFv antibody is shown in 
panel B. DAPI, 4’,6-diamidino-2-phenylindole; DIC, differential interference contrast. Scale bars represent 10 µm and 3 µm respectively in panels A 
and B.  
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4.3 Discussion 
 
4.3.1- Isolation of anti-T. gondii scFv antibodies with specific target binding 
advantage through an optimized selective screening procedure. 
 
 In the current study, a scFv antibody fragment to T. gondii tachyzoites was 
generated from a polyclonal filamentous phage display scFv library derived from 
immunized mouse B cells. We employed a procedure using an intact cell surface for the 
biopanning screen to select for phage particles bearing scFv antibodies with the ability 
to bind to native antigen on the tachyzoite cell surface. However, biopanning on intact 
cell surfaces poses a challenge of capturing false positive ligands due to the innate 
complexity of cell surfaces with multimeric and non-specific antigens (D. L. Siegel, 
2001). 
 
 To address this challenge, a subtractive biopanning round was incorporated into 
an optimized biopanning procedure to quench for false positive binders by using 
WRL68 hepatocytes cell line. The WRL68 cell line was used as absorber cells in the 
subtractive biopanning steps, which is also referred to as negative selection. Several 
subtractive biopanning procedures documented thus far (Eisenhardt et al., 2007; Hof, 
Cheung, Roossien, Pruijn, & Raats, 2006) involves several cycles of positive and 
negative selection rounds, without empirical analysis of the number of negative 
selection rounds that is required for adequate quenching. In the present study, the 
quenching ratio of the negative selection rounds was first monitored in a mock 
biopanning test prior to running the procedure against the target cells. It was found that 
the quenching ratio drops and plateaus after 3 negative selection rounds against the 
absorber cells WRL68 (Appendix V). Therefore, 3 subtractive biopanning rounds 
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followed by a single antigen biopanning round were carried out to recover for T. gondii 
– binding scFv antibodies. 
 
 Analysis of the scFv antibodies captured through the biopanning procedure by 
PCR showed the recovery of 9 functional full-length scFv clones. These 9 scFv clones 
were selected and fingerprinted with the restriction enzyme MvaI, with results 
demonstrating diversity in the scFv gene sequences captured. In various procedures for 
the standard analysis of antibodies, fingerprinting with either of the restriction enzymes 
MvaI, BstN1 or BstOI is a useful approach commonly employed to analyze antibody 
fragment clones for diversity relatively quickly and inexpensively (Barbas, Burton, 
Scott, & Silverman, 2001). The restriction enzymes MvaI, BstN1 and BstOI are 
isoschizomers of each other and can be used interchangeably for this purpose.  
However, upon further analysis, stop codon mutations was discovered in 5 out of the 9 
clones, which led to a truncated scFv display on the phage g3p protein (Appendix VII). 
Due to the complexity of cell membrane surfaces, biopanning procedures had the 
propensity to enrich for truncated, non full-length scFv antibodies due to the ‘trapping’ 
of smaller ligands on cell surfaces and the enhanced growth rates of bacteria harbouring 
aberrant phage particles with smaller protein expression (Kramer et al., 2003). To avoid 
enriching for these aberrant phages displaying truncated scFvs and the loss of clonal 
diversity, antigen biopanning was limited to a single round. A single biopanning round 
is also favourable to obtain scFv antibodies with maximal diversity, as another study 
has also shown that performing additional rounds of panning does not increase the 
chances of recovering binders already detected in the first round (Pansri, Jaruseranee, 
Rangnoi, Kristensen, & Yamabhai, 2009).  Through the optimized biopanning selection 
procedure carried out in this study, 4 functional full-length scFv clones were recovered 
and each antibody fragment showed diversity in its unique fingerprint profile. 
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The recovery of 4 functional full-length scFv antibodies against the parasite 
target in this study is comparable to several other phage display experiments with the 
final isolation of 1 – 4 candidate antibody clones specific against a target of interest 
(Kabir, Krishnaswamy, Miyamoto, Furuichi, & Komiyama, 2009; Kupsch et al., 1999; 
Muraoka et al., 2009; Pansri et al., 2009). This is because the basic aim of a phage 
display study is to leverage the high-throughput screening of an antibody or peptide 
library to narrow down the leads to a few specific target binders. However, the 
specificity of scFv antibodies against a target can also be further improved with the 
construction of a large phage displayed-antibody library in the range of 109 – 1011 cfu 
(Vaughan et al., 1996). In another effort to circumvent the well known problem of 
truncated scFv-pIII fusion in phage display libraries due to stop codons and frameshift 
mutations introduced during library construction, Kramer and co-workers have 
developed a mutant helper phage system that partially ameliorates this by enriching for 
functional scFvs by 3-fold (Kramer et al., 2003). However, at present time this mutant 
helper phage is not available commercially and is therefore beyond the reach of most 
laboratories.  
 
 Considering the high artefact background obtained despite the optimized 
biopanning procedure and stringent washing rounds, the scFvs that were eluted from the 
T. gondii tachyzoites may either have demonstrated false positive binding due to 
aggregation or miscellaneous influence by the background aberrant Fv fragment 
displays, or the eluted scFvs may in fact be true antigenic binders to T. gondii 
tachyzoites. In order to distinguish between these two possibilities, each isolated 
monoclonal antibody was compared in their mean binding titers to Toxoplasma and 
WRL68. Determination of the binding titers against T. gondii for the shortlisted scFv 
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clones – scFv TG64, TG69, TG116 and TG130, showed that among the 4 scFv 
antibodies, only one scFv antibody - TG130 displayed statistically significant binding 
specificity to T. gondii tachyzoites with up to 5-fold binding advantage over negative 
absorber cells. Therefore, results of this study showed that the optimized selective 
screening procedure with empirically determined-subtractive biopanning rounds was 
effective in the development of a specific scFv antibody capable of distinguishing 
between negative absorber cells and its’ antigenic target – T. gondii. 
 
 
4.3.2- ScFv antibody TG130 displays sequence diversity and structural divergence 
from homologous germline antibody structures. 
 
 The closest murine antibody germline to the VH gene of scFv TG130 is 
IgHV1S29*02 of the VH1 family and JH3 for the V and J segments respectively (Table 
4.3). A survey of literatures  revealed several mouse antibody genes inducing protective 
immunity in parasitic infections that belonged mainly to either the VH1 or VH5 family. 
An inhibitory monoclonal antibody against T. gondii heat shock protein-70 (TgHSP70) 
also consisted of a heavy chain fragment of the VH1 family, but the closest J segment 
was from JH1 (M. Chen, Aosai, Norose, Mun, & Yano, 2003). In another study, 
protective antibody repertoire to parasitic enteric helminth infections displayed a 
preference for both the VH1 and VH5 gene families (McCoy et al., 2008). Similarly, 
protective murine antibody specific against the Apical Membrane Antigen 1 of 
Plasmodium vivax (PvAMA1), which is involved in erythrocyte invasion; had a heavy 
chain fragment of the VH5 family, but had JH3 as its’ closest germline sequence for the 
J segment (Igonet et al., 2007) – similar to the scFv in this study, scFv TG130.  
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 The closest V germline to the VL chain is IgKV6-17*01 of the Vκ6 family and 
Jκ5 for the J segment of the antibody’s light chain (Table 4.3). Unlike the predominance 
of VH1 and VH5 gene family preference in the heavy chain repertoire of antibodies 
involved in parasitic infections immune responses, there is a parity of studies done on 
mouse antibody light chain preference for parasitic diseases. In two examples, it was 
found that a monoclonal anti-PvAMA1 antibody displayed Vκ4 and Jκ4 in its V and J 
segments respectively, and another antibody against the Merozoite Surface Protein 1 of 
Plasmodium falciparum (PfMSP1) also displayed its closest germline light chain gene 
homology to the Vκ4 family (Igonet et al., 2007; Lazarou et al., 2009). Interestingly, 
another protective antibody against falciparum malaria, specific for the PfMSP1 
antigen, showed the exact same V gene family usage to scFv TG130, in both the VH and 
VL chains (Lazarou et al., 2009). Both antibodies had a heavy chain fragment from the 
VH1 family, although anti-PfMSP1 carried a different VH1 classification, which was 
IgVH1S81*02; while scFv TG130 was of the IgVH1S29*02 classification. The light 
chain fragment of both anti-PfMSP1 and scFv TG130 antibodies are of the Vκ6 family 
and even shares an identical classification – IgKV6-17*01.    
 
The VH region shows numerous mutations with a homology to its’ closest 
germline sequences at 94.8% at the amino acid level, typical of an affinity-matured 
antigen-driven immune response. This finding is in good agreement with several other 
studies on the characterization of antigen-binding scFv and IgG antibody phage-displays 
that showed comparable levels of somatic hypermutation levels with our candidate scFv 
against T. gondii. For instance, the VH region homology percentage of antibody 
fragments characterized thus far ranges from 93% to 94% for several cancer-targeting 
antibodies (Hansen, Nielsen, & Ditzel, 2002; Ho et al., 2005), and from 92.8% to 99.0% 
for several other virus-targeting antibodies (David, Goossens, Desgranges, Thèze, & 
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Zouali, 1995; Ray, Embleton, Jailkhani, Bhan, & Kumar, 2001). A similar trend can 
also be observed for the VL regions somatic mutations in these antibodies. 
 
It is also interesting to note that although the CDR-L3 region of the antibody 
light chain had twice as many mutations (4 amino acid substitutions) compared to the 
CDR-H3 region (2 amino acid substitutions), molecular superimposition of the scFv 
structure to its closest germline homology structure revealed that the greatest structural 
deviation to be located at the heavy chain CDR-H3 loop, and not the CDR-L3 (Figure 
4.16). Viewing the molecular structure of TG130 indicates that 6 out of the 15 somatic 
mutations relative to its germline counterpart [His  Tyr-L88 (CDR-L3), Tyr  Asn-
L89 (CDR-L3), Thr  Tyr-L91 (CDR-L3), and Pro  Tyr-L93 (CDR-L3), Ala  
Asp-H100 (CDR-H3), Trp  Gly-H101 (CDR-H3)],  which are fixed within the CDR3 
loops, forms the antigen binding site (Figure 4.16). Nine other mutated residues are 
located in vernier positions that are not directly contacting the antigen. Calculation of 
the mutation ratios within the antibody’s CDRs and framework regions of the variable 
domains revealed a higher percentage of amino acid residue changes within the CDRs 
compared to the framework regions; with 14.3% mutations within the CDRs and 5.1% 
mutations within the framework regions. This is also in close agreement with observed 
trends in the process of somatic hypermutation of the humoral response, whereby 
average mutational probabilities for core and antigen-combining site residues are ~4% 
and ~12% respectively (Clark, Ganesan, Papp, & van Vlijmen, 2006). 
 
As shown in Figure 4.16, the 6 amino acids mutations concentrated at the CDR3 
loops forms a dramatically different antigen combining site compared to the antibody’s 
germline structure (Figure 4.16-A and B). Somatic mutations of an antibody repertoire’s 
variable regions provides increased ligand diversity and is also an established hallmark 
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of its’ affinity maturation for a more effective immune response (French, Laskov, & 
Scharff, 1989; Tonegawa, 1983). As such, the structural changes found within scFv 
TG130 is taken to be indicative of an antigen-driven selective process in the maturation 
of the antibody from its germline precursors.   
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FIGURE 4.16 
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4.3.3- ScFv antibody TG130 shows binding to T. gondii tachyzoites membrane 
surface. 
 
The surface adhesins of T. gondii have been implicated to be connected to the 
adherence and invasion of host cells. Several experiments employing the use of 
antibodies targeted against proteins expressed on the parasite surface have shown 
evidence of inhibition of cellular invasion to varying degrees (Vern B. Carruthers et al., 
1999; Fu et al., 2011; Hehl et al., 2000), although a subset of these antibodies had no 
effect on blocking invasion, indicating that there are functional epitopes within these 
parasite surface adhesins (Grimwood & Smith, 1996). Inhibitory antibodies against 
parasite surface proteins have ranged from constitutive to transiently-expressed proteins. 
The parasite surface is primarily coated with the immunogenic and closely-related 
antigens from the surface antigen 1 (SAG1)-related sequences (SRS) superfamily which 
consists of at least 160 members, with some members being developmentally expressed 
(Jung, Lee, & Grigg, 2004; Manger et al., 1998). In addition to the abundant SRS 
antigens on the surface of T. gondii, several other surface adhesins involved in the host 
cell attachment and penetration process includes the microneme-secreted proteins, 
which are also known as MICs; and includes the apical membrane antigen 1 (AMA1) 
protein which bears interesting homology to the AMA1 of Plasmodium spp. 
(Carruthers, 2002; Hehl et al., 2000).  
 
In lieu of the present evidences of the favourable ability of antibodies targeted to 
the membrane surface of T. gondii in blocking host cell adherence and invasion, this 
study was formed to develop scFv antibodies based on its ability to bind to native 
antigens on intact extracellular tachyzoite surface with higher affinity. A limitation with 
the shaping of the humoral response in vivo is the inability to select for antigen-reactive 
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antibodies with affinities higher than the ceiling dissociation rate constant (koff) of 12 
minutes, which is the approximate time needed for B cell receptors (BCR) 
internalization of antigens (Batista & Neuberger, 1998; Foote & Eisen, 1995). 
Therefore, to mitigate the intrinsic affinity ceiling for antibodies selected in vivo, 
through this study, antibody biopanning selection on intact tachyzoite cell surface was 
carried out with 5 rounds of washing and a corresponding off-rate selection of at least 
30 min, which is nearly double of the 12 minutes BCR internalization rate window 
period. Currently, it is unclear on which parasite surface ligands the scFv TG130 
antibody is binding to on the parasite surface; however, confocal microscopy in the 
present study demonstrates that scFv TG130 recognizes an antigen distributed over the 
entire surface of extracellular tachyzoites (Figure 4.15). Studies to identify these 
parasitic ligands on T. gondii that reacts to the recombinant antibody is needed, and 
further experiments on refining the binding properties of TG130 could potentially see 
this developed as a diagnostic tool or a blocking antibody against parasite invasion. 
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4.4 General Conclusion 
 
In conclusion, through the subtractive cell suspension-based biopanning strategy 
developed for T. gondii in this study, a scFv antibody with evidence of a 5-fold binding 
advantage to tachyzoites was successfully isolated and characterized. The present study 
shows results of the scFv TG130’s specific recognition of T. gondii tachyzoites by 
binding titers testing and immunofluorescence assays. Further affinity maturation 
designs may improve the current levels of binding selectivity and affinity of the TG130 
scFv against T. gondii tachyzoites. Development of the second generation antibody is 
being undertaken, and further investigations are needed to elucidate the affinity of the 
antibody once the antigenic target has been identified. From the early reports on the 
genome constitution of this organism (Ajioka et al., 1998a), knowledge of the genes 
controlling biological traits of this evolutionarily-divergent parasite is growing 
(Adomako-Ankomah, Wier, & Boyle, 2011). The present study was designed to 
facilitate the rapid discovery of new binding ligands to complement genetic and 
genomic information on potential antigenic targets that could be used to further 
understand this pathogen and its interaction with the host cells. Overall, the biopanning 
strategy outlined in this study has potentially useful applications in the biopanning of 
phage-displayed antibody fragment libraries and other formats of ligands such as 
random peptides, haptens and immunotoxins against the complex, mutimeric, and native 
landscape of T. gondii cell surface. The current findings on the scFv antibody TG130 
recognizing T. gondii antigens could also form the base of further investigations on 
improving antibody affinity and selectivity to the target parasite cell. 
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CHAPTER 5.  RESULTS & DISCUSSION (PART 2): DEVELOPMENT 
OF AN ANTI-TOXOPLASMA GONDII ScFv ANTIBODY 
WITH IMPROVED BINDING PROPERTIES 
  
5.1 - Strategy 
 
 The aim of this study was to improve the binding properties of the scFv antibody 
TG130 against T. gondii tachyzoites by affinity maturation. This necessitated the 
identification of antibody CDR hotspot regions as targets for affinity maturation through 
analysis by the V-Quest (IMGT) (Lefranc, 2001) software. Hotspots, which are DNA 
sequences within the antibody’s variable regions that are naturally prone to somatic 
hypermutations during the in vivo affinity maturation of the humoral immune response 
to pathogens; are most often located in the CDRs, particularly CDR1 (Neuberger et al., 
1998). One of the hot-spots nucleotide sequence motifs that is often favoured for 
affinity maturation is the (A/G)G(C/T)(A/T) sequences or also known as the RGYW 
motifs. The frequency of somatic mutations introduced at or very near these RGYW 
motifs is a total of 50 – 60% (Neuberger et al., 1998). Therefore, it can be surmised that 
targeting the RGYW motifs for the in vitro affinity maturation of the antibody scFv 
TG130 could lead to improvements in its’ antigenic binding properties (Chowdhury & 
Pastan, 1999). 
 
  Identification of hot-spots within the antibody V-regions was followed by an 
optimized rapid in vitro antibody affinity maturation procedure by site-directed point 
mutagenesis using degenerate primers. The point-mutated second generation TG130 
scFv library was assessed to determine for successfully randomized point mutated 
amino acids; and subsequently screened again with more stringent conditions than 
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employed in the previous study with the parental antibody (TG130) to isolate improved 
binders. The putatively affinity-matured scFv isolated was characterized for its target 
binding titers and molecular structure divergence relative to the originating parental 
antibody; as well as scFv immunofluorescence localizations on tachyzoites. The 
strategy of this section of study is shown in Figure 5.1.  
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V-Quest program analysis of candidate scFv TG130 
 
 
Determination of hot spots DNA residues target for antibody affinity maturation 
 
 
Development of 2nd generation affinity-matured antibody library 
 
 
Increased dissociation rate screening of affinity-matured antibody library against T. 
gondii 
 
 
Characterization of anti-T. gondii scFv antibody with improved binding properties. 
 
 
FIGURE 5.1 The workflow of procedures for the development of an anti-T. gondii 
scFv antibody with improved binding properties is summarized in this schematic 
diagram. 
 
 
 
 
 
 
 
 
 
• Site-directed point mutagenesis 
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5.2 - Results 
 
5.2.1- Identification and selection of antibody hotspot residues for site-directed 
affinity maturation. 
 
 In the strategy to develop an antibody with improved affinity against T. gondii, 
an in vitro site-directed hot-spot point-mutagenesis procedure was employed with the 
phage-display platform. For the selection of a RGYW motif hot-spot for the affinity 
maturation procedure, an analysis of scFv TG130 sequence through V-Quest at IMGT 
(imgt.cines.fr/texts/vquest/) (Lefranc, 2001) revealed a total of 5 hot-spots within the 
variable regions, which are all located within its’ CDRs (Figure 5.2). The results are 
summarized in Table 5.1. These RGYW hot-spots within the antibody are located either 
at germline genes or close to non-germline residues – which are presumably mutated 
during the somatic hypermutation of B cells. For this study, the selection for a site-
directed mutagenesis target was focused on germline hot-spots. Both of the hot-spots 
clusters within VL CDR3 (Positions 314-317 and Positions 325-328) are considered to 
be non-germline residues hot-spots and are therefore not considered as mutagenesis 
candidates.  
 
 A check of the distance measurements of the three-dimensional molecular model 
of TG130 generated through PyMOL (Figure 5.3) shows that the VL CDR1 and VH 
CDR2 loops are located closer to the VH CDR3 loop (16.15 Å and 13.95 Å 
respectively), compared to VL CDR2 (16.85 Å); suggesting a higher likelihood that both 
of the closer loops may be involved in key antibody-antigen interactions. As there 
seems to be a correlation between a lower number of germline hot-spots with higher 
affinity and matured antibodies (Ho et al., 2005), the VL chain was deemed to be less-
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matured and therefore a preferred target for affinity maturation due to its higher number 
of hotspot clusters (Table 5.1).  In the present study, the germline-type RGYW hotspot 
sequence motif within VL CDR1 was chosen as the target residues for the antibody 
affinity maturation (Figure 5.3). 
 
TABLE 5.1 DNA sequence hot-spots with RGYW motifs within the variable 
regions of antibody scFv TG130. The sequence cluster selected for affinity maturation 
of the antibody is highlighted in yellow. All residues are numbered according to the 
IMGT numbering scheme.  
 
 
 
Motif Positions Hot-spots Type 
VH ggta 190-193 (CDR2) Germline 
VL 
agta 106-109 (CDR1) Germline 
ggca 168-171 (CDR2) Germline 
agca 314-317 (CDR3) Non-germline 
agct 325-328 (CDR3) Non-germline 
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ScFv TG130 
 
VL                                 
  1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  19  20   
TG130 (aa) M   T   Q   S   H   K   F   M   S   T   S   V   G   D   R   V   S   I   T   C    
TG130 (nt)    atg acc cag tct cac aaa ttc atg tcc aca tca gta gga gac agg gtc agc atc acc tgc 
  
 
                               CDR1 - IMGT                
  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40                      
TG130 (aa) K   A   S   Q   D   V   S   T   A   V   A   W   Y   Q   Q   K   P   G   Q   S      
TG130 (nt)   aag gcc agt cag gat gtg agt act gct gta gcc tgg tat caa cag aaa cca gga caa tct 
 
 
                                        CDR2 - IMGT 
  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60    
TG130 (aa) P   K   L   L   I   Y   S   A   S   Y   R   Y   T   G   V   P   D   R   F   T      
TG130 (nt)   cct aaa cta ctg att tac tcg gca tcc tac cgg tac act gga gtc cct gat cgc ttc act                            
 
 
                                          
  61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80    
TG130 (aa) G   S   G   S   G   T   D   F   T   L   T   I   S   N   V   Q   S   E   D   L     
TG130 (nt)   ggc agt gga tct ggg acg gat ttc act ctc acc atc agc aat gtg cag tct gaa gac ttg              
 
 
 
                                 CDR3 -  IMGT 
  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  
TG130 (aa) A   E   Y   F   C   Q   Q   Y   N   S   Y   P   Y   T   F   G   A   G   T   K     
TG130 (nt)   gca gag tat ttc tgt cag caa tat aac agc tat ccg tac acg ttc ggt gct ggg acc aag              
       
                          
 
  101 102 103 104 
TG130 (aa) L   E   L   K   
TG130 (nt)   ctg gag ctg aaa    
 
 
VH                                
             1   2   3   4   5   6   7   8   9   10  11  12  13  14  15  16  17  18  19  20     
TG130 (aa) E   V   H   L   V   E   S   G   P   E   L   V   K   P   G   A   S   V   K   I    
TG130 (nt)   gag gtg cat ctt gtt gag tca gga cct gag ctg gtg aaa cct ggg gcc tca gtg aag ata 
 
               
  
                                          CDR1 - IMGT    
             21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  
TG130 (aa) S   C   K   A   S   G   Y   T   F   T   D   Y   N   M   H   W   V   K   Q   S 
TG130 (nt)    tcc tgc aag gct tct gga tac aca ttc act gac tac aac atg cac tgg gtg aag cag agc 
 
 
                                    CDR2 - IMGT 
             41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   
TG130 (aa) H   G   K   S   L   E   W   I   G   Y   I   Y   P   Y   N   G   G   T   G   Y 
TG130 (nt)   cat gga aag agc ctt gag tgg att gga tat att tat cct tac aat ggt ggt act ggc tac  
 
 
                                                    
             61  62  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80      
TG130 (aa) N   Q   K   F   K   S   K   A   T   L   T   V   D   N   S   S   S   T   A   Y 
TG130 (nt)   aac cag aag ttc aag agc aag gcc aca ttg act gta gac aat tcc tcc agc aca gcc tac  
 
 
                                                                               CDR3 - IMGT   
              81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100   
TG130 (aa) M   E   L   R   S   L   T   S   E   D   S   A   V   Y   Y   C   A   R   G   D 
TG130 (nt)    atg gag ctc cgc agc ctg aca tct gag gac tct gca gtc tat tac tgt gca aga ggg gat  
                                
                 
              101 102 103 104 105 106 107 108 109 110 111 112 113 114 115                
TG130 (aa) G   F   A   Y   W   G   Q   G   T   L   V   T   V   S   A   
TG130 (nt)      ggg ttt gct tac tgg ggc caa ggg act ctg gtc act gtc tct gca             
 
 
FIGURE 5.2 Nucleotide and aligned amino acid sequences of VH and VL regions of 
scFv TG130.  Regions mutated from germline origin sequences are boxed in red, and RGYW-
motif hotspots are highlighted in yellow. The targeted hotspot mutagenesis is circled in red.
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FIGURE 5.3 Measurements of distance between candidate RGYW hot-spots residues and somatic mutations in VH CDR3. The somatic 
mutations within VH CDR3 (CDR3 100 Asp and CDR3 101 Gly) are located at the apex of the CDR3 loop, suggesting of its involvement in key 
antigen-binding interactions. The average distances between the VH CDR3 apex with VL CDR1 hot-spot residue (CDR1 27 Ser) is 16.15 Å (A), with 
VL CDR2 hot-spot residue (CDR2 48 Ala) is 16.85 Å (B), and with VH CDR2 hot-spot residue (CDR2 57 Gly) is 13.95 Å (C).  
The VL CDR3 88 Tyr residue in images of panels (A) and (B) is hidden for clarity. All images and measurements were generated with PyMOL.
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5.2.2- Generation of an affinity-matured scFv TG130 antibody library by site-
directed mutagenesis. 
 
 Through an efficient site-directed mutagenesis protocol which was developed, an 
affinity-matured or second generation TG130 scFv library was able to be generated within 
a relatively short period of only 2 days. An additional 1 day was required to further sub-
clone the randomized-point-mutated TG130 phagemids from E. coli XL10-Gold into E. 
coli TG1 to facilitate downstream experiments of phage rescue and biopannings. Several 
key modifications were introduced into a standard protocol optimized from the 
Stratagene’s QuikChange® Lightning Site-Directed Mutagenesis Kit (Agilent 
Technologies) manufacturer’s conditions to enable the generation of randomized point-
mutants. The modifications (indicated by symbol ɸ) include a pretreatment with 
Annealing Buffer and generation of degenerate adapters oligonucleotides (Figure 5.4). 
 
From two point mutagenesis reactions targeted to the RGYW motif within TG130 
and two proceeding transformations, a second generation scFv library consisting of a 
complexity of at least 4.0 × 104 independent clones was obtained. A check of twenty 
randomly picked clones from the second generation library through PCR showed 100% 
full-length scFv DNA in all clones (Figure 5.5). A further examination of five randomly 
picked clones through sequencing found no evidence of truncated clones detectable from 
this scFv library; which shows that the rational design of degenerate primers done in the 
present study to introduce randomized mutations at the RGYW motifs was effective at 
preventing the aberrant encoding of stop codons (UAA – Ochre, UAG – Amber, UGA – 
Opal) within the antibody fragments. It is important to avoid the incorporation of the stop 
codons’ termination signal in the in vitro affinity maturation procedure to circumvent the 
generation of truncated, loss-of-function antibody molecules which is frequently observed 
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in in vivo systems. To analyze the diversity of the scFv repertoire in the second generation 
library, the sequencing results of the clones were aligned in BioEdit and compared with the 
parental TG130 antibody sequence (Appendix XII). Out of a sampling of five random 
clones examined, four clones had sequences differing from the parental antibody while one 
clone retained the parental sequence. All five clones had sequences differing from one 
another, demonstrating that the targeted hot-spot residues were successfully randomized 
(Table 5.2) (Appendix XII). 
 
RGYW-point mutagenesis degenerate primers design 
 
ɸ  Treatment of forward and reverse mutagenesis primers in Annealing Buffer 
 
ɸ  Overnight generation of RGYW-degenerate oligonucleotide adapters 
 
Mutant strand synthesis reaction 
 
Digestion of parental DNA template 
 
Transformation into E. coli XL10-Gold 
 
Subcloning into E.coli TG1 
 
Sequencing verification 
 
FIGURE 5.4 The modified procedure for the RGYW-site directed mutagenesis of the 
second generation scFv TG130 library is summarized in this schematic diagram. 
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FIGURE 5.5 PCR verification of E. coli TG1-transduced RGYW-mutant scFv within 
phagemid vector pCANTAB5E. A sampling of 20 randomly picked mutant clones 
amplified by colony PCR is shown. All clones showed full-length scFv inserts 
(approximately 900 bp), and sequencing analysis revealed no occurrence of sequence 
truncation. 
 
 
 
 
TABLE 5.2 A sampling of sequence diversity within the RGYW-site-directed 
mutagenesis of second generation scFv TG130 antibody library. The four RGYW 
sequence residues which were targeted for randomization in the present study are indicated 
in bold, italicized fonts; together with its’ corresponding mutated amino acids at positions 
27 and 28 of VL CDR1. 
 
 
Clone 
Number 
RGYW 
Mutations 
Amino acid 
Translation 
Type 
1 CTG  GCT Leu  Ala Non-parental 
2 AGG  TCT Arg  Ser Non-parental 
3 ACG  GCT Thr  Ala Non-parental 
4 AAC  GCT Asn  Ala Non-parental 
5 AGT  ACT Ser  Thr Parental 
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5.2.3- Screening of affinity-matured scFv antibody library for improved antigen 
binders. 
 
 Because the created second generation library is several magnitudes larger than 
necessary for a four nucleotide mutagenesis and there are no evidence of truncated scFv 
clones, only one round of selection was performed on T. gondii tachyzoites during 
biopanning. In order to reduce the likelihood of recovering phages that bound non-
specifically or weaker binders than the parental antibody, a more stringent biopanning 
procedure was employed whereby the selective incubation duration with T. gondii was 
halved and washing rounds (off-rate) were doubled, as described in the Methodology 
section 3.3.d-ii. Through this modified procedure, the total duration of the off-rate 
selection was at least 100 min, which was double the duration of the primary antibody’s 
screening selection procedure described previously. The biopanning screening of both the 
secondary antibody library and the originating primary antibody TG130 to T. gondii was 
carried out in parallel. Through this biopanning, it was found that the scFv phage output 
titer of the secondary library was 6.0 × 103 cfu, while the output titer for the primary 
antibody was 1.7 × 104 cfu – which is approximately three times higher than the secondary 
library. Although the secondary antibody library had a lowered phage recovery output 
compared to the primary scFv, this is not an entirely unexpected result considering the 
polyclonality of the secondary antibody library versus the monoclonal TG130 antibody. 
Following the biopanning screening, up to 111 clones were randomly picked and their 
sequences analyzed to determine the diversity and frequency of binding scFv clones (Table 
5.3). Four of the most frequently occurring clones were selected for further 
characterization. Among the mutant clones recovered from the biopanning was scFv with 
identical sequences as the parental TG130 antibody. Frequency for these clones was 17 out 
of 111 clones. But unlike its mutant counterparts, there was no multiple codon usage. The 
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only codon used for these parental antibody reproductions was the originating germline 
sequences (AGT  A..), indicating a probable bias in the mutant strand synthesis reaction to 
reproduce the parental sequence, which explains the higher frequency of these clones 
recaptured from biopanning. 
 
 The mutant residues with the highest frequency were found to be Thr27-Pro28 and 
Pro27-Thr28. Each of these clones appeared eight times and five times respectively. More 
than one codon was used in these clones containing Thr27-Pro28 and Pro27-Thr28, suggesting 
of a strong selection for these amino acid residues.  Furthermore, nucleophilic amino acids 
such as Thr and Ser were conserved in all of these highest occurring scFv binders, except 
for clone Arg27-Ala28. Multiple codon usage was also observed for all other frequently 
occurring mutant clones (Table 5.3). 
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TABLE 5.3 Sequences of the most frequently occurring RGYW-mutant phage 
clones obtained after panning. Amino acid sequences and its corresponding nucleotide 
codons of mutant phage isolated after an increased off-rate biopanning procedure are 
listed. Only sequences of clones with a combined frequency higher than 4 are shown. 
 
RGYW 
Mutation 
Amino Acids 
Nucleotide 
Sequence Frequency 
Combined 
Frequency 
Thr  Pro ACG  C.. 4 8 ACC  C.. 4 
Pro  Thr CCG  A.. 4 5 CCC  A.. 1 
Arg  Ser AGG  T.. 2 5 CGG  T.. 3 
Thr  Ala ACG  G.. 4 5 ACC  G.. 1 
Arg  Ala 
AGG  G.. 3 
5 CGC  G.. 1 
CGG  G.. 1 
Leu  Thr CTG  A.. 3 4 CTC  A.. 1 
Arg  Thr AGG  A.. 2 4 CGC  A.. 2 
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5.2.4- Immunofluorescence detection and biopanning of affinity-matured scFv 
antibodies binding to T. gondii. 
 
 Following biopanning of the second generation library and sequence analysis of the 
captured clones, monoclonal scFvs were prepared from several highest occurring phage 
clones and tested for their ability to bind to T. gondii tachyzoites in a binding titer assay. 
The second generation scFv clones chosen for the monoclonal testings are the Thr-Pro 
(TP60), Arg-Ser (RS55), Arg-Ala (RA15), Leu-Thr (LT3) and Arg-Thr (RT51) point 
mutants (Sequencing results in Appendix XII). Following the phage rescue of each of these 
mutant scFvs and its co-incubation with tachyzoites, binding titers experiments revealed 
that scFv clone TP60 had the highest binding titers relative to the parental antibody 
TG130, showing a 1.6-fold increase in averaged binding titer [Figure 5.6, Appendix X (c)]. 
The remaining four mutant scFvs displayed either lower (RA15, RS55 and RT51) or 
similar levels (LT3) of T. gondii - binding titers to scFv TG130. Confocal microscopy of 
scFv TP60’s reactivity to tachyzoites revealed that the entire surface of extracellular 
tachyzoites were stained (Figure 5.7). These findings are consistent with the highest 
frequency of the TP60 mutant clone recovered from selection against the target antigen 
(Table 5.3). Based on these results, further characterization of the affinity-matured 
antibody was narrowed down to scFv TP60. 
 
 To further determine the binding specificity of the shortlisted scFv clone TP60, the 
monoclonal antibody fragment was examined for its binding advantage to T. gondii 
compared to negative selection cell line WRL68. Biopanning of scFv TP60 and its parental 
scFv TG130 revealed that the affinity-matured TP60 antibody demonstrated improved 
selectivity for its’ target antigen T. gondii, while having a nearly two-fold increase in its 
binding titers to the parasite compared to the parental antibody (Figure 5.8), which is a 
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similar result as obtained in the previous experiment to determine the binding titers of the 5 
shortlisted mutant scFvs. However, with an increased off-rate biopanning with a 
cumulative duration of 100 minutes, it seems the parental antibody TG130 had lost its’ 
binding advantage to T. gondii above the negative control cells. Average binding titers of 
scFv TG130 to negative selection cells WRL68 was found to be 8.9 × 103 cfu, which was 
slightly higher than the 7.0 × 103 cfu average binding titers to T. gondii. 
 
 In comparison, with similar stringent biopanning conditions, the affinity matured 
antibody fragment TP60 demonstrated a statistically significant binding advantage to T. 
gondii compared to the negative control. Average binding titers of scFv TP60 to T. gondii 
was 1.25 × 104 cfu, which is more than a two times greater binding enrichment than its’ 
binding to WRL68 with an average of 6.07 × 103 cfu (Figure 5.8). It is worth noting that 
the enrichment factors of phage scFvs from cell surface panning is typically lower than 
with panning on immobilized antigens (Rader et al., 2001), as was also demonstrated by 
another study by Pansri and co-workers in which phage scFvs showed approximately two 
times higher binding specificity to a cancer cell surface over negative cell lines (Pansri et 
al., 2009). This finding indicates that the affinity maturation of antibody fragments by hot-
spot mutagenesis can generate mutant scFv that has reduced non-specific binding than the 
starting molecule. Although obtaining specific antibodies through cell surface panning is 
generally more difficult due to the complex antigen surface on viable cells, the present 
study demonstrates that through the advantage of mimicking in vivo natural selection of the 
humoral immune responses against T. gondii invasion coupled with in vitro affinity 
maturation; improved antigenic binders to target cells can be achieved.   
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FIGURE 5.6 Monoclonal TG-RGYW mutant scFv clones binding titer assay. Five 
scFv antibodies with the highest occurrence of clones binding to T. gondii tachyzoite cells 
were tested in a binding titer assay to determine its relative binding advantage compared to 
the parental antibody TG130. Point-mutated scFv TP60 showed the highest binding titers 
against T. gondii relative to scFv TG130, with a 1.6-fold increase in binding. Error bars, ± 
S.E.M. from the means of duplicate or triplicate experiments. 
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FIGURE 5.7 Confocal laser-scanning microscopy of the T. gondii antigen recognized by affinity-matured scFv TP60. Fixed extracellular 
tachyzoites were incubated with phage scFv TP60 and then with Alexa Flour 488-conjugated monoclonal antibody to M13 gp8 (green). Nuclei were 
ounterstained with DAPI (blue). Both parasite samples in (A) and (B) were processed similarly, with panel (B) showing a magnified view. DAPI, 4’,6-
diamidino-2-phenylindole; DIC, differential interference contrast. Scale bar, 3 µm. 
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FIGURE 5.8 Monoclonal phage scFvs of parental antibody TG130 and affinity-
matured antibody TP60 were tested for their binding advantage to T. gondii 
tachyzoites. Phage scFvs were biopanned against T. gondii with increased off-rate 
selection as described under ‘Methodology’, WRL68 cells were used as negative selection 
control. Binding titers of monoclonal scFvs to T. gondii (black column) and WRL68 (gray 
column) is shown. Affinity-matured antibody TP60 showed a greater binding specificity to 
T. gondii compared to the parental antibody.  Error bars represent the standard deviation 
for duplicate experiments, and asterisk denotes a statistically significant difference. 
 
 
 
 
 
 
 
 
 
 
167 
 
5.3 - Discussion 
 
5.3.1- Optimized site-directed mutagenesis of germline hotspots. 
 
 Advances in protein engineering have frequently used site-directed mutagenesis to 
generate randomized amino acid libraries to facilitate the screening and isolation of amino 
acid combinations that confers the best improvement in activity. However, randomized 
site-directed mutagenesis is often a process that is laborious and requires the use of ssDNA 
templates. Alternative random mutagenesis approaches such as error-prone PCR, is 
designed to introduce single-base mutations and therefore presents inherent limitations as 
only 5.7 amino acids substitutions on average are accessible from any given amino acid 
residue (Miyazaki & Arnold, 1999). In order to access a larger fraction of protein sequence 
space and ideally introduce all 20 amino acid side chains at a targeted site, site-directed 
saturation mutagenesis is commonly employed (Hogrefe, Cline, Youngblood, & Allen, 
2002). 
 
 The second generation scFv antibody library generated through the optimized 
mutagenesis protocol yielded a size of 4.0 × 104 independent transformants. This is a 
library size that is comparable to that reported using a different kit recommended for use 
with degenerate primers mutations yielding 8.8 × 104 transformants (Hogrefe et al., 2002). 
This demonstrates that the protocol used in conjunction with the QuikChange Lightning 
Site-Directed Mutagenesis (QCM) kit is sufficient to generate a randomized amino acid 
library. In addition, the optimized protocol enables the construction of the randomized 
library within 2 days and with just a single PCR amplification, without additional steps 
required to randomize the amino acids. This is significantly quicker and less laborious 
compared to conventional PCR / ligation-based protocols which typically requires 5 – 8 
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days (Table 5.4) (Ling & Robinson, 1997). In the present study, two amino acids were 
randomized by incorporating the degenerate primers with randomized codons VNSN 
(Sense) and NSNB (Antisense) (N = A or G or C or T, V = A or C or G, S = C or G, B = C 
or G or T), and are complementary to one another. These degenerate primers were not only 
designed to be positioned at the RGYW sequence hot-spot motif, but also to exclude the 
incorporation of stop codons within the antibody fragment. One of the crucial factors 
determining the minimum number of clones needed to contain all possible mutations is the 
frequency of the least represented mutants (Hogrefe et al., 2002). For the VNSN codons, 
the frequency (f) of the least-represented mutants can be calculated as (⅓×¼×½×¼) = 
1/96. Assuming a 100% mutation efficiency, there is a greater than 95% probability of 
observing all possible mutants in a random sampling of about 300 clones [0.95 = 1 – (1 – 
f)n, where f = frequency of the least-represented mutants, and n = number of clones 
screened. (Jeltsch & Lanio, 2002)]. Therefore, the second generation scFv antibody library 
generated in this study is more than 100 times larger than the minimum size needed to 
ensure representations of all possible combinations of double amino acid mutants.  
 
Although the primers which were used in this study had a Tm below the ≥ 78°C 
range recommended by the QCM kit manufacturer (both of the RGYW mutation primers 
had a Tm of 74.8°C), to decrease the likelihood of primer pairs self-annealing; what the 
experimental design for this mutagenesis protocol sought out to accomplish instead was 
actually to form primer dimers from the degenerate oligonucleotides before running the 
mutagenesis PCR. This approach was based on the postulation that site-directed saturation 
mutagenesis are often inefficient due to incorrect pairing of degenerate primers on its’ 
DNA template.  Therefore, the degenerate primers were pretreated with an Annealing 
Buffer (Appendix I) and allowed to form complementary oligonucleotide adapters for the 
mutagenesis reaction in order to create the second generation scFv library. Despite the 
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lowered Tm primers and the purposeful generation of ‘primer dimers’ (oligonucleotide 
adapters), it is shown here that the mutagenesis reaction still worked and generated a 
randomized antibody library of a robust size. Another study by Zheng L. and co-workers 
reported the use of partially overlapping degenerate primers instead of completely 
overlapping primers to construct a site-directed saturation mutagenesis library, as the 
standard practice of using completely overlapping primers failed to yield mutant strands 
(Zheng, Baumann, & Reymond, 2004). However, here we show evidence that the 
utilization of completely overlapping degenerate primers with a lower-than-ideal Tm to 
encourage sense and antisense primer dimer formations, could efficiently generate a site-
directed saturation mutagenesis library with the QCM platform; and that it is not necessary 
to use partially overlapping primers and purified PCR products as they did. These findings 
are in good agreement with another publication, with the only difference being in the 
methodology where the study randomized one amino acid (Steffens & Williams, 2007), 
while the present study here randomized two amino acids. This simpler protocol reduces 
both the costs and turnaround time required to produce randomized libraries in directed 
evolution applications. 
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TABLE 5.4 Comparison of major methods of in vitro mutagenesis. (Source: Ling & 
Robinson, 1997) 
 
 Duration 
(day)a 
Man. 
Time (h)b 
Advantage Disadvantage 
     
Connection PCRc 6 9 – 10 Good efficiency, fast Relatively shorter 
mutant products. 
Megaprimer PCRd 5 6 – 9 High efficiency, fast, 
larger mutant 
products. 
Needs careful setup 
of parameters and 
conditions. 
Inverse PCR 5 6 – 9 High efficiency, fast, 
simple, mutant 
product already in a 
plasmid. 
Needs to amplify 
long PCR products. 
Hybride     
Without selection 5 - 8 15 Mutant product 
already in a plasmid. 
Very low efficiency, 
lengthy, laborious. 
With selection 
(USE) 
7 12 – 14 High efficiency. Lengthy, laborious, 
some unique sites 
not suitable for this 
method. 
Gapped circle 7 13 - 15 Mutant product 
already in a plasmid. 
Relatively poor 
efficiency, lengthy, 
laborious, complex. 
a Duration is the total time from the beginning to the confirmation of mutant clones by 
sequencing, including waiting time (e.g., E. coli growth overnight). 
b Man. Time (manipulation time) is the time the operator needs to spend on performing all steps 
of that procedure.  
c Connection PCR includes ligation, homologous recombination, and overlap extension of two PCR 
products to form the mutant product. 
d Only One-STEP version was used for evaluation. 
e Both methods with and without selection were evaluated. Without selection, the method needs 
time-consuming screening with radioactive selective hybridization. 
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5.3.2-  In vitro antibody affinity maturation. 
 
 The results from this study showed that a scFv antibody with improved activity can 
be generated through an in vitro antibody affinity maturation by an evolution strategy 
targeting intrinsic mutational hot-spots. As previous work has shown that affinity 
maturation of germline hot-spots are more effective at generating improved antibody 
affinities compared to non-germline residues (Ho et al., 2005), therefore the VL CDR1 
germline hot spot was selected as target for the affinity maturation exercise. 
 
 The mutated hot-spot residues in the evolved antibody TP60 was found to have 
arisen out of triple mutations at the first, second and third positions in each codon of both 
variants of the TP60 clone (the ACG-CCT and ACC-CCT variant). This is a very 
uncommon occurrence in the process of somatic hypermutation of B cells (Jolly et al., 
1996). The changing of nucleotide residues from AGT-ACT (Ser27 Thr28) in the parental 
antibody TG130 to ACG-CCT and ACC-CCT (Thr27 Pro28) in mutant TP60 involved three 
nucleotide point mutations, in which nucleotides in the second and third positions in the 
first codon are mutated and the nucleotide in the first position of the second codon was 
mutated. Dramatic mutations such as these are highly improbable in the in vivo somatic 
hypermutation process as it normally only mutate one nucleotide in each codon at the hot-
spots. This observation lends credence to another published study on the advantages of in 
vitro-based hot-spots antibody affinity maturation as compared with the in vivo somatic 
hypermutation process in expanding the sampling of the mutation points to all 19 other 
amino acids (Ho et al., 2005).   
 
 To further examine the phage-scFv antigen-binding characteristics, the binding 
titers of both scFv TG130 and affinity-matured scFv TP60 were compared at different off-
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rate selection durations of 50.0 min and 100.0 min (Figure 5.9). As was previously 
discovered, the parental scFv TG130 had a binding enrichment that was more than five 
times higher for T. gondii compared to the negative selection cells WRL68. However, this 
target-binding selectivity could not be maintained at the 100 min off-rate, where there were 
nearly similar binding titers for both the intended target antigen and the negative selector at 
7.0 × 103 cfu and 8.87 × 103 cfu respectively (Figure 5.9). It is interesting to note that 
although the affinity matured scFv TP60 showed an initial high background binding to 
WRL68 (4.94 × 105 cfu/ml) compared to TG130 (9.80 × 104 cfu/ml) at the 50 min 
selection duration (Figure 5.9a); the antibody demonstrated consistent binding advantage 
of over two magnitudes to T. gondii relative to WRL68 over both the 50 min and 100 min 
off-rate selection. At 100 min off-rate selection, scFv TP60 also showed a lower binding to 
WRL68 compared to TG130 at 6.1 × 103 cfu and 8.87 × 103 cfu respectively. This suggests 
that the mature TP60 antibody does possess a 2-fold higher binding specificity with the 
ability to distinguish between target parasite cells and non-target cells. In addition, the 
mature TP60 antibody displayed greater binding titers to T. gondii compared to its’ 
parental scFv TG130 over both off-rate selection duration, with a 5-fold and nearly 2-fold 
enrichment respectively for the 50 min and 100 min off-rate selection. The higher 
background binding to the non-target cells WRL68 could be due to the inherent problem of 
non-specific binding and lower enrichment factors associated with cell-surface 
biopannings (Rader et al., 2001). However, the cell-surface biopanning strategy allows the 
advantage of screening of antibodies against the native conformational or carbohydrate 
epitopes of the parasite; which more effectively mimics in vivo conditions of the humoral 
response.  
 
Thus, the affinity maturation of scFv TG130 antibody resulted in the mutant scFv 
TP60 which had a 1.8-fold increase in binding potency to T. gondii, but more than a two-
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fold higher specificity for its’ target-binding over an extended period of off-rate selection. 
However, one cannot rule out the possibility that the phage-bound format of the scFv may 
influence higher background binding to the negative selector cells; as was demonstrated in 
another study which showed an approximately two-fold higher ELISA signals of target 
over negative cells binding in the phage-scFv format but a twenty-fold higher ELISA 
signals with the same test using soluble scFvs (Yu et al., 2005).  It is also worth noting that 
there is a possibility that the apparent flux in specific binding titers of the antibodies to the 
complex surface of the target is actually resulting from the different expression levels of 
the recognized antigen (Pansri et al., 2009). Therefore, further characterization of these 
antibodies and identification of its specifically associated parasite binding ligands are 
needed to be done. Among some further characterization studies to be carried out would 
include the production of soluble scFvs, grafting of scFv V-regions into Fab fragments or 
full-sized IgG molecules, and determination of binding affinities of these antibody 
modalities to T. gondii. These future studies could aid in the evaluation these antibody 
molecules’ utility as diagnostic or therapeutic molecules.      
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FIGURE 5.9 Binding selectivity of affinity-matured (TP60) and parental (TG130) scFv antibodies at different off-rates. The antibody 
fragments were incubated with either T. gondii tachyzoites (black columns) or negative selection cells WRL68 (grey columns) and subjected to off-rate 
durations of 50.0 min (A) and 100.0 min (B). ScFv TP60 demonstrated better ability at distinguishing between target and non-target cells over both 
time periods. Asteriks marks statistically significant difference at alpha value = 0.05. Error bars represent the standard error for duplicate experiments. 
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5.3.3- Structural implications of mutations. 
 
 The structural analysis of both the parental scFv TG130 and the mutant scFv 
TP60 showed that the hotspot mutation site is located at surface-exposed residues 
positions (Figure 5.11), which is in agreement to a previous publication showing highly-
exposed antibody hotspot localization (Ho et al., 2005). Affinity maturation of 
antibodies by somatic mutations and point mutagenesis is normally a result of the 
reorganization of hydrogen bonding, electrostatic, and Van der Waals interactions 
networks between variable region residues. Another study has reported that these 
affinity-enhancing interactions between variable region amino acid residues can extend 
over distances of 15 Å (Wedemayer, Patten, Wang, Schultz, & Stevens, 1997). 
Although Figure 5.11 showed minimal structural deviations in the affinity-matured scFv 
compared to its’ parental counterpart; upon closer examination, it was discovered that 
there is a closer shift between the mutated residue positions on VL CDR1 to the VH 
CDR3 loop apex. From an initial average distance of 16.15 Å between the molecules in 
the unmutated parental antibody (Figure 5.2), the average distance has decreased to 11.6 
Å in the matured antibody TP60 – bringing the VL CDR 1 and VH CDR3 loops closer 
together by 4.55 Å and within the distance range for effective molecular interactions 
(Figure 5.11). This may be a contributing factor to the better binding selectivity of the 
mutated scFv TP60. However, the study currently faces a restriction from finer analysis 
of the molecular interactions between the scFv antibody and its’ antigenic partner as the 
binding antigen has not been elucidated. Further studies to determine the recognized 
antigen would prove beneficial in this respect. This can be achieved by 
immunoprecipitation to pull-down the target antigen via the scFv antibodies, followed 
by tandem mass spectrometry for the antigen identification. 
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 It is interesting to note that the point mutations in the affinity-matured scFv 
(Ser27  Thr27, Thr28  Pro28) mimics the trend of sequence changes in the in vivo 
somatic hypermutation process of mouse and human humoral responses (Clark et al., 
2006). The published study by Clark and co-workers demonstrated that antibody 
evolution at hot-spot mutations are not merely random events, but are biased to certain 
characteristic changes that favours modifications contributing to antibody stability and 
affinity (Clark et al., 2006). Among the more frequently observable sequence 
conversions at the antibody-antigen (Ab-Ag) interface are Ser  Thr and Ser  Arg, 
along with Glu ↔ Asp, Lys  Arg, Asn ↔ Asp and Gln  Glu (Clark et al., 2006). 
The mutation from Ser27 to the larger residue Thr27 observed in TP60 in the present 
study could be due to the conservation of hydrogen bonding at the CDR loops while 
maintaining solution stability. With due consideration that all except one of the most 
frequently occurring mutant clones recovered from biopanning of the second generation 
antibody library showed a conservation of polar nucleophilic amino acids at the hot-spot 
evolution positions (Table 5.3), it can be postulated that hydrogen bonding interactions 
may play an essential role in the antigen combining interface. However, the lower 
binding titers of 3 of the mutant clones (RA15, RS55 and RT51) compared to scFv 
TG130 may be ascribed to the introduction of the Ser  Arg mutation which could 
repel antigen binding due to the strongly positive charge of Arginine residue. The large 
hydrophobic Leucine residue incorporated in mutated scFv clone LT3 may also be 
responsible for the lack of favourable increase in antibody binding titers to T. gondii due 
to steric hindrance.  
 
It is rare for proline residues to occur in the germline sequences at the Ab-Ag 
interface of naïve antibodies, but increased proline usage are frequently observed in 
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matured antibodies (Clark et al., 2006). The second point mutation from Thr28  Pro28 
in scFv TP60 may contribute to the stabilization of beneficial loop conformations. The 
stabilizing influence of proline may potentially reduce the entropy cost of antigen 
binding and increase antibody affinity, which can be seen in the higher antibody binding 
titers of TP60.    
 
 Overall, the results of the present study indicates that with only two amino acid 
changes within the parental antibody; this has resulted in a small, but appreciable 
increase in the binding selectivity of affinity-matured antibody TP60. In view of several 
published observations that the affinity improvement of antibodies is effected by small, 
additive changes instead of a few large effects (Patten et al., 1996; Wedemayer, Patten 
et al., 1997; Wedemayer, Wang, Patten, Schultz, & Stevens, 1997), there is a possibility 
that further improvements of the scFv properties can be made by several more 
saturation mutagenesis antibody evolutions. 
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FIGURE 5.10  Molecular superimposition of scFv TG130 (red) with mutant 
scFv TP60 (purple). Alignment of the two antibody structures showed minimal 
deviations at the RGYW mutation sites at the VL CDR1 loops. RGYW hot-spot residues 
Ser27-Thr28 in TG130 is shown as yellow side chains, while mutated residues Thr27-
Pro28 is shown as green side chains. Superimposed structures were generated by 
PyMOL.   
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FIGURE 5.11  Distance measurements of affinity-matured scFv TP60 
between VL CDR1 mutated residue Thr27 with the VH CDR3 apex residues Asp100-
Gly101. The same measurements between the unmutated parental antibody residue Ser27 
with the VH CDR3 apex molecules yielded an average distance of 16.15 Å (Figure 5.3). 
Equivalent measurements done with mutated scFv TP60 shown here revealed a decrease 
in the average distance between the molecules to 11.6 Å. Mutated VL CDR1 residues 
are shown in green while VH CDR3 apex molecules are shown in yellow. Measurements 
are taken between atoms likely to contribute to hydrogen bonding. Hydrogen, oxygen 
and nitrogen atoms of these residues are indicated with white, red and blue colours 
respectively. View is looking down into the antigen combining site. Measurements are 
generated through the PyMOL software. 
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5.4 - General Conclusions 
 
 
 The present study demonstrates the successful application of an in vitro site-
directed point mutagenesis for the affinity maturation of a scFv antibody fragment 
targeting T. gondii tachyzoites. The optimized saturation mutagenesis protocol 
described here reduces the time and labour associated with conventional point 
mutagenesis procedures, whereby the second generation mutated antibody library can 
be produced within two days with a robust library size and effectively-randomized 
sequence diversity.  
 
Biopanning of the second generation scFv antibody library resulted in the 
isolation of the affinity-matured scFv TP60 which displayed only a slight increase in 
binding potency to T. gondii, but an improved robust selectivity for its’ target parasite 
relative to negative selection cells over extended periods of off-rates selection. Although 
various studies on affinity maturation of antibody variable regions have documented 
gains of affinity in the order of between 2-fold to 30,000 fold (Ho et al., 2005; 
Wedemayer, Patten et al., 1997), the modest 2-fold increase in the binding titers of the 
affinity-matured scFv TP60 to its target may be ascribed to three reasons. First, 
dramatic gains of affinity are more frequently observed with antibody binding to 
purified ligands, and not complex cell surfaces (Rader et al., 2001). Second, the parasite 
binding ligand recognized by the scFv has not been determined; thus the affinity 
constant for the target epitope cannot be ascertained for direct comparisons. Third, one 
cannot rule out the possibility that there may in fact be no significant increase in the 
mutant antibody’s affinity, but only an appreciable improvement in binding selectivity – 
as evidenced in the binding titers assessment. Additional randomization of sequences at 
remaining antibody hot-spot motifs might be appropriate to further increase the binding 
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potency of the scFv in a step-wise antibody evolution approach. Furthermore, the 
antibody hotspots affinity maturation strategy described here could also have potential 
useful applications for modifications of enzymes, receptors, ligands and other 
biologically important proteins; as the somatic hypermutation mechanism is a global 
phenomenon in the genome with DNA hotspots extending beyond immunoglobulin 
genes (Wang, Harper, & Wabl, 2004). 
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CHAPTER 6  OVERALL CONCLUSIONS 
 
 The present study was undertaken to design and characterize the properties of 
single-chain variable fragment (scFv) antibodies targeted to T. gondii, the etiologic 
agent of toxoplasmosis infection. A T. gondii-immunized scFv antibody library was first  
generated by PCR assembly of polyclonal V regions harvested from immunized mouse 
splenic cells. Through this research, an optimized subtractive cell-based biopanning 
protocol was developed to isolate antibody fragments recognizing T. gondii tachyzoites 
in a solution phase screening. The optimized biopanning protocol involved multiple 
rounds of negative selection against absorber cells WRL68 to deplete unspecific binders 
before proceeding with a single round of selection against T. gondii to reduce loss of 
antibody diversity. The first generation scFv antibody library targeted to T. gondii was 
at a complexity of 1.62 × 104 cfu independent transformants. Despite a small library 
size, this study showed that utilization of this small, immunized library in conjunction 
with the optimized biopanning protocol was sufficient to isolate a specific scFv 
antibody against the parasite cells. The isolated phage-scFv antibody, TG130, 
demonstrated a statistically significant binding specificity to tachyzoite cells with an 
average binding titer of 5-fold magnitude higher binding advantage relative to negative 
selection cells. A caveat that needs to be noted regarding the present study is that 
despite the incorporation of an empirically-determined, optimized negative selection 
rounds in the biopanning, several unspecific scFv antibodies were still recovered along 
with specific binders to T. gondii. The reasons to this could be that the WRL68 
hepatocytes were not entirely suitable as a negative selection cell line, or that the 
optimized subtractive biopanning procedure wasn’t robust enough to completely quench 
unspecific antibodies. However, in lieu of the successful isolation of specific scFv 
binders to T. gondii shown here, it is proposed that further refinements to the optimized 
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biopanning protocol would have potential benefits in the rapid isolation of antibody 
fragments on complex cell surfaces; especially when there is a paucity of defined and 
purified antigens. 
 
 To further enhance the antigen-targeting properties of scFv TG130, an in vitro 
affinity maturation was carried out based on hotspots site-directed mutagenesis. 
Through this study, an efficient saturation mutagenesis protocol targeted at the 
antibody’s variable region hotspots was developed. The results of this protocol show 
that the optimized protocol effectively randomized two amino acid positions within the 
VL CDR1 fragment and generated a mutated scFv library of a robust size (4.0 × 104 cfu 
independent transformants) that was approximately 100-fold higher than the minimal 
requirements. This development has potential implications in providing a rapid and 
simple saturation mutagenesis protocol that targets multiple amino acid residues 
simultaneously, with a capability to generate a randomized mutation library within two 
days, and therefore saving costs, time and labour. 
 
 Utilization of the affinity-matured scFv library for biopanning screening for 
improved target binders resulted in the discovery of scFv clone TP60. The TP60 clone 
demonstrated binding titers 1.8-fold higher than its parental counterpart TG130, and 
also a binding advantage that is 2-fold higher for T. gondii relative to the negative 
absorber cell line WRL68, at an extended off-rate selection period of 100.0 min. 
Evidence of the matured scFv’s binding specificity was shown through binding titers 
experiments as well as immunofluorescence imaging. In comparison, at the same 
extended off-rate selection parameters, the parental antibody scFv TG130 could not 
maintain binding selectivity to its’ target tachyzoite cells, but showed slightly lower 
binding titers to T. gondii compared to WRL68. This is translated to mean that the 
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parental antibody TG130 displayed specificity to its target antigen for at least 50.0 min, 
which was the initial off-rate duration employed in the scFv screenings; but loses its’ 
specificity by the 100th min. Therefore, these findings suggested that the affinity 
maturation of scFv TG130 into scFv TP60 by mutating two hot-spots amino acids 
brought modest but appreciable improvements in the scFv antibody’s binding affinity 
and specificity, that was observable over an extended off-rate period of 100.0 min, 
which was more than eight times longer than the established in vivo B-cell receptor 
(BCR) internalization window period of approximately 12 min. An implication of this is 
the possibility that further experiments for affinity maturation at alternative V region 
hot-spots within the antibody could lead to increased improvements in the scFv’s 
binding specificity and potency in a step-wise antibody evolution manner. The current 
investigation was limited by the identification of the parasite binding partner of these 
scFv antibodies. Elucidation of the binding antigen could aid in the finer determination 
of antibody binding affinity constants (KD) and the rational design of scFv refinements 
through bioinformatics analysis. Further research might explore this need to identify an 
antigenic determinant to the developed scFv antibodies, as well as test the soluble scFv 
expression through an E. coli system. 
 
 Taken together, the T. gondii-targeting scFv antibodies developed through this 
study could have potential implications to be developed further into potent antibody 
fragments as an alternative intervention for the disease of toxoplasmosis. At present 
time, there are no chemotherapeutic agents to completely prevent or cure toxoplasmosis, 
while vaccine formulations thus far provided partial reduction of parasitaemia but sterile 
immunity was not achieved (Tan et al., 2010). While a vaccine against T. gondii is 
desirable, this opportunistic infection is problematic in immunocompromised patients 
due to their reduced cellular immunity. Therefore, a passive immunization strategy 
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using recombinant antibodies to inhibit parasite-host invasion is a desirable treatment 
solution. Future work on investigating the reactive properties of these scFv antibodies 
against T. gondii would also be beneficial to evaluate the potential utility of the 
antibodies as bioimaging or therapeutic ligands. In addition, current treatment regime of 
toxoplasmosis in pregnant women with the pyrimethamine-sulfadiazine combination 
drugs is less than ideal due to the teratogenicity of the administered compounds (Gagne, 
2001). There is therefore a growing need to develop alternative treatment strategies such 
as immunotherapeutic antibodies that can decrease parasitaemia and alleviate associated 
disease pathology in immune-deficient hosts. 
 
  These scFv fragments could also be reconstructed into full-length intact IgG for 
the study of its inhibition of infection by the recruitment of effector functions mediated 
by the stem Fc domain. While the scFv molecule has the advantage of improved 
pharmacokinetics, blood clearance properties, simplicity and economically favourable 
expression and isolation due to its smaller size; the drawback associated with the scFv is 
its’ poorer stability compared to its IgG counterpart. In fact, the intact IgG is often the 
antibody format of choice used in immunotherapeutics (Holliger & Hudson, 2005). The 
conversion of the scFv fragments into whole IgG molecules would be an interesting 
study to explore due to the properties of increased functional affinity, induction of 
cytotoxic effector functions and high retention times on cell-surface receptors and 
antigens mediated by a full-length antibody. Immunity to T. gondii infection is a 
combination of cellular and humoral immune responses. B-cell deficient mice are often 
more susceptible to disease mortality compared to immunocompetent mouse (Johnson 
& Sayles, 2002; Kang et al., 2000). Therefore, antibodies against toxoplasmosis can be 
considered as candidates of immune effectors limiting fatal disease in vivo. This study 
reports two scFvs that shows reactivity to the T. gondii parasite surface, and it is 
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believed that these two antibody fragments likely represent only a portion of the parasite 
binding antibodies occurring in infected mice. The scFv library generated in this study 
would remain a useful resource for further studies of the humoral immune response to 
T. gondii epitopes.  
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APPENDICES 
Appendix I: Formulations for mini preparation of plasmid DNA, culture media, & 
other molecular biology reagents. 
 
a) Chemical reagents for mini preparation of plasmid DNA 
 
Solution 1 (per 50 ml) 
1 M Tris.Cl (pH 8.0)      1.25 ml 
0.5 M EDTA (pH 8.0)     1.00 ml 
Glucose       450 mg 
 
 
Solution 2 (per 3000 µl) 
10 M NaOH       60 µl 
10 % SDS       300 µl 
Sterile distilled water      2640 µl 
 
Freshly prepared prior to use 
 
 
Solution 3 (per 250 ml) 
5 M Potassium acetate     150 ml 
Glacial acetic acid      28.75 ml 
Sterile distilled water      71.25 ml 
 
 
 
b) Miscellaneous molecular biology reagents 
 
Annealing Buffer 
10 mM Tris.HCl (pH 7.5) 
60 mM NaCl 
 
 
Biopanning Elution Buffer 
0.1 M HCl  
 
Adjusted to pH 2.2 with glycine. 
 
 
(5%) BSA Blocking Buffer stock (per 100 ml) 
Bovine serum albumin (BSA)    5.00 g 
1X PBS       to 100 ml 
 
 
15 % DMSO (per 20 ml) 
Dimethyl sulfoxide (DMSO, Molecular biology grade) 3.0 ml 
1X PBS       17.0 ml 
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10% NBF (Neutral Buffered Formalin) Fixation Solution (per 100 ml) 
Formaldehyde (Molecular Biology grade)   10.0 ml 
1X PBS       90.0 ml 
 
10% NBF is equivalent to 4% Formaldehyde fixation solution. Solution is stored at 4°C. 
 
 
1X PBS (Phosphate-buffered Saline) 
137 mM NaCl    10X Stock:  80.00 g of NaCl 
2.7 mM KCl       2.00 g of KCl 
12 mM Na2HPO4      17.00 g of Na2HPO4 
1.2 mM KH2PO4      1.63 g of KH2PO4 
 
Adjusted to pH 7.4 with HCl. PBS 10X stock solution was brought to 1 liter with sterile 
distilled water and autoclaved.      
 
 
PEG/Nacl (per 250 ml) 
Polyethylene glycol 8000     50.00 g 
NaCl        36.53 g 
Sterile distilled water      to 250 ml 
 
Solution mixture was heated to dissolve before autoclaving. 
 
 
TB (CaCl2) Solution (for chemical transformation) (per 100 ml) 
10 mM PIPES, Sodium salt     0.6706 g 
55 mM MnCl2.4H2O      1.0885 g 
15 mM CaCl2.2H2O      0.2205 g 
250 mM KCl       1.8637 g 
 
All the components except for MnCl2 were mixed and the pH was adjusted to 6.7 with 
KOH. 
After adjustment to pH 6.7, MnCl2 was dissolved in and solution was filter-sterilized. 
TB Solution was stored at 4°C. 
 
 
Toxoplasma Homegenization Buffer (THB) 
20 mM HEPES/KOH (pH 7.0) 
50 mM Potassium acetate 
10 % (w/v) Sucrose 
1 mM EDTA 
 
 
5X Tris-borate-EDTA buffer (per liter) 
 
Tris base       54.00 g 
Boric acid       27.50 g 
0.5 M EDTA (pH 8.0)     20 ml 
Sterile distilled water      to 1L 
 
Working concentration of TAE buffer is 0.5X. 
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TE Buffer 
10 mM Tris.Cl (pH 8.0) 
1 mM EDTA (pH 8.0) 
 
 
 
c) Culture media and associated reagents 
All media and reagents are sterilized by autoclaving for 15 min at 15 psi on a liquid 
cycle unless otherwise noted. 
 
LB Medium (per 100 ml) 
Bacto-tryptone      1.00 g 
Yeast extract       0.50 g 
NaCl        0.50 g 
 
For plates, add in 1.5g of Bacto-agar before autoclaving. 
 
 
LB Top Agar (per 50 ml) 
LB medium (Gibco-BRL)     1.25 g 
Bacto-agar       0.35 g 
 
Media was autoclaved and stored at 4°C. Before use, it is melted in microwave. 
 
 
M9 Minimal Medium Plates (per 100 ml) 
Bottle A: 
Na2HPO4 (dibasic)      0.60 g 
KH2PO4 (monobasic)      0.30 g 
NH4Cl        0.10 g 
Adjust pH to 7.4 with NaOH 
Sterile distilled water      to 50 ml 
 
Bottle B: 
Bacto-agar       1.50 g 
Sterile distilled water      to 49 ml 
 
Both bottles were autoclaved simultaneously to sterilize. Bottles were cooled down to 
50-60°C and combined. The following pre-filter-sterilized solutions were then added in: 
 
1M MgCl2.6H2O      100 µl 
1M CaCl2.2H2O      100 µl 
1M Thiamine Hydrochloride     100 µl 
20 % Glucose       500 µl 
 
Plates were poured immediately. 
 
 
NZY+ Broth (per 100 ml) 
NZ Amine (Casein hydrolysate)    1.00 g 
Yeast extract       0.50 g 
NaCl        0.50 g 
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Sterile distilled water was added to ~ 100 ml. The pH was adjusted to 7.5 using NaOH 
and autoclaved. Media was allowed to cool to 50-60°C, before addition of the following 
pre-filter-sterilized solutions prior to use: 
 
1M MgCl2.6H20      1.25 ml 
1M MgSO4       1.25 ml 
20% (w/v) Glucose      2.00 ml 
 
 
SOC Medium (per 100 ml) 
Bacto-tryptone      2.00 g 
Yeast extract       0.50 g 
NaCl        0.06 g 
250 mM  KCl       1.0 ml 
1 M MgCl2.6H20      1.0 ml 
1 M MgSO4       1.0 ml 
2 M Glucose       1.0 ml 
 
Media was adjusted to pH 7.0 by adding 10 N NaOH prior to autoclaving. 
Filter-sterilized 2M Glucose was added after media was autoclaved and cooled down to 
at least 50°C - 60°C. 
 
 
SB (Super Broth) (per 100 ml) 
MOPS (3(N-Morpholino) propanesulfonic acid)  1.00 g 
Bacto-tryptone      3.00 g 
Yeast exract       2.00 g 
 
Adjust pH to 7.0. 
 
 
SOBAG Plates (per 500 ml) 
Bacto-tryptone      10.00 g 
Yeast extract        2.50 g 
NaCl        0.25 g 
Bacto-agar       7.50 g 
 
Media was autoclaved and cooled down to 50-60°C before adding in the following pre-
filter-sterilized solutions: 
 
1M MgCl2.6H2O      5.0 ml 
2M Glucose       27.8 ml 
100 mg/ml Ampicillin     500 µl 
 
 
2X YT Medium (per 1 L) 
Bacto-tryptone      17.00 g 
Yeast extract       10.00 g 
NaCl        5.00 g 
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2X YT-AG Medium 
2X YT medium containing 100 µg/ml Ampicillin and 2% Glucose. 
 
 
2X YT-AK Medium 
2X YT medium containing 100 µg/ml Ampicillin and 50 µg/ml Kanamycin. 
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Appendix II: Sterilization procedure for working with phage. 
(adapted from General Procedures section in Phage Display: A Laboratory Manual 
(Barbas et al., 2001)) 
 
 
All plasticware, glassware and complex solutions (such as PEG/NaCl and media) are 
sterilized in an autoclave that was never used to autoclave biological wastes. This was 
meant to keep the phage load in the autoclave to a minimum, as phages are known to 
survive standard autoclaving conditions. 
 
All glass and plasticware to be used or recycled for phage procedures are treated for 
phage decontamination by heat-treating dry, autoclaved materials in an oven for 4 hours 
at 105°C, or by simply drying the autoclaved materials overnight at the same 
temperature. 
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Appendix III: Table of primer sequences for VH and VL regions amplification. 
 
PRIMER SEQUENCE D 
 
Vκ 5’ / sense 
(Sfi 1) 
  
MSCVK-1 GGG CCC AGC CGG CCG AGC TCG AYA TCC AGC TGA CTC AGA C 2 
MSCVK-2 GGG CCC AGC CGG CCG AGC TCG AYA TTG TTC TCW CCC AGT C 3 
MSCVK-3 GGG CCC AGC CGG CCG AGC TCG AYA TTG TGM TMA CTC AGT C 4 
MSCVK-4 GGG CCC AGC CGG CCG AGC TCG AYA TTG TGY TRA CAC AGT C 4 
MSCVK-5 GGG CCC AGC CGG CCG AGC TCG AYA TTG TRA TGA CMC AGT C 4 
MSCVK-6 GGG CCC AGC CGG CCG AGC TCG AYA TTM AGA TRA MCC AGT C 4 
MSCVK-7 GGG CCC AGC CGG CCG AGC TCG AYA TTC AGA TGA YDC AGT C 4 
MSCVK-8 GGG CCC AGC CGG CCG AGC TCG AYA TYC AGA TGA CAC AGA C 3 
MSCVK-9 GGG CCC AGC CGG CCG AGC TCG AYA TTG TTC TCA WCC AGT C 3 
MSCVK-10 GGG CCC AGC CGG CCG AGC TCG AYA TTG WGC TSA CCC AAT C 4 
MSCVK-11 GGG CCC AGC CGG CCG AGC TCG AYA TTS TRA TGA CCC ART C 5 
MSCVK-12 GGG CCC AGC CGG CCG AGC TCG AYR TTK TGA TGA CCC ARA C 5 
MSCVK-13 GGG CCC AGC CGG CCG AGC TCG AYA TTG TGA TGA CBC AGK C 4 
MSCVK-14 GGG CCC AGC CGG CCG AGC TCG AYA TTG TGA TAA CYC AGG A 3 
MSCVK-15 GGG CCC AGC CGG CCG AGC TCG AYA TTG TGA TGA CCC AGW T 3 
MSCVK-16 GGG CCC AGC CGG CCG AGC TCG AYA TTG TGA TGA CAC AAC C 2 
MSCVK-17 GGG CCC AGC CGG CCG AGC TCG AYA TTT TGC TGA CTC AGT C 2 
 
Vκ 3’ / 
antisense 
  
MSCJK12-B GGA AGA TCT AGA GGA ACC ACC TTT KAT TTC CAG YTT GGT CCC 3 
MSCJK4-B GGA AGA TCT AGA GGA ACC ACC TTT TAT TTC CAA CTT TGT CCC 1 
MSCJK5-B GGA AGA TCT AGA GGA ACC ACC TTT CAG CTC CAG CTT GGT CCC 1 
 
Vλ 5’/ sense 
(Sfi 1) 
  
MSCVL-1 GGG CCC AGC CGG CCG AGC TCG ATG CTG TTG TGA CTC AGG AAT C 1 
 
Vλ 3’/ 
antisense-
short linker 
  
MSCJKL-B GGA AGA TCT AGA GGA ACC ACC GCC TAG GAC AGT CAG TTT GG 1 
VH 5’ / sense   
MSCVH1 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTR MAG CTT CAG GAG TC 3 
MSCVH2 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTB CAG CTB CAG CAG TC 3 
MSCVH3 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAG CTG AAG SAS TC 3 
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PRIMER SEQUENCE D 
MSCVH4 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAR CTG CAA CAR TC 3 
MSCVH5 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTY CAG CTB CAG CAR TC 4 
MSCVH6 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTY CAR CTG CAG CAG TC 3 
MSCVH7 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAC GTG AAG CAG TC 1 
MSCVH8 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAS STG GTG GAA TC 3 
MSCVH9 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AWG YTG GTG GAG TC 3 
MSCVH10 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAG SKG GTG GAG TC 3 
MSCVH11 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAM CTG GTG GAG TC 2 
MSCVH12 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG CTG ATG GAR TC 2 
MSCVH13 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG CAR CTT GTT GAG TC 2 
MSCVH14 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTR AAG CTT CTC GAG TC 2 
MSCVH15 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAR STT GAG GAG TC 3 
MSCVH16 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTT ACT CTR AAA GWG TST G 4 
MSCVH17 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTC CAA CTV CAG CAR CC 3 
MSCVH18 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG TTG GAA GTG TC 1 
MSCVH19 GGT GGT TCC TCT AGA TCT TCC CTC GAG GTG AAG GTG ATC GAG TC 1 
   
VH 3’ / 
antisense 
(Not1) 
  
MSCG1ab-B CCT GCG GCC GCC CAC TAG TGA CAG ATG GGG STG TYG TTT TGG 3 
MSCG3-B CCT GCG GCC GCC CAC TAG TGA CAG ATG GGG CTG TTG TTG T 1 
   
MSC-F GCG GGG CCC AGC CGG CCG AGC TCG 1 
RSC-B GCC TGC GGC CGC ACT AGT GAC AGA 1 
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Appendix IV: The map of pCANTAB5E phagemid vector (GE Life Sciences 
(formerly Amersham Biosciences), Recombinant Phage Antibody System) 
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Appendix V: Subtractive biopanning quenching of phage-scFv unspecific 
paratopes against normal hepatocytes cell line WRL68. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                           
5
 Quenching ratio = phage titer of previous round / phage titer of test round. 
SUBTRACTIVE BIOPANNING ROUND 
PHAGE-BINDING TITER 
(cfu/ml) 
QUENCHING RATIO5 
1 2.2 X 105 - 
2 1.1 X 105 2.0 
3 3.1 X 104 3.6 
4 3.9 X 104 0.8 
5 8.0 X 104 0.5 
6 1.2 X 104 0.7 
 
7 9.0 X 104 1.3 
Supplementary Graph: ScFv Subtractive Biopanning Quenching Profile
Subtractive Biopanning Rounds
0 2 4 6 8
Qu
e
n
ch
in
g 
Ra
tio
s
0
1
2
3
4
Subtractive Biopanning Round vs Quenching Ratio
197 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix VI: Chromatograms of scFv sequences  
 
• Appendix VI-i: Chromatogram of scFv TG64 
• Appendix VI-ii: Chromatogram of scFv TG69 
• Appendix VI-iii: Chromatogram of scFv TG116 
• Appendix VI-iv: Chromatogram of scFv TG130 
• Appendix VI-v: Protein translation of scFv sequences 
 
 
 
 
 
 
 
 
 
 
 
 
198 
 
Appendix VI-i : Chromatograms of scFv sequences – scFv TG64 
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Appendix VI-ii : Chromatograms of scFv sequences – scFv TG69 
 
 
 
 
 
 
 
 
200 
 
Appendix VI-iii : Chromatograms of scFv sequences – scFv TG116 
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scFv TG116 – continued. 
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Appendix VI-iv : Chromatograms of scFv sequences – scFv TG130 
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Appendix VI-v : Protein translation of scFv sequences 
 
 
i. ScFv TG64 
 
MT Q S P A I L S A S P G E K V TMT C R A S S S I S YMH W Y Q Q K P 
G T S P K R W I Y D T S K L A S G V P A R F S G S G S G T S Y S L T I S 
SME A E D A A T Y Y C H Q R S S Y P Y T F G G G T K L E I K G G S S 
R S S L E VML V E S G A E L A R P G A S V KMS C K A S G Y T F T S 
Y TMH W V K Q R P G Q G L E W I G Y I N P S S G Y T N Y N Q K F K 
D K A T L T A D K S S S T A YMQ L S S L T S E D S A V Y Y C A R E A 
W F A Y W G Q G T L V T V S A 
 
 
 
ii. ScFv TG69 
 
MT Q S H K FMS T S V G D R V S I T C K A S Q D V G T A V A W Y Q 
Q K P G Q S P K L L I Y W A S T R H T G V P D R F T G S G S G T D F T 
L T I S N V Q S E D L A D Y F C Q Q Y S S Y H T F G G G T K L E I K G 
G S S R S S L E V Q L Q Q S G A E L V R S G A S V K L S C T A S G F N 
I K D T YMH W V K Q R P E Q G L E W I G R I D P A N G N T K Y D P 
K F Q D K A T I T A D T S S N T A Y L Q L S S L T S E D T A V Y Y C A 
R L P Y W G Q G T T L T V S S 
 
 
 
iii. ScFv TG116 
 
MT Q S H K FMS T S V G D R V S I N C K A S Q D V S T A V A W Y Q 
Q K P G Q S P K L L I Y S A S N R Y T G V P D R F T G S G S G T D F T 
L T I S NMQ S E D L A D Y F C Q Q Y S S Y P Y T F G G G T K L E I K 
G G S S R S S L E V Q L Q Q S G A E L V K P G A S V K L S C T A S G F 
N I K D T YMH W V K Q R P E Q G L E W I G R I D P A N G N T K Y D 
P K F Q G K A T I T A D T S S N T A Y L Q L S S L T S E D T A V Y Y C 
A S S H G Y E D Y F D Y W G Q G T T L T V S S 
 
 
 
iv. ScFv TG130 
 
MT Q S H K FMS T S V G D R V S I T C K A S Q D V S T A V A W Y Q Q 
K P G Q S P K L L I Y S A S Y R Y T G V P D R F T G S G S G T D F T L 
T I S N V Q S E D L A E Y F C Q Q Y N S Y P Y T F G A G T K L E L K G 
G S S R S S L E V H L V E S G P E L V K P G A S V K I S C K A S G Y T 
F T D Y NMH W V K Q S H G K S L E W I G Y I Y P Y N G G T G Y N Q 
K F K S K A T L T V D N S S S T A YME L R S L T S E D S A V Y Y C A 
R G D G F A Y W G Q G T L V T V S A 
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Appendix VII: Chromatograms of truncated scFv 
sequences  
 
• Appendix VII-i: Chromatogram of scFv 18 
• Appendix VII-ii: Chromatogram of scFv 48 
• Appendix VII-iii: Chromatogram of scFv 103 
• Appendix VII-iv: Chromatogram of scFv 109 
• Appendix VII-v: Chromatogram of scFv 118 
• Appendix VII-vi: Protein translation of truncated scFv sequences 
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Appendix VII-i : Chromatograms of truncated scFv sequences – scFv 18 (Stop 
codon is indicated in red box). 
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Appendix VII-i i: Chromatograms of truncated scFv sequences – scFv 48 (Stop 
codon is indicated in red box). 
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Appendix VII-iii: Chromatograms of truncated scFv sequences – scFv 103 (Stop 
codon is indicated in red box). 
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Appendix VII-iv: Chromatograms of truncated scFv sequences – scFv 109 (Stop 
codon is indicated in red box). 
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Appendix VII-v: Chromatograms of truncated scFv sequences – scFv 118 (Stop 
codon is indicated in red box). 
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Appendix VII-vi : Protein translation of truncated scFv sequences 
 
 
scFv 18 
 
MT Q S P A S L A V S L G Q R A T I S C R A S Q S V S T S S Y S YMH 
W Y Q Q K P G Q P P K L L I K Y A S N L E S G V P A R F S G S G S G T 
D F T L N I H P V E E E D T A T Y Y C Q H S W E I P Y T F G G G T K L 
E I K G G S S R S S L E V Q L V E S G P E L V R P G L Q Stop 
 
 
 
scFv 48 
 
MT R L Q Q S C L H L Q G R R S P Stop 
 
 
 
scFv 103 
 
MT Q S P A S L A V S L G Q R A T I S C R A S Q S V S T S S Y S YMH 
W Y Q Q K P G Q P P K L L I K Y A S N L E S G V P A R F S G S G S G T 
D F T L N I H P V E E E D T A T Y Y C Q H S W E I P Y T F G G G T K L 
E I K G G S S R S S L E V Q L V E S G P E L V R P G L Q Stop 
 
 
 
scFv 109 
 
MT Q S H K FMS T S V G D R V S I T C K A S Q D V G T A V A W Y Q 
Q K P G Q S P K L L I Y W A S T R H T G V P D R F T G S G S G T D F T 
L T I S N V Q S E D L A D Y F C Q Q Y S S Y P T F G A G T K L E L K G 
G S S R S S L E V H G W S L G Q S L Stop 
 
 
 
scFv 118 
 
MT Q S P A LMS A S P G E K V TMT C S A S S S V S YMY W Y Q Q K P 
R S S P K P W I Y L T S N L A S G V P A R F S G S G S G T S Y S L T I S 
SME A E D A A T Y Y C H Q R S S Y P Y T F G G G T K L E L K V V P L 
D L P S R S S C S S Q D L S W Stop 
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Appendix VIII (a): Closest germline sequence homology alignment with biopanned scFv nucleotide and amino acid sequences. 
 
 
ScFv TG64 
 
VL                                                  CDR 1 – IMGT 
                  1               5                   10                  15                  20                  25                  30                  35                  40 
TG64 (aa)  M   T   Q   S   P   A   I   L   S   A   S   P   G   E   K   V   T   M   T   C   R   A   S   S   S   I   S   Y   M   H   W   Y   Q   Q   K   P   G   T   S   P    
TG64 (nt)      atg acc cag tct cca gca atc ctg tct gca tct cca ggg gag aag gtc aca atg act tgc agg gcc agc tca agt ata agt tac atg cac tgg tac cag cag aag cca ggc acc tcc ccc 
Germ (nt)  c-c --- --- --- --- --- --- a-- --- --- --- --- --- --- --- --- --c --- --c --- --t --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)  L   -   -   -   -   -   -   M   -   -   -   -   -   -   -   -   -   -   -   -   S   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -    
 
                                      CDR2 - IMGT 
                                  45                  50                  55                 60                  65                  70                  75                   80  
TG64 (aa)  K   R   W   I   Y   D   T   S   K   L   A   S   G   V   P   A   R   F   S   G   S   G   S   G   T   S   Y   S   L   T   I   S   S   M   E   A   E   D   A   A    
TG64 (nt)     aaa aga tgg att tat gac aca tcc aaa ctg tct gga gtc cct gct cgc ttc agt ggc agt ggg tct ggg acc tct tat tct ctc aca gct atc agc agc atg gag gct gaa gat gct gcc 
Germ (nt)      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)       -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -    
 
    CDR3 -  IMGT 
                                         85                  90                  95                  100         103 
TG64 (aa)  T   Y   Y   C   H   Q   R   S   S   Y   P   Y   T   F   G   G   G   T   K   L   E   I   K 
TG64 (nt)       act tat tac tgc cat cag cgg agt agt tac ccg tac acg ttc gga ggg ggg acc aaa ctg gaa ata aaa 
Germ (nt)       --- --- --- --- --- --- --- --- --- --- --a --- --- --- --- --- --- --- --g --- --- --- --- 
Germ (aa)       -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -                                                                                                        
 
 
VH                                CDR1 - IMGT 
                      1               5                  10                  15                  20                  25                   30                  35                  40 
TG64 (aa)  E   V   M   L   V   E   S   G   A   E   L   A   R   P   G   A   S   V   K   M   S   C   K   A   S   G   Y   T   F   T   S   Y   T   M   H   W   V   K   Q   R 
TG64 (nt)     gag gtg atg ttg gtg gag tct ggg gct gaa ctg gca aga cct ggg gcc tca gtg aag atg tcc tgc aag gct tct ggc tac acc ttt act agc tac acg atg cac tgg gta aaa cag agg 
Germ (nt)      c-- --c ca- c-- ca- c-- --- --- --- --- --- --- --- --- --t --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)       Q   -   Q   -   Q   Q   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -    
 
                                         CDR 2 - IMGT 
                                         45                  50                   55                  60                  65                  70                  75                  80 
TG64 (aa)  P   G   Q   G   L   E   W   I   G   Y   I   N   P   S   S   G   Y   T   N   Y   N   Q   K   F   K   D   K   A   T   L   T   A   D   K   S   S   S   T   A   Y 
TG64 (nt)       cct gga cag ggt ctg gaa tgg att gga tac att aat cct agc agt ggt tat aat aac tac aat cag aag ttc aag gac aag gcc aca ttg act gca gac aaa tcc tcc agc aca gcc tac 
Germ (nt)       --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --g --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)      -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   K   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   - 
                                                                       
                                                                                                           CDR3 - IMGT 
                                         85                  90                  95                  100                 105              110              115     
TG64 (aa)  M   Q   L   S   S   L   T   S   E   D   S   A   V   Y   Y   C   A   R   E   A   W   F   A   Y   W   G   Q   G   T   L   V   T   V   S   A 
TG64 (nt)        atg caa ctg agc agc ctg aca tct gag gac tct gca gtc tat tac tgt gca aga gag gcc tgg ttt gct tac tgg ggc caa ggg act ctg gtc act gtc tct gca 
Germ (nt)       --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)       -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   - 
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Appendix VIII (b): Closest germline sequence homology alignment with biopanned scFv nucleotide and amino acid sequences. 
 
 
ScFv TG69 
 
VL                                                 CDR1 - IMGT 
                         1               5                   10                  15                 20                   25                  30                  35                  40 
TG69 (aa)  M   T   Q   S   H   K   F   M   S   T   S   V   G   D   R   V   S   I   T   C   K   A   S   Q   D   V   G   T   A   V   A   W   Y   Q   Q   K   P   G   Q   S 
TG69 (nt)       atg aca cag tct cac aaa ttc atg tcc aca tca gta gga gac agg gtc agc atc acc tgc aag gcc agt cag gat gtg ggt act gct gta gcc tgg tat caa cag aaa cca ggg caa tct 
Germ (nt)      --- --c --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)      -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -    
 
                                                 CDR2 - IMGT 
                                         45                  50                  55                  60                  65                  70                   75                 80 
TG69 (aa)  P   K   L   L   I   Y   W   A   S   T   R   H   T   G   V   P   D   R   F   T   G   S   G   S   G   T   D   F   T   L   T   I   S   N   V   Q   S   E   D   L 
TG69 (nt)        cct aaa cta ctg att tac tgg gca tcc acc cgg cac act gga gtc cct gat cgc ttc aca ggc agt gga tct ggg aca gat ttc act ctc acc att agc aat gtg cag tct gaa gac ttg 
Germ (nt)       --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)       -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -    
                                                                            
                                                       CDR3 - IMGT   
                                         85                  90                  95                  100         103 
TG69 (aa)  A   D   Y   F   C   Q   Q   Y   S   S   Y   H   T   F   G   G   G   T   K   L   E   I   K 
TG69 (nt)     gca gat tat ttc tgt cag caa tat agc agc tat cac acg ttc gga ggg ggg acc aag ctg gaa ata aaa 
Germ (nt)      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)    -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -                                                                            
 
 
VH                                               CDR1 - IMGT   
                       1               5                  10                  15                  20                   25                  30                  35                  40 
TG69 (aa)  E   V   Q   L   Q   Q   S   G   A   E   L   V   R   S   G   A   S   V   K   L   S   C   T   A   S   G   F   N   I   K   D   T   Y   M   H   W   V   K   Q   R 
TG69 (nt)     gag gtt cag ctg cag cag tct ggg gca gag ctt gtg agg tca ggg gcc tca gtc aag ttg tcc tgc aca gct tct ggc ttc aac att aaa gac acc tat atg cac tgg gtg aag cag agg 
Germ (nt)       --- --- --- --- --- --- --- --- --- --- --- --- -a- c-- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)       -   -   -   -   -   -   -   -   -   -   -   -   K   P   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -    
 
                                      CDR2 - IMGT 
                                         45                  50       55                  60                  65                  70                  75   80 
TG69 (aa)  P   E   Q   G   L   E   W   I   G   R   I   D   P   A   N   G   N   T   K   Y   D   P   K   F   Q   D   K   A   T   I   T   A   D   T   S   S   N   T   A   Y 
TG69 (nt)       cct gaa cag ggc ctg gag tgg att gga agg att gat cct gcg aat ggt aat act aaa tat gac ccg aag ttc cag gac aag gcc act ata aca gca gac aca tcc tcc aac aca gcc tac 
Germ (nt)       --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -g- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)       -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   G   -   -   -   -   -   -   -   -   -   -   -   -   -   -                                
                                      
                                                                                            CDR3 -  IMGT 
                                         85                  90                  95                  100                 105                 110     112 
TG69 (aa)  L   Q   L   S   S   L   T   S   E   D   T   A   V   Y   Y   C   A   R   L   P   Y   W   G   Q   G   T   T   L   T   V   S   S 
TG69 (nt)      ctg cag ctc agc agc ctg aca tct gag gac act gcc gtc tat tac tgt gct aga ctg ccc tac tgg ggc caa ggc acc act ctc aca gtc tcc tca 
Germ (nt)       --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- t-t ga- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)       -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   F   D   -   -   -   -   -   -   -   -   -   -   -   -                                  
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Appendix VIII (c): Closest germline sequence homology alignment with biopanned scFv nucleotide and amino acid sequences. 
 
 
ScFv TG116 
 
VL 
                                  CDR1 - IMGT 
               1               5                  10                  15                  20                   25                  30                  35                  40 
TG116 (aa)  M   T   Q   S   H   K   F   M   S   T   S   V   G   D   R   V   S   I   N   C   K   A   S   Q   D   V   S   T   A   V   A   W   Y   Q   Q   K   P   G   Q   S 
TG116 (nt)     atg aca cag tct cac aaa ttc atg tcc aca tca gta gga gac agg gtc agc atc aac tgc aag gcc agt cag gat gtg agt act gct gta gcc tgg tat caa cag aaa cca gga caa tct 
Germ (nt)      --- --c --- --- --a --- --- --- --- --- --- --- --- --- --- --- --- --- -c- --- --- --- --- --- a-- --- g-- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)     -   -   -   -   Q   -   -   -   -   -   -   -   -   -   -   -   -   -   T   -   -   -   -   -   N   -   G   -   -   -   -   -   -   -   -   -   -   -   -   -    
  
                                                  CDR2 - IMGT 
                                         45                  50   55                  60                  65                  70                  75                  80 
TG116 (aa)  P   K   L   L   I   Y   S   A   S   N   R   Y   T   G   V   P   D   R   F   T   G   S   G   S   G   T   D   F   T   L   T   I   S   N   M   Q   S   E   D   L 
TG116 (nt)      cct aaa cta ctg att tac tcg gca tcc aat cgg tac act gga gtc cct gat cgc ttc aca ggc agt gga tct ggg aca gat ttc act ctc acc atc agc aat atg cag tct gaa gac ctg 
Germ (nt)     --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)     -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -    
  
                                                                        CDR3 - IMGT 
                                         85                  90                  95                  100             104 
TG116 (aa)  A   D   Y   F   C   Q   Q   Y   S   S   Y   P   Y   T   F   G   G   G   T   K   L   E   I   K 
TG116 (nt)      gca gat tat ttc tgc cag caa tat agc agc tat ccg tac acg ttc gga ggg ggg acc aaa ctg gaa ata aaa 
Germ (nt)     --- --- --- --- --- --- --- --- --- --- --- --t --- --- --- --- --- --- --- --g --- --- --- --- 
Germ (aa)      -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -                                    
 
 
VH 
                                      CDR1 - IMGT 
               1               5                   10                  15                  20                  25     30                  35                  40 
TG116 (aa)  E   V   Q   L   Q   Q   S   G   A   E   L   V   K   P   G   A   S   V   K   L   S   C   T   A   S   G   F   N   I   K   D   T   Y   M   H   W   V   K   Q   R 
TG116 (nt)      gag gtt cag ctg cag cag tct ggg gca gag ctt gtg aag cca ggg gcc tca gtc aag ttg tcc tgc aca gct tct ggc ttc aac att aaa gac acc tat atg cac tgg gtg aag cag agg 
Germ (nt)       --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)       -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -    
 
                                         CDR2 - IMGT 
                               45                  50              55                  60                  65                  70                  75                  80 
TG116 (aa)  P   E   Q   G   L   E   W   I   G   R   I   D   P   A   N   G   N   T   K   Y   D   P   K   F   Q   G   K   A   T   I   T   A   D   T   S   S   N   T   A   Y 
TG116 (nt)     cct gaa cag ggc ctg gag tgg att gga agg att gat cct gcg aat ggt aat act aaa tat gac ccg aag ttc cag ggc aag gcc act ata aca gca gac aca tcc tcc aac aca gcc tac 
Germ (nt)      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)      -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -    
                                                          
        CDR3 - IMGT 
                        85                  90                  95                 100   105                 110                 115             119 
TG116 (aa)  L   Q   L   S   S   L   T   S   E   D   T   A   V   Y   Y   C   A   S   S   H   G   Y   E   D   Y   F   D   Y   W   G   Q   G   T   T   L   T   V   S   S 
TG116 (nt)     ctg cag ctc agc agc ctg aca tct gag gac act gcc gtc tat tac tgt gct agt tca cat ggt tac gaa gac tac ttt gac tac tgg ggc caa ggc acc act ctc aca gtc tcc tca 
Germ (nt)       --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
Germ (aa)       -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -   -           
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Appendix IX: V-Quest Antibody V-Regions sequence analysis results. 
 
 
ScFv 64 VL sequence analysis: 
 
Result summary:  Productive IGK rearranged sequence (no stop codon 
and in-frame junction) 
V-GENE and allele IGKV4-70*01 score = 1276 
identity = 97,75% 
(261/267 nt) 
J-GENE and allele IGKJ2*01 score = 176 identity = 97,30% (36/37 
nt) 
[CDR1-IMGT.CDR2-IMGT.CDR3-IMGT] 
lengths and AA JUNCTION [5.3.9] CHQRSSYPYTF 
 
 
 
ScFv 64 VH sequence analysis: 
 
Result summary:  Productive IGH rearranged sequence (no stop codon 
and in-frame junction) 
V-GENE and allele IGHV1-4*01 score = 1345 
identity = 96,53% 
(278/288 nt) 
J-GENE and allele IGHJ3*01 score = 240 identity = 100,00% (48/48 
nt) 
D-GENE and allele by IMGT/JunctionAnalysis No results - 
[CDR1-IMGT.CDR2-IMGT.CDR3-IMGT] lengths 
and AA JUNCTION [8.8.8] CAREAWFAYW 
 
 
 
ScFv 69 VL sequence analysis: 
 
Result summary:  Productive IGK rearranged sequence (no stop codon 
and in-frame junction) 
V-GENE and allele IGKV6-23*01 score = 1336 
identity = 99,63% 
(269/270 nt) 
J-GENE and allele IGKJ2*01 score = 175 identity = 100,00% (35/35 
nt) 
[CDR1-IMGT.CDR2-IMGT.CDR3-IMGT] 
lengths and AA JUNCTION [6.3.8] CQQYSSYHTF 
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ScFv 69 VH sequence analysis: 
 
Result summary:  Productive IGH rearranged sequence (no stop codon 
and in-frame junction) 
V-GENE and allele IGHV14-3*02 score = 1408 
identity = 98,96% 
(285/288 nt) 
J-GENE and allele IGHJ2*01 score = 179 identity = 90,70% (39/43 
nt) 
D-GENE and allele by IMGT/JunctionAnalysis IGHD6-1*01 D-REGION is in reading frame 1 
[CDR1-IMGT.CDR2-IMGT.CDR3-IMGT] lengths 
and AA JUNCTION [8.8.5] CARLPYW 
 
 
 
ScFv 116 VL sequence analysis: 
 
Result summary:  Productive IGK rearranged sequence (no stop codon 
and in-frame junction) 
V-GENE and allele IGKV6-13*01 score = 1300 
identity = 98,15% 
(265/270 nt) 
J-GENE and allele IGKJ2*01 score = 176 identity = 97,30% (36/37 
nt) 
[CDR1-IMGT.CDR2-IMGT.CDR3-IMGT] 
lengths and AA JUNCTION [6.3.9] CQQYSSYPYTF 
 
 
 
ScFv 116 VH sequence analysis: 
 
Result summary:  Productive IGH rearranged sequence (no stop codon 
and in-frame junction) 
V-GENE and allele IGHV14-3*02 score = 1435 
identity = 100,00% 
(288/288 nt) 
J-GENE and allele IGHJ2*01 score = 240 identity = 100,00% (48/48 
nt) 
D-GENE and allele by IMGT/JunctionAnalysis IGHD2-2*01 D-REGION is in reading frame 3 
[CDR1-IMGT.CDR2-IMGT.CDR3-IMGT] 
lengths and AA JUNCTION [8.8.12] CASSHGYEDYFDYW 
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ScFv 130 VL sequence analysis: 
 
Result summary:  Productive IGK rearranged sequence (no stop codon 
and in-frame junction) 
V-GENE and allele IGKV6-17*01 score = 1255 
identity = 95,93% 
(259/270 nt) 
J-GENE and allele IGKJ5*01 score = 167 identity = 94,59% (35/37 
nt) 
[CDR1-IMGT.CDR2-IMGT.CDR3-IMGT] 
lengths and AA JUNCTION [6.3.9] CQQYNSYPYTF 
 
 
 
ScFv 130 VH sequence analysis: 
 
Result summary:  Productive IGH rearranged sequence (no stop codon 
and in-frame junction) 
V-GENE and allele IGHV1S29*02 score = 1372 
identity = 97,57% 
(281/288 nt) 
J-GENE and allele IGHJ3*01 score = 213 
identity = 93,75% (45/48 
nt) 
D-GENE and allele by IMGT/JunctionAnalysis No results - 
[CDR1-IMGT.CDR2-IMGT.CDR3-IMGT] 
lengths and AA JUNCTION [8.8.8] CARGDGFAYW 
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Appendix X: Data for binding titers of phage-scFv biopanning experiments. 
 
 
a) ScFv binding titers of monoclonal scFv screenings. 
 
 
 
ScFv Binding Titers (cfu / ml) 
 
TG64 TG69 TG116 TG130 
Sample 1 3.00 X 105 3.35 X 105 1.25 X 106 4.00 X 105 
Sample 2 1.20 X 105 3.50 X 105 6.75 X 105 4.15 X 105 
Sample 3 9.60 X 104 3.00 X 105 4.20 X 105 4.00 X 105 
Sample 4 1.00 X 106 2.60 X 105 3.00 X 105 1.50 X 105 
Sample 5 8.50 X 105 2.40 X 105 1.75 X 105 8.00 X 104 
Sample 6 3.50 X 105 3.50 X 105 1.80 X 105 8.70 X 104 
Sample 7 2.65 X 105 4.00 X 105 1.46 X 105 5.00 X 104 
Sample 8 3.70 X 105 5.40 X 105 1.35 X 106 6.00 X 104 
Sample 9 N/D N/D N/D 6.00 X 104 
Sample 10 N/D N/D N/D 4.10 X 104 
Sample Mean 4.19 X 105 3.47 X 105 5.62 X 105 1.74 X 105 
Sample Standard error 1.17 X 105 3.31 X 104 1.72 X 105 5.12 X 104 
Negative Control (NC) Mean 2.90 X 105 1.20 X 105 6.00 X 105 3.75 X 104 
NC Standard error 0.00ɸ 0.00 ɸ 0.00 ɸ 7.50 X 103 
 
_______________________ 
*N/D, not determined. 
ɸ Although duplicate experiments were carried out for these negative control sets, titers could not be 
determined due to media plates were confluent with bacterial colonies from the phage-output recovery 
fraction. 
 
 
 
b) ScFv binding titers of parental scFv TG130 and affinity-matured scFv TP60 at 
different off-rate durations. 
 
 
ScFv Binding Titers (cfu / ml) 
 
Off-rate 50.0 min Off-rate 100.0 min 
 
TG130 TP60 TG130 TP60 
Replicate 1 2.73 X 105 9.80 X 105 7.00 X 103 1.40 X 104 
Replicate 2 1.61 X 105 N/D* 7.00 X 103 1.10 X 104 
Sample Mean 2.17 X 105 9.80 X 105 7.00 X 103 1.25 X 104 
Sample Standard Error 5.60 X 104 0.00 0.00 1.50 X 103 
Negative Control (NC) Mean 9.80 X 104 4.94 X 105 8.87 X 103 6.07 X 103 
NC Standard Error 0.00 1.02 X 105 1.87 X 103 6.17 X 102 
 
                                                           
*
 N/D, not determined. ScFv binding titers could not be determined as media plate was confluent with 
bacterial colonies from the phage-output recovery fraction. 
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c) Monoclonal TG-RGYW mutant scFv clones binding titers. 
 
 
 
ScFv Binding Titers (cfu / ml) 
 
TG130 RA15 RS55 TP60 RT51 LT3 
Replicate 1 7.00 X 103 1.40 X 103 7.00 X 103 1.40 X 104 3.50 X 103 1.40 X 104 
Replicate 2 7.00 X 103 4.20 X 103 4.90 X 103 1.10 X 104 2.80 X 103 4.90 X 103 
Replicate 3 5.60 X 103 - - 7.00 X 103 - 4.90 X 103 
Sample Mean 6.53 X 103 2.80 X 103 5.95 X 103 1.07 X 104 3.15 X 103 7.93 X 103 
Sample Standard 
error 4.67 X 102 1.40 X 103 1.05 X 103 2.03 X 103 3.50 X 102 3.03 X 103 
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Appendix XI: Statistical test results of the difference in scFv TG130 antibody recognition between target antigen T. gondii and negative 
control cell line. Statistical significance comparison between the two test groups were assessed using the non-parametric Wilcoxon Mann-Whitney 
one-tailed test at alpha value = 0.05, and n = 12. Results were obtained using the Analyse-it for Windows v2.22 statistics software. 
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Appendix XII: Sequencing results of TG130-
RGYW mutant scFv clones. 
 
• Appendix XII-i: Alignment of 5 randomly selected RGYW clones. 
• Appendix XII-ii: Chromatogram of scFv TG130-RGYW 1 
• Appendix XII-iii: Chromatogram of scFv TG130-RGYW 3 
• Appendix XII-iv: Chromatogram of scFv TG130-RGYW 4 
• Appendix XII-v: Chromatogram of scFv TG130-RGYW 21 
• Appendix XII-vi: Chromatogram of scFv TG130-RGYW 27 
• Appendix XII-vii: Alignment of 5 selected RGYW scFv clones from 
biopanning 
• Appendix XII-viii: Chromatogram of scFv TP60 
• Appendix XII-ix: Chromatogram of scFv RA15 
• Appendix XII-x: Chromatogram of scFv RS55 
• Appendix XII-xi: Chromatogram of scFv RT51 
• Appendix XII-xii: Chromatogram of scFv LT3 
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Appendix XII-i: Alignment of 5 randomly selected RGYW clones. 
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Alignment (page 2 of 2) 
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Appendix XII-ii: Chromatogram of scFv TG130-RGYW 1. 
 
  
 
 
 
 
 
 
224 
 
Appendix XII-ii: Chromatogram of scFv TG130-RGYW 1 (continued). 
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Appendix XII-iii: Chromatogram of scFv TG130-RGYW 3 
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Appendix XII-iii: Chromatogram of scFv TG130-RGYW 3 (continued) 
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Appendix XII-iv: Chromatogram of scFv TG130-RGYW 4. 
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Appendix XII-iv: Chromatogram of scFv TG130-RGYW 4 (continued) 
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Appendix XII-v: Chromatogram of scFv TG130-RGYW 21. 
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Appendix XII-v: Chromatogram of scFv TG130-RGYW 21 (continued) 
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Appendix XII-vi: Chromatogram of scFv TG130-RGYW 27.  
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Appendix XII-vi: Chromatogram of scFv TG130-RGYW 27 (continued) 
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Appendix XII-vii: Alignment of 5 selected RGYW scFv clones from biopanning. 
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Alignment (page 2 of 2) 
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Appendix XII-viii:  Chromatogram of scFv TP60. 
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Appendix XII-viii:  Chromatogram of scFv TP60 (continued) 
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Appendix XII-ix:  Chromatogram of scFv RA15. 
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Appendix XII-ix:  Chromatogram of scFv RA15 (continued) 
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Appendix XII-x:  Chromatogram of scFv RS55. 
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Appendix XII-x:  Chromatogram of scFv RS55 (continued) 
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Appendix XII-xi:  Chromatogram of scFv RT51. 
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Appendix XII-xi:  Chromatogram of scFv RT51 (continued) 
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Appendix XII-xii:  Chromatogram of scFv LT3. 
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Appendix XII-xii:  Chromatogram of scFv LT3 (continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
245 
 
Appendix XIII: Statistical test results output of the difference in affinity-matured scFv TP60 antibody recognition between target antigen T. 
gondii and negative control cell line. A t-test comparison between the binding titer readings of both test groups was performed at alpha value = 0.05 
using the SigmaPlot 11.0 statistical software programme. The test result shows a statistically significant difference between the binding titers of 
antibody TP60 and the negative control cell line. 
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Appendix XIV: Table of sequences of 2nd generation mutant scFv antibody clones 
(TG-RGYW library) recovered from biopanning to T. gondii. Clones were 
randomly selected and only mutated regions with its’ corresponding amino acid residues 
are shown. Most frequently occurring clones (≥ 4) are highlighted in yellow. Legend for 
amino acid structures are S – small, N – nucleophilic, H – hydrophobic, A – acidic, B – 
basic and AM – amide.  
 
 
Clone Number Nucleotide Sequence Amino Acid Translation Amino Acid Structures 
1 GCC T A  S S  N 
2 GCC  T A  S S  N 
3 GCC A A  T S  N 
4 GCG  A A  T S  N 
5 GAC G D  A A  S 
6 GAC  G D  A A  S 
7 GAC  C D  P A  H 
8 GAC  T D  S A  N 
9 GAC  T D  S A  N 
10 GAC  A D  T A  N 
11 GAG C E  P A  H 
12 GAG C E  P A  H 
13 GAG  T E  S A  N 
14 GGG G G  A S  S  
15 GGG G G  A S  S  
16 GGG T G  S S  N 
17 GGG  T G  S S  N 
18 GGC  A G  T S  N 
19 CAC G H  A B  S 
20 CAC  G H  A B  S 
21 CAC  C H  P B  H 
22 CAC A H  T B  N 
23 CAC A H  T B  N 
24 ATC C I  P H  H 
25 ATC  T I  S H  H 
26 ATC A I  T H  N 
27 AAG  G K  A B  S 
28 CTG  G L  A H  S 
29 CTG  C L  P H  H 
30 CTG  C L  P H  H 
31 CTC T L  S H  N 
32 CTC T L  S H  N 
33 CTC A L  T H  N 
34 CTG  A L  T H  N 
35 CTG  A L  T H  N 
36 CTG  A L  T H  N 
37 ATG  G M  A H  S 
38 ATG C M  P H  H 
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Clone Number Nucleotide Sequence Amino Acid Translation Amino Acid Structures 
39 AAC C N  P AM  H 
40 GAC A N  T AM  N 
41 AAC  A N  T AM  N 
42 CCG G P  A H  S 
43 CCG G P  A H  S 
44 CCC  T P  S H  N 
45 CCC A P  T H  N 
46 CCG A P  T H  N 
47 CCG A P  T H  N 
48 CCG  A P  T H  N 
49 CCG  A P  T H  N 
50 CAG  G Q  A AM  S 
51 CAG C Q  P AM  H 
52 CAG T Q  S AM  N 
53 CAG T Q  S AM  N 
54 CAG A Q  T AM  N 
55 AGG  G R  A B  S 
56 AGG  G R  A B  S 
57 CGC  G R  A B  S 
58 AGG  G R  A B  S 
59 CGG  G R  A B  S 
60 AGG C R  P B  H 
61 CGC  C R  P B  H 
62 CGG T R  S B  N 
63 CGG  T R  S B  N 
64 AGG  T R  S B  N 
65 AGG  T R  S B  N 
66 CGG  T R  S B  N 
67 AGG A R  T B  N 
68 AGG A R  T B  N 
69 CGC A R  T B  N 
70 CGC A R  T B  N 
71 AGC  G S  A N  S 
72 AGC  G S  A N  S 
73 AGC T S  S N  N 
74 AGC  T  S  S   N  N 
75 ACG G T  A N  S 
76 ACG G T  A N  S 
77 ACC G T  A N  S 
78 ACG  G T  A N  S 
79 ACG  G T  A N  S 
80 ACG C T  P N  H 
81 ACC C T  P N  H 
82 ACG C T  P N  H 
83 ACC C T  P N  H 
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Clone Number Nucleotide Sequence Amino Acid Translation Amino Acid Structures 
84 ACC C T  P N  H 
85 ACG  C T  P N  H 
86 ACG  C T  P N  H 
87 ACC  C T  P N  H 
88 ACG T T  S N  N 
89 ACG  T T  S N  N 
90 ACG A T  T N  N 
91 GTG G V  A H  S 
92 GTC  G V  A H  S 
93 GTC  C V  P H  H 
94 GTC  A V  T H  N 
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Appendix XV: Useful website and links. 
 
 
For up-to-date information and news regarding the protozoan parasite Toxoplasma 
gondii: 
• http://toxoplasmaparasite.blogspot.com/ 
 
For  protein translation tool: 
• http://web.expasy.org/translate/ 
 
For downloading the BioEdit sequence analysis and alignment software: 
• http://en.bio-soft.net/format/BioEdit.html 
 
For analyzing and aligning antibody sequences software: 
• V-QUEST (http://www.imgt.org/IMGT_vquest/share/textes/) 
• Igblast (human and mouse antibody gene sequences  
(http://www.ncbi.nlm.nih.gov/igblast/) 
 
For visualizing, analyzing, and superimposition of antibody molecular structures: 
• VMD version 1.8.7 (2009) (www.ks.uiuc.edu/) 
• SwissPdb-Viewer (DeepView) version 4.0.1 (2008) (http://spdbv.vital-it.ch/) 
• PyMOL v1.4.1 software (http://pymol.org/educational/) 
 
For homology modelling of antibody structures: 
• Rosetta Antibody: Structure Prediction server, by the Department of Chemical 
and Biomolecular Engineering, Johns Hopkins University 
(http://antibody.graylab.jhu.edu/) 
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• Web Antibody Modelling (WAM) server (http://antibody.bath.ac.uk/) 
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